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 ABSTRACT 
HYPOTHALAMIC PITUITARY ADENYLATE CYCLASE-ACTIVATING 
POLYPEPTIDE:  IMPACT ON ENERGY HOMEOSTASIS 
AND GLUTAMATE SIGNALING 
 
 
Jon Michael Resch 
 
Marquette University, 2014 
 
 
 Pituitary adenylate cyclase-activating polypeptide (PACAP) is a member of the 
secretin-glucagon superfamily of peptide hormones, with homology to vasoactive intestinal 
polypeptide (VIP) and activity at both the VIP receptors and the PACAP specific PAC1 
receptor (PAC1R). Abundantly expressed in the hypothalamus, PACAP was recently 
discovered to regulate energy balance when central injections produced hypophagia and 
increased metabolic rate. However, the neurocircuitry mediating these effects in the 
hypothalamus are poorly understood.   
 
 To characterize how hypothalamic PACAP signaling affects energy homeostasis we 
microinjected PACAP site-specifically into the hypothalamic paraventricular (PVN) and 
ventromedial nuclei (VMN) and examined feeding behavior and metabolism. PACAP 
injected into both areas significantly decreased food intake, while only VMN injections 
increased core body temperature and spontaneous locomotor activity.  In addition, all 
responses resulting from hypothalamic PACAP administration were blocked by pretreatment 
with a PAC1R antagonist. Retrograde-labeling from the PVN or VMN identified PACAP 
afferents originating from the brainstem, amygdala, and hypothalamus that co-expressed 
PACAP mRNA. These projections to the PVN and VMN represent the first description of 
PACAP circuits regulating energy balance. 
 
 PACAP signaling is also important for modulating glutamate neurotransmission, 
however whether glutamatergic signaling is necessary for PACAP-induced hypophagia is 
unknown. Though PACAP-PAC1R signaling potentiates postsynaptic NMDA receptor 
activity, PACAP treatment was found to also augment the activity of the astrocytic cystine-
glutamate antiporter, system xc-, in primary cortical cultures suggesting another possible 
means of glutamatergic modulation by PACAP. PACAP increased VMN system xc- mRNA 
expression in vivo, however, inhibition of system xc- activity did not attenuate PACAP-
induced hypophagia. Conversely, NMDA receptor antagonism prior to PACAP 
administration in the VMN did block PACAP-mediated decreases in feeding, suggesting that 
PACAP neurotransmission in the VMN augments glutamate signaling by potentiating 
postsynaptic NMDA receptors.  
 
 The current findings suggest that PACAP signaling, from both hypothalamic and 
extrahypothalamic sites, potently regulates energy balance by decreasing food intake and 
increasing metabolism. Furthermore, the results of our studies involving PACAP-mediated 
modulation of glutamate neurotransmission indicate that PACAP affects glutamatergic 
signaling in multiple ways, however, modulation of NMDA receptor activity in the 
hypothalamus may be the primary mechanism for the regulation of food intake. 
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CHAPTER I 
 
 
INTRODUCTION 
 
 
General Introduction 
 
  
 Body weight homeostasis is achieved through the balance of energy intake and 
energy expenditure. The brain maintains this balance by integrating a myriad of hormonal 
signals and environmental stimuli followed by appropriate behavioral, endocrine, and 
autonomic nervous system responses (Shin et al. 2009). Thus, aspects of energy 
regulation such as feeding behavior are the culmination of several neural systems that 
converge to produce a behavioral output that reflects the body's current energy status (e.g. 
hunger or satiety; Figure 1.1). However, this delicate balance can be overridden by a 
number of internal and external factors resulting in imbalances, which over extended 
periods of time result in serious pathologies such as eating disorders and obesity. In 
recent decades obesity has grown as a public health concern, as the prevalence has 
reached epidemic proportions around the globe (Caballero 2007).  
 Unfortunately, increased body size and negative body image are not the lone 
drawbacks of becoming overweight or obese, as both are major risk factors for co-morbid 
diseases including diabetes, cardiovascular disease, cancer, and stroke (Khaodhiar et al. 
1999), which, not surprisingly, lead to higher healthcare costs and greater economic and 
societal burden (Lehnert et al. 2013). Therefore, continued research in the area of central 
mechanisms of body weight regulation is needed in order to counteract the startling trend 
of rising obesity rates by learning how imbalances in energy regulation can develop 
through interactions between pharmacological, environmental, and genetic mechanisms.  
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Hypothalamic regulation of feeding behavior 
 As the primary homeostatic regulator in the brain, the hypothalamus controls food 
intake through bidirectional neural connections between intra- and extrahypothalamic 
brain regions and detection of circulating hormones that signal either energy deficit or 
excess (Schwartz et al. 2000). Monitoring energy resources is a critical aspect of energy 
balance regulation as the hypothalamus sits proximal to the median eminence, a 
circumventricular organ that allows peripheral hormones to reach hypothalamic cell 
Figure 1.1. Central control of feeding behavior. Food intake is affected by multiple systems 
regulated by several brain structures throughout the brain. ARC, arcuate nuclei; BLA, basolateral 
amygdala; BNST, bed nucleus of the stria terminalis; LH, lateral hypothalamus; LPB, lateral 
parabrachial nuclei; mPFC, medial prefrontal cortex;  NAc, nucleus accumbens; NTS, nucleus 
tractus solitarius; PVN, paraventricular nuclei; SCN, suprachiasmatic nuclei; VMN, ventromedial 
nuclei; VTA, ventral tegmental area. 
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groups. By monitoring the peripheral milieu hypothalamic neurons are stimulated or 
inhibited to affect feeding behavior in a manner that restores energy balance back to a set 
point (Williams and Elmquist 2012). Though there are countless peripheral signals that 
affect food intake, leptin, a potent anorectic hormone released from adipocytes (Ingalls et 
al. 1950; Zhang et al. 1994), and ghrelin, a hormone secreted from the gut to stimulate 
appetite (Kojima et al. 1999), appear to have the broadest impact on hypothalamic 
regulation of feeding behavior (Cummings 2006; Elmquist et al. 2005; Nogueiras et al. 
2008; Vong et al. 2011; Wren et al. 2001).  
 Anatomically, the hypothalamus is comprised of several small nuclei, in very 
close proximity, to which each can be ascribed uniquely distinct functions. Of these 
nuclei, feeding behavior is generally coordinated by the mediobasal cell groups 
containing the dorsomedial nuclei (DMN), ventromedial nuclei (VMN) and arcuate 
nuclei (ARC), in addition to the lateral hypothalamus (LH) and paraventricular nuclei 
(PVN) that reside outside the mediobasal area (Figure 1.2). Within this collection of 
hypothalamic nuclei connected with feeding behavior, the VMN may be the most studied 
but also the most enigmatic. Coined the "satiety center" several decades ago (Kennedy 
1950), the VMN were once the primary focus of hypothalamic feeding research (King 
2006b). However, as experimental stimulation and lesioning techniques improved and 
allowed for more precise manipulations, the function of these nuclei became less clear 
(Gold 1973). Nevertheless, it was established that electrical stimulation of the VMN 
reduces food intake (Beltt and Keesey 1975; Ruffin and Nicolaidis 1999; Takaki et al. 
1992) and both temporary inactivation or permanent lesions generate obesity (Avrith and 
Mogenson 1978; Brobeck et al. 1943; Choi and Dallman 1999). Despite the decades of 
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accumulating evidence, whether obesity from lesions to the VMN is the result of 
hyperphagia is continued to be debated (Cox and Powley 1981).   
 
  
  
 Although it is known that VMN neurons are almost completely glutamatergic in 
nature (Fu and van den Pol 2008; Tong et al. 2007; Ziegler et al. 2002), the hypothalamus 
as a whole is typically thought to regulate feeding behavior exclusively through 
neuropeptide signaling (van den Pol 2012). Despite the rapid discoveries of 
Figure 1.2.  Hypothalamic nuclei controlling feeding behavior. The left depicts hypothalamic cell 
groups that promote feeding and the right highlights areas that promote satiety with known feeding 
neuropeptides expressed within each nuclei. Green = glutamatergic nuclei; Red = GABAergic nuclei; 
Green/Red pattern = heterogeneous cell population. ARC, arcuate; LH, lateral hypothalamus; PVN, 
paraventricular nuclei; VMN, ventromedial nuclei; opt, optic tract; 3V, third ventricle; AgRP, agout-
related peptide; AVP, vasopression; BDNF, brain-derived neurotrophic factor; CRF, corticotropin-
releasing factor; MCH, melanin-concentrating hormone; NPY, neuropeptide Y; OXY, oxytocin; 
PACAP, pituitary adenylate cyclase-activating polypeptide; POMC, pro-opiomelanocortin; TRH, 
thryrotropin-releasing hormone.  
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neuropeptides involved in homeostatic regulation, few were ever found to originate in the 
VMN until recently. These peptides were pituitary adenylate cyclase-activating 
polypeptide (PACAP) (Segal et al. 2005) and brain-derived neurotrophic factor (BDNF) 
(Xu et al. 2003), neither of which was previously linked to feeding behavior. Since their 
detection in the VMN, however, both BDNF and PACAP, which is the focus of this 
thesis and discussed at length in later sections, have been shown to be critical for VMN 
control of feeding and metabolism. For instance, VMN/DMN-specific knockout of 
BDNF produces hyperphagia and obesity (Unger et al. 2007), whereas site-specific 
injections of BDNF into the VMN produce long-lasting hypophagia (Wang et al. 2007).  
The VMN also participate in sensing peripheral hormones important for the regulation of 
feeding and metabolism. Direct injections of leptin into the VMN produce profound 
hypophagia (Jacob et al. 1997), and VMN-specific deletion of leptin receptors results in 
obesity (Dhillon et al. 2006). 
 Just ventral to the VMN are the hypothalamic arcuate nuclei (ARC), containing 
an immensely heterogeneous population of neurons that both stimulate and inhibit food 
intake. Neuropeptide Y (NPY)/agouti-related polypeptide (AgRP)-expressing neurons of 
the ARC drive feeding behavior generally under conditions when energy stores are 
depleted such as during fasting (Levine and Morley 1984; Li et al. 1998; Liu et al. 
2012a). However, acute and specific stimulation of these NPY/AgRP neurons in 
physiologically replete animals also produces robust feeding behavior suggesting these 
neurons may be part of a hard-wired motivational feeding circuit (Aponte et al. 2011; 
Atasoy et al. 2012; Betley et al. 2013; Krashes et al. 2011). By contrast, ARC neurons 
that express pro-opiomelanocortin (POMC), the precursor to the hypophagia-inducing α-
6 
melanocyte-stimulating hormone (α-MSH), inhibit feeding and are significantly 
regulated by circulating levels of leptin (Balthasar et al. 2004; Zhan et al. 2013). 
 The LH and PVN also have considerable roles in regulating feeding behavior 
especially given their strong afferents from the VMN and ARC. The LH functions to 
stimulate feeding behavior through extensive stimulatory outputs to the motive circuit, 
which includes interactions between LH neurons, the ventral tegmental area, and the 
nucleus accumbens (Leinninger et al. 2009; Stratford and Kelley 1999). Once considered 
a center of feeding control, in contrast to the VMN, the LH was frequently referred to as 
the "hunger center" (Anand and Brobeck 1951). While the "dual center" hypothesis (LH 
= hunger vs. VMN = satiety) has long since fallen out of favor (Elmquist et al. 1999), it 
still holds that LH lesions produce physiological wasting (Bernardis et al. 1992). Later it 
was discovered that two unique neuropeptide populations exist within the LH designated 
melanin-concentrating hormone (MCH) and orexin/hypocretin. Central administration of 
either of these neuropeptides stimulate food intake consistent with the role of the LH in 
feeding behavior. Finally, the PVN represents a hub for most intrahypothalamic feeding 
circuits with extensive innervation coming from both ARC NPY/AgRP and POMC 
neurons (Atasoy et al. 2012; Betley et al. 2013; Kim et al. 2000). Composed of a very 
heterogeneous population of neurons itself, lesions to the PVN produce a decidedly 
hyperphagic obesity (Choi and Dallman 1999; Leibowitz et al. 1981; Tokunaga et al. 
1986), perhaps due to the extensive connections with other hypothalamic nuclei, the 
brainstem, and autonomic ganglia, as well as significant control over pituitary secretions 
(Swanson and Kuypers 1980; Swanson and Sawchenko 1980; Swanson et al. 1980). 
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However, the downstream mediators of PVN regulated feeding are still being determined 
(Atasoy et al. 2012; Krashes et al. 2014).  
Hypothalamic regulation of the autonomic nervous system 
 Control over autonomic nervous system activity, via manipulation of both the 
sympathetic and parasympathetic arms, is a key means of how the hypothalamus 
regulates energy expenditure and other aspects of energy balance such as glucose 
homeostasis (Kalsbeek et al. 2010). Of particular interest in rodent models of energy 
balance is non-shivering brown adipose tissue (BAT) thermogenesis. Brown fat is 
composed of adipocytes containing an extraordinary amount of mitochondria giving it a 
brown appearance in comparison to white adipose tissue (WAT). During BAT 
thermogenesis, brown adipocytes work to expend energy as heat by reducing ATP 
production during oxidative phosphorylation in their mitochondria and instead allow for 
protons leak across mitochondrial membranes due to their expression of uncoupling 
protein 1 (UCP1) (Cannon and Nedergaard 2004). Thus, heat production through 
activation of BAT represents a principal means of regulating core body temperature and a 
significant source of total energy expenditure in the rodent that is commonly altered 
following hypothalamic manipulations (Morrison et al. 2012). Increased sympathetic 
activity to BAT drives thermogenesis and creates an upregulation in UCP1 activity and 
expression that can be a useful marker of increased BAT thermogenesis and sympathetic 
nervous system activation (Bamshad et al. 1999; Cannon and Nedergaard 2004; Lean et 
al. 1983). Though once thought to exist only to a small degree, recent evidence suggests 
that there is actually a considerable amount of BAT in adult humans (Cypess et al. 2009; 
van Marken Lichtenbelt et al. 2009; Virtanen et al. 2009), making the study of BAT 
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physiology that much more relevant to understanding human metabolism and not merely 
a useful index of rodent physiology.  
 Several hypothalamic nuclei influence BAT function, including those cell groups 
involved in feeding behavior. Furthermore, the adipostatic hormone leptin has 
considerable stimulatory effects on BAT thermogenesis, likely mediated by hypothalamic 
leptin receptors in the DMN and ARC (Kong et al. 2012; Zhang et al. 2011). Another key 
stimulatory pathway involves orexin-expressing neurons of the LH sending direct 
excitatory projections to the rostral raphe pallidus (RPa) leading to sympathetic activation 
of BAT thermogenesis (Tupone et al. 2011). Interestingly, a favored mechanism for 
unloading excess energy following food intake appears to be activation of BAT (diet-
induced thermogenesis) (Lowell and Flier 1997). 
 The hypothalamus also contains inhibitory circuits to BAT. Excitation of PVN 
neurons can result in decreased BAT thermogenesis (Madden and Morrison 2009), a 
circuit that is inhibited by ARC rat insulin promoter (RIP) neurons that do not co-express 
NPY, AgRP, or POMC (Kong et al. 2012). However, the PVN may also have other 
mechanisms influencing BAT activity depending on which cell subpopulation is 
stimulated, as glutamate injections into the PVN are also reported to increase BAT 
thermogenesis (Amir 1990b). ARC NPY/AgRP neurons may also decrease BAT 
thermogenesis, as specific stimulation of these neurons significantly reduces energy 
expenditure (Krashes et al. 2011), likely due, in part, to reduced BAT activity (personal 
communication).   
 There are many questions surrounding the role of the VMN in regulation of BAT 
thermogenesis, primarily stemming from polysynaptic tract tracing studies using 
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pseudorabies virus resulting in the labeling of all the hypothalamic nuclei discussed 
above except the VMN, even after long incubation periods (Bamshad et al. 1999; 
Oldfield et al. 2002). This is a surprising result considering the initial studies involving 
hypothalamic regulation of BAT demonstrated that the VMN have a stimulatory effect 
(Amir 1990a; Perkins et al. 1981; Yoshimatsu et al. 1993). Unfortunately, due to the 
close proximity of the VMN to the DMN and ARC and lack of retrograde tracing from 
BAT, these pioneering studies, and others like them (Wang et al. 2010), have been 
dismissed due to lack of confidence in injection site accuracy (Morrison et al. 2012). 
Recent transgenic approaches have been able to provide a better indication of whether the 
VMN are involved in BAT regulation. Postnatal elimination of the VMN-specific 
transcription factor steroidogenic factor 1 (SF-1), allowing for normal development of the 
VMN, causes a deficit in diet-induced thermogenesis when these animals are challenged 
with a high fat diet that is also coupled with decreased UCP1 expression (Kim et al. 
2011). Still, evidence from anatomical tracing studies may be needed for a universal 
acceptance of VMN-induced BAT thermogenesis. 
  In addition to temperature regulation, there are many other aspects of energy 
metabolism that the hypothalamus governs through regulation of hypothalamic-pituitary 
axes such as glucocorticoid and thyroid hormone production and through other targets of 
the autonomic nervous system including the adrenal gland, liver, pancreas, and white 
adipose tissue to name a few. Many of these hypothalamic processes revolve closely 
around glucose homeostasis, especially those involving adrenal, hepatic, and pancreatic 
outputs (Hamelink et al. 2002; Kreier et al. 2006). The capability of this tight 
hypothalamic control over glycemic levels stems from various nuclei equipped with 
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glucose-sensing neurons that can either be excited or inhibited by changes in circulating 
levels of glucose (Karnani and Burdakov 2011). While alterations in glucose levels do 
not appear to have a significant impact on food intake (Dunn-Meynell et al. 2009), they 
do lead to changes in autonomic activity to maintain euglycemia (Buijs et al. 2001). As 
such, the VMN are thought to be necessary for the counterregulatory response to 
hypoglycemia by stimulating peripheral catecholamine and glucagon release (Borg et al. 
1997; Borg et al. 1994; Borg et al. 1995; Fioramonti et al. 2010; Levin et al. 2008; Tong 
et al. 2007), and have been proposed to excite preautonomic neurons of the PVN to 
stimulate hepatic glucose production (Yi et al. 2010).   
Pituitary adenylate cyclase-activating polypeptide (PACAP) 
 Isolated from ovine hypothalamus, PACAP was first described to stimulate 
adenylate cyclase activity in pituitary cells (Miyata et al. 1989). Upon characterization it 
was discovered that PACAP belonged to the evolutionarily well-conserved secretin-
glucagon superfamily of peptide hormones, which also includes gastric inhibitory 
peptide, growth hormone-releasing factor, and vasoactive intestinal polypeptide (VIP), 
suggesting this peptide is essential to normal physiology (Sherwood et al. 2000). The 
PACAP gene encodes a precursor peptide that after posttranslational processing yields 
the biologically inactive (in mammals) PACAP-related peptide (PRP) and PACAP of 
either 27 or 38 amino acids (aa) in length (Ogi et al. 1990; Okazaki et al. 1992). Although 
PACAP27 and PACAP38 undergo different posttranslational processes both peptides are 
functionally very similar, with PACAP38 the decidedly predominant form in the CNS 
(Ghatei et al. 1993; Hannibal et al. 1995a). Abundant CNS expression is found in the 
hypothalamus, limbic system, and brainstem (Ghatei et al. 1993; Hannibal 2002; 
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Hannibal et al. 1995a; Piggins et al. 1996), where PACAP signaling is functionally linked 
to a wide array of systems including learning, memory, circadian rhythms, stress, mating, 
cell survival, autonomic nervous system activity, and energy homeostasis (Agarwal et al. 
2005; Ago et al. 2013; Apostolakis et al. 2004; Arimura et al. 1994; Hammack et al. 
2010; Hannibal et al. 2000; Harrington et al. 1999; Hawke et al. 2009; Otto et al. 2001; 
Seaborn et al. 2011; Tanida et al. 2010).  
 As its name implies, PACAP also has significant effects on endocrine function 
through stimulation of several pituitary hormones (Rawlings and Hezareh 1996), in 
addition to expression in the periphery found in the adrenal gland, gonads, pancreas, and 
peripheral nervous system (Vaudry et al. 2009). It is important to note that the extent to 
which bidirectional PACAP signaling occurs between central and peripheral 
compartments is very low, as peripheral PACAP is similar to other peptide hormones that 
exhibit limited distribution and rapid blood clearance, even though both saturable and 
nonsaturable mechanisms exist for PACAP transport across the blood-brain barrier 
(Banks et al. 1993; Bourgault et al. 2011). Furthermore, an extensive efflux component, 
peptide transport system-6 (PTS-6), in the blood-brain barrier represents a considerable 
obstacle to PACAP influx from the periphery (Dogrukol-Ak et al. 2009).  
 The PACAP receptors are all members of the B1 subclass of G protein-coupled 
receptors (GPCR), and include the PACAP type I receptor (PAC1R) and the VIP 
receptors, VPAC1R and VPAC2R, due to approximately 68% homology between 
PACAP and VIP (Dickson and Finlayson 2009). Among the various receptor types, 
PAC1R has a much greater affinity for both PACAP27 and PACAP38 than for VIP, 
while VPAC1R and VPAC2R bind PACAP and VIP equally (Table 1.1) (Gottschall et al. 
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1990; Lam et al. 1990). Because of this overlap in receptor activity between PACAP and 
VIP several pharmacological agents have been discovered or derived in order to isolate 
one of the three receptors specifically and determine its function, however, all of the 
selective ligands thus far are peptidergic in nature and usually display some activity at 
one of the other PACAP receptors (Table 1.1) (Dickson et al. 2006; Dickson and 
Finlayson 2009; Fishbein et al. 1994; Gourlet et al. 1995; Lerner et al. 2007; Robberecht 
et al. 1992; Summers et al. 2003; Vaudry et al. 2009). 
 
Table 1.1. PACAP receptor binding affinities and selective ligands 
Receptor 
 
Dissociation 
Constant 
(Kd) 
 
Agonists Antagonists 
PAC1R PACAP ≈ 0.5 nM 
VIP > 500 nM Maxadilan 
 
PACAP6-38 
(VPAC2R activity) 
 
M65 
 
VPAC1R PACAP ≈ VIP ≈ 1 nM [K15,R16,L27]VIP(1-7)/ GRF(8-27) 
 
PG 97-269 
 
VPAC2R PACAP ≈ VIP ≈ 1 nM BAY 55-9857 (VPAC1R activity) 
 
PG 99-465 
(VPAC1R/PAC1R activity) 
 
 
(Dickson and Finlayson 2009; Vaudry et al. 2009) 
  
 As with the rest of the B1 subclass of GPCRs, PACAP receptor signaling is 
coupled to Gαs and stimulation of adenylate cyclase activity, however, many other signal 
transduction pathways are activated by either VPAC or PAC1 receptors (Dickson and 
Finlayson 2009). Consequently, PACAP receptors are also capable of coupling to other G 
proteins such as Gαq, and can result in a diverse array of intracellular signals outside of 
cAMP production including activation of phospholipase C, protein kinase C,  
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phospholipase D, and/or intracellular calcium release (Figure 1.3) (Dickson and 
Finlayson 2009). This broad impact mediated by PACAP receptors is attributed to the 
existence of multiple variants, especially in the PAC1R, as it is described as one of the 
most alternatively spliced GPCRs known (Dautzenberg et al. 1999; Kilpatrick et al. 
1999). Splice variants occur throughout the PAC1 receptor at the N-terminus (Daniel et 
al. 2001; Dautzenberg et al. 1999; Lutz et al. 2006; Pantaloni et al. 1996), transmembrane 
domains (Chatterjee et al. 1996), and third intracellular loop (Braas and May 1999; 
Journot et al. 1995; Spengler et al. 1993), however, the majority of PAC1R variants arise 
from inclusion or removal of the third intracellular loop cassettes, designated hip (28 aa), 
hop1 (28 aa), and hop2 (27 aa). No matter the location, all of the approximately 15 
PAC1R isoforms have functional consequences resulting in changes in potency of 
PACAP/VIP and/or second messenger activation (Dickson and Finlayson 2009). The 
heavy alternative splicing that results in variations of pharmacological profile and 
 
 
Figure 1.3. PACAP/VIP receptor signaling pathways. G protein-coupling to Gαs, Gαq, or Gαi/o allow 
for diverse intracellular signal transduction in the cell by PACAP receptors. Figure adapted from 
Dickson and Finlayson, 2009.  
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receptor signaling demonstrate the complexity of the PACAP/VIP neuropeptide system, 
and illustrates the need for development of selective ligands for PAC1 and VPAC 
receptors (Bourgault et al. 2009), as they are often expressed in the same tissue (Nguyen 
et al. 1993; Robberecht et al. 1991; Tatsuno et al. 1990).  
Regulation of feeding behavior by central PACAP signaling 
 The first observations of PACAP-mediated regulation of food intake were 
observed soon after its discovery (Miyata et al. 1989), when intracerebroventricular (icv) 
injections of PACAP were found to significantly reduce food intake in food-deprived 
mice (Morley et al. 1992). Later, icv PACAP administration was also observed to 
decrease feeding behavior in goldfish, chicks, and rats (Matsuda et al. 2005; Mizuno et al. 
1998; Tachibana et al. 2003). Pretreatment with PACAP6-38, a truncated form of 
PACAP that antagonizes the PAC1 receptor (Robberecht et al. 1992), abolishes the 
hypophagic response to icv PACAP injections indicating that control of food intake can 
be mediated by PAC1 receptors (Hawke et al. 2009; Mounien et al. 2009). Considering 
these results, it is surprising that PACAP, PAC1R, and VPAC2R knockout (KO) mice are 
lean (Adams et al. 2008; Asnicar et al. 2002; Jamen et al. 2000; Nakata et al. 2004; 
Tomimoto et al. 2008). Furthermore, PACAP KO mice eat significantly less food than 
their wild-type littermates when normalized for body weight, and exhibit reduced NPY 
mRNA expression (Nakata et al. 2004). The lean phenotype of PACAP related KO mice 
conflicts with behavioral data collected from central pharmacological experiments 
suggesting that peripheral PACAP signaling also contributes to feeding behavior, and 
possibly that multiple PACAP-expressing circuits in the brain drive either hunger or 
satiety. Moreover, constitutive deletion of either PACAP or PAC1R results in early 
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lethality suggesting an essential role for this neuropeptide (Gray et al. 2001; Otto et al. 
2004). To date, limited technology allowing for cell-type specific manipulation has 
hindered the isolation of specific PACAP circuits and their contributions to feeding 
behavior (until recently (Krashes et al. 2014)), leaving pharmacology and expression 
analyses as the primary avenues of investigation.  
Although central PACAP neurocircuitry is largely unknown, the decreased 
feeding produced by exogenous PACAP injections has been attributed mainly to 
signaling within the hypothalamus. This is due, in part, to reports of PACAP-mediated 
attenuation of NPY-induced feeding (Chance et al. 1995; Morley et al. 1992) and 
extensive expression of PAC1 receptors in multiple hypothalamic nuclei (Hashimoto et 
al. 1996; Resch et al. 2011). In further support, there is a distinct abundance of PACAP 
protein expression in the hypothalamus with greater concentrations than in both the 
amygdala and extended amygdala and with protein concentrations of approximately 25 
times that found in the cerebral cortex (Hannibal et al. 1995a). In situ hybridization and 
immunohistochemistry techniques have specifically identified major hypothalamic cell 
groups expressing PACAP to include the PVN (Hannibal et al. 1995b; Nomura et al. 
2000), VMN, and some subnuclei of the mammillary bodies (Hannibal 2002). In 
addition, immunohistochemical analysis of PACAP immunoreactivity demonstrates 
virtually every hypothalamic area receives intense labeling of PACAP nerve fibers 
(Hannibal 2002; Piggins et al. 1996).  
Importantly, hypothalamic PACAP mRNA expression is responsive to energy 
signaling. Mice maintained on a high energy diet for 8 weeks show increased levels of 
circulating leptin associated with increased PACAP mRNA expression in the VMN, and 
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conversely 48 hours of fasting causes significantly decreased levels (Hawke et al. 2009). 
Of note, leptin treatment in fasted animals normalizes VMN PACAP mRNA expression, 
and furthermore, leptin deficiency or deletion of leptin receptors from the VMN results in 
reduced PACAP mRNA expression. The relationship between leptin and PACAP is also 
demonstrated by pretreatment with the PAC1R antagonist PACAP6-38 eliminating 
leptin-mediated hypophagia (Hawke et al. 2009) and the attenuated hypophagia observed 
following icv leptin administration in PACAP KO mice (Tanida et al. 2013). These data 
indicate that PACAP neurotransmission, likely involving the VMN, may be a mediator of 
leptin-mediated inhibition of food intake. 
Like PACAP, hypothalamic pro-opiomelanocortin (POMC) mRNA expression is 
also reduced following a 48 hour fast in mice. (Mounien et al. 2009). POMC is the 
precursor to α-melanocyte-stimulating hormone (α-MSH), a potent neuropeptide signal 
that has a significant role in body weight regulation through stimulating central 
melanocortin receptors (MC3/4R) (Zhan et al. 2013). Notably, PACAP also dose-
dependently increases POMC mRNA in ARC hypothalamic slices (Mounien et al. 
2006b), indicating a possible relationship between the two neuropeptide signals. 
Remarkably, both PACAP6-38 and the melanocortin receptor antagonist SHU9119 block 
PACAP-induced decreases in feeding after icv injection, and in situ hybridization 
decisively shows increased c-fos mRNA expression in ARC POMC neurons one hour 
following PACAP icv injections, perhaps localizing PACAP-induced hypophagia to the 
ARC (Mounien et al. 2009). Given the relationships between PACAP and both leptin and 
POMC in the hypothalamus, it is conceivable that leptin stimulates excitatory VMN 
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PACAP neurons projecting to ARC POMC neurons, leading to decreased food intake 
(Balthasar et al. 2004; Dhillon et al. 2006; Hawke et al. 2009; Mounien et al. 2009). 
Although the hypothalamus appears to be the primary target for regulation of food 
intake by PACAP signaling, very few have attempted to ascertain the intrahypothalamic 
PACAP circuitry or site-specific contributions that regulate feeding behavior. The 
hypothalamus possesses an abundance of PAC1R mRNA in many of its nuclei compared 
to a more restricted expression pattern of VPAC2R mRNA (Hashimoto et al. 1996; 
Mounien et al. 2006a; Resch et al. 2011; Usdin et al. 1994; Yi et al. 2010), suggesting 
that hypothalamic control of feeding utilizes PACAP-PAC1R signaling. Hypothalamic 
injections of PACAP into the perifornical area of the lateral hypothalamus (PFH) produce 
potent hypophagia, exemplified by PACAP-mediated inhibition of NPY-induced feeding 
in the PFH (Chance et al. 1995). Furthermore, animals with restricted access to food 
continue to respond with decreased food intake following PACAP injections into the PFH 
demonstrating that PACAP-induced decreases in feeding may not be limited strictly to 
inhibition of NPY-induced feeding (Chance et al. 1995). The alterations in PFH neuron 
activity leading to changes in feeding behavior driven by NPY and PACAP are likely a 
product of cAMP second messenger signaling cascades, as PACAP reduces cAMP 
response element (CRE) binding in nuclear extracts of PFH tissue, while food deprivation 
and NPY significantly increase CRE binding (Sheriff et al. 1997). Of note, PACAP 
signaling in the PFH may also regulate fluid intake, although PFH PACAP administration 
has been reported to produce both adipsogenic (Chance et al. 1995) and dipsogenic (Puig 
de Parada et al. 1995) effects. These discrepancies may result from differences in the 
concentration of PACAP injections delivered into the PFH or an apparent differential 
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response of fluid intake to rostral and caudal injection sites of the PFH to PACAP. While 
the circuitry responsible for regulation of ingestive behavior in the PFH is still undefined, 
it is clear that PACAP has a diverse role in regulating PFH function. 
 Another pair of hypothalamic nuclei that utilize PACAP to regulate feeding 
behavior are the paraventricular nuclei (PVN). The PVN express a large amount of 
PAC1R mRNA, as well as an abundance of PACAP-like immunoreactivity in perikarya 
and terminals (Das et al. 2007; Hannibal et al. 1995b; Hashimoto et al. 1996; Legradi et 
al. 1998). Furthermore, PACAP synapses terminate specifically onto PVN corticotropin-
releasing factor (CRF) neurons, and icv injection of PACAP increases PVN CRF mRNA 
(Grinevich et al. 1997; Legradi et al. 1998). Importantly, PACAP is hypothesized to 
excite CRF neurons in the PVN, resulting in stimulation of the hypothalamic-pituitary-
adrenal (HPA) axis, which supports the results that icv PACAP injections increase blood 
corticosterone levels (Dore et al. 2013; Yi et al. 2010). Stress can have a significant 
impact on feeding and body weight and given the apparent association between PACAP 
signaling and CRF neurons of the PVN, site-specific PACAP injections into PVN may 
produce significant alterations in a number of physiological systems including feeding 
behavior. Behavioral analysis following microinfusion of PACAP into the PVN shows 
increased face washing and body grooming and decreased rearing and locomotor activity 
irrespective of whether animals received mild restraint stress (Norrholm et al. 2005). 
Unfortunately, food intake following PACAP injections into the PVN was not reported 
leaving a significant gap in knowledge regarding feeding, stress, and PACAP signaling. 
However, icv pretreatment with a CRF antagonist prior to PACAP administration does 
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not block hypophagia and reductions in body weight induced by PACAP (Dore et al. 
2013), perhaps separating the hypophagic and stress responses to central PACAP.  
Autonomic regulation by central PACAP signaling 
 Multiple sites within the hypothalamus not only control energy intake but also 
energy expenditure. This is also true of PACAP signaling as central injections dose-
dependently reduce feeding under both normal and food-deprived conditions and increase 
metabolism through regulation of the autonomic nervous system, causing increases in 
core body temperature (Hawke et al. 2009; Masuo et al. 1995; Pataki et al. 2000), 
locomotor activity (Masuo et al. 1995), and oxygen consumption (Hawke et al. 2009). 
The impact of increased energy expenditure driven by these effects on body weight are 
clearly demonstrated in pair-feeding experiments where animals receiving icv PACAP 
lose significantly more body weight in a 24 hour period than both controls and animals 
restricted to the amount of food eaten by PACAP treated animals (Hawke et al. 2009). 
Furthermore, both PACAP and PAC1R KO mice have notable metabolic deficiencies. 
The first reports of PACAP/PAC1R KO mice described lean undernourished pups with a 
high incidence of lethality accompanied by elevated circulating levels of ketones, 
triglycerides, cholesterol, and corticosterone, in addition to very low liver glycogen (Gray 
et al. 2001; Otto et al. 2004). Moreover, PACAP/PAC1R null mice show signs of 
pulmonary hypertension, enlarged hearts, intracellular lipid accumulation in cardiac cells, 
and increased levels of serum free fatty acids consistent with the possibility of 
cardiovascular problems contributing to early lethality (Gray et al. 2001; Otto et al. 
2004). 
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Interestingly, survival of PACAP null mice is greatly improved if the animals are 
housed at an elevated ambient temperature (24° C vs. 21° C) suggesting a crucial role for 
PACAP in thermoregulation (Gray et al. 2002). Additionally, PACAP knockout mice 
housed at 24° C challenged with a 21° C climate lost their body temperature significantly 
faster than wild-type littermates, yet brown adipose tissue (BAT) in these animals 
appeared to be fully capable of non-shivering thermogenesis (Gray et al. 2002). 
Therefore, lack of temperature regulation in these mice was attributed to decreased 
stimulation of brown fat by norepinephrine from sympathetic nerves.  
Given pharmacological and genetic data signifying a crucial role for PACAP 
signaling in thermoregulation, the catabolic response to icv injections of PACAP is likely 
due to modulation of autonomic nerve activity, as energy expenditure driven by increased 
core body temperature is often mediated by sympathetic activation of BAT 
thermogenesis in rodents. Indeed, third ventricle injection of PACAP increases mean 
arterial pressure and heart rate, as well as altering a host of autonomic nerve pathways. 
Renal, adrenal, celiac, lumbar, liver, and interscapular brown adipose sympathetic nerve 
activities all significantly increase following PACAP injections, while parasympathetic 
gastric vagal and celiac vagal nerve activities decrease (Tanida et al. 2011a; Tanida et al. 
2010). As observed with the regulation of feeding behavior, PACAP signaling may work 
synergistically with leptin and melanocortin signaling to regulate metabolism. Central 
pretreatment with the PAC1R antagonist PACAP6-38 icv blocks stimulation of white 
adipose tissue sympathetic nerve activity and hyperthermia induced by leptin injections, 
suggesting that central actions of leptin may include stimulating PACAP release, perhaps 
from the VMN (Hawke et al. 2009; Tanida et al. 2013). In addition to the interaction with 
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leptin, the melanocortin receptor antagonist SHU9119 inhibits some of the effects of 
PACAP on autonomic nerve activity, including effectively blocking PACAP-induced 
modulation of the parasympathetic gastric vagal nerve and sympathetic nerves 
innervating the liver and brown adipose tissue (Tanida et al. 2011a). Meanwhile, 
SHU9119 does not inhibit PACAP’s effect on mean arterial pressure or heart rate, 
suggesting that the melanocortin system may only participate in the digestive and 
thermogenic processes regulated by PACAP, but not other physiological systems 
stimulated by central PACAP injection (Tanida et al. 2011a).   
PACAP regulation of glucose homeostasis  
 PACAP plays a diverse role in glucose homeostasis. Impaired glucose tolerance 
or insulin hypersensitivity following glucose and insulin tolerance tests are observed in 
PACAP, PAC1R, and VPAC2R knockout mice (Adams et al. 2008; Asnicar et al. 2002; 
Jamen et al. 2000; Tomimoto et al. 2008). PACAP knockouts also display low basal 
levels of insulin (Adams et al. 2008; Tomimoto et al. 2008) and a hypersensitivity to 
insulin-induced lethality (Hamelink et al. 2002), while PAC1R KO mice exhibit 
compromised insulin secretion and glucagon response to insulin-induced hypoglycemia 
(Jamen et al. 2000; Persson and Ahren 2002). These abnormalities of insulin secretion 
and signaling suggest pancreatic dysfunction, however PACAP knockout mice also show 
insufficient catecholamine production indicated by low adrenal epinephrine levels and 
tyrosine hydroxylase activity following insulin challenge (Hamelink et al. 2002), and a 
blunted glucose response to stressful stimuli (Tanida et al. 2010), all of which point to 
orchestration of glucose regulation through PACAP signaling in other organs such as the 
adrenal gland. Given the rich expression of PACAP both centrally and peripherally it is 
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difficult to pinpoint a single target for the abnormal glucose homeostasis in PACAP 
knockout animals, especially since PACAP expression exists in a number of peripheral 
organs such as the pancreas (Filipsson et al. 1998; Portela-Gomes et al. 2003) and adrenal 
(Ghatei et al. 1993; Kantor et al. 2002; Moller and Sundler 1996).   
 Central PACAP regulation of glucose does impact peripheral blood glucose 
independent of peripheral actions via modulation of the autonomic nervous system. 
Plasma glucose concentrations rise rapidly following central PACAP injections, in 
addition to plasma glucagon and corticosterone levels. Interestingly, glucose production 
stimulated by central PACAP occurs through endogenous glucose production largely due 
to liver glycogenolysis, and to a smaller extent gluconeogenesis (Mounien et al. 2009; Yi 
et al. 2010). In support of liver involvement, central PACAP administration increases 
phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) 
mRNA, and drastically decreases glycogen content in the liver. Furthermore, hepatic 
sympathetic, but not hepatic parasympathetic denervation abolishes the effects of central 
PACAP injection on plasma glucose (Yi et al. 2010).  
 Using retrograde tracing from the intermediolateral (IML) column of the thoracic 
spinal cord, where liver projecting sympathetic neurons reside, in combination with Fos 
immunohistochemistry, neurons in the paraventricular nuclei (PVN) of the hypothalamus 
were co-labeled with tracer and Fos immunoreactivity following central PACAP 
administration, suggesting that PACAP activates preautonomic PVN neurons that 
stimulate hepatic sympathetic nerve activity and in turn glucose production (Yi et al. 
2010). These results are further supported by the increased glucose production that occurs 
following direct microinjection of PACAP into the PVN (Resch et al. 2013; Yi et al. 
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2010). Interestingly, the effects of centrally administered PACAP on glucose would 
appear to be distinct from that of feeding and metabolism because it is not blocked by 
either PAC1R or melanocortin receptor antagonists. Instead the glycemic response 
appears to be mediated by the vasoactive intestinal polypeptide 2 receptor (VPAC2R), as 
VPAC2 receptor antagonism inhibits plasma glucose production induced by central 
PACAP (Yi et al. 2010).  
Glutamate neurotransmission and its modulation by PACAP 
 Glutamate plays a significant role in several pathways of cellular metabolism 
including energy production and protein synthesis and degradation (Kelly and Stanley 
2001), however, it is also the primary excitatory neurotransmitter in the brain. 
Elimination of synaptic glutamate release, through targeted gene knockout strategies, is 
incompatible with life demonstrating that glutamate neurotransmission is absolutely 
essential to CNS function and survival (Moechars et al. 2006; Wojcik et al. 2004). 
Glutamate signaling occurs through several ionotropic (Lodge 2009) or metabotropic 
(Niswender and Conn 2010) receptor subtypes that are expressed in various locations in 
and around the synapse, leading to complex regulation of excitatory communication 
(Figure 1.4). Adding to this complicated system are neuromodulatory transmitters that 
can affect glutamate signaling by altering presynaptic release (Pancani et al. 2014), 
postsynaptic receptor activity (Kempadoo et al. 2013), or even reuptake (Brown 2000). 
The neuropeptide PACAP, which is co-expressed with some populations of glutamate 
neurons (Fig. 5.1) (Engelund et al. 2010; Fahrenkrug and Hannibal 2004; Hannibal et al. 
2000), is positioned to be an essential modulator as it appears to have multifaceted effects 
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on glutamate neurotransmission through signaling both on neurons (Macdonald et al. 
2005) and astrocytes (Figiel and Engele 2000). 
 Activation of ionotropic glutamate receptors provide fast-acting depolarizing 
current at the postsynaptic neuron following synaptic glutamate release, with each 
receptor type capable of different subunit compositions that can significantly modify 
receptor kinetics (Dingledine et al. 1999). The low affinity ionotropic glutamate receptors 
α-amino-3-hydroxy-5-methyl-4-isoxazolproprianic acid (AMPA) and kainate are 
trafficked near to synaptic release sites where concentrations of glutamate are highest 
upon vesicular release (Franks et al. 2002; Raghavachari and Lisman 2004; Zheng et al. 
2008). N-methyl-D-aspartate (NMDA) receptors are high affinity ionotropic glutamate 
receptors, however, they also require the presence of co-agonists glycine or D-serine to 
become activated (Johnson and Ascher 1987; Schell et al. 1995). Furthermore, within the 
ion channel of NMDA receptors exists a voltage-dependent magnesium block that is 
removed by depolarization, usually done so by AMPA/kainate activation, which exhibit 
rapid gating (Nowak et al. 1984). Contributing to glutamate receptor activation, PACAP 
signaling through both VPAC and PAC1 receptors appear to potentiate activity of 
ionotropic glutamate receptors, specifically AMPA (Cho et al. 2012; Costa et al. 2009) 
and NMDA receptors (Harrington et al. 1999; Macdonald et al. 2005; Wu and Dun 1997; 
Yaka et al. 2003), however presynaptic modulation of glutamate release may also be 
involved (Otto et al. 1999). Likewise, depression of AMPA and NMDA receptor currents 
have been reported under conditions of excessive PACAP concentrations in the 
hippocampus (Costa et al. 2009; Macdonald et al. 2005). 
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 In addition to ionotropic forms, multiple subtypes of high affinity metabotropic 
glutamate receptors (mGluR) exist. The mGluRs are divided into three categories based 
on sequence homology, G protein-coupling, and ligand selectivity (Niswender and Conn 
2010). Group I mGluRs (mGluR1,5) are generally postsynaptic and excitatory through 
coupling to Gαq/11 and activation of phospholipase C (Hermans and Challiss 2001). By 
contrast, group II (mGluR2-3) and group III (mGluR4,6-8) receptors are often located 
presynaptically (especially group III) and inhibit neurotransmitter release (Niswender and 
Conn 2010). Considering both mGluRs and PACAP signaling have modulatory roles it is 
not surprising that little evidence exists for interactions between them, however, PACAP 
signaling in the suprachiasmatic nuclei may reduce the calcium induction caused by 
group I mGluR activation (Kopp et al. 2001). 
Glial glutamate regulation and the potential role for PACAP  
 Glutamate homeostasis may be more dependent on the function of glia than any 
other cell type in the CNS. This is supported by the importance of sodium-dependent 
glial glutamate transporters (GLT-1 and GLAST) to remove vesicular glutamate release 
from the synapse in order to prevent spillover into other synaptic compartments (Figure 
1.4) (Asztely et al. 1997; Diamond and Jahr 2000) and to signal for glycolysis activation 
to replenish energy resources following increased neuronal activity (Pellerin and 
Magistretti 1994). However, a poorly studied aspect of glutamate neurotransmission is 
astrocytic glutamate release (Baker et al. 2002; Parpura and Haydon 2000; Ye et al. 
2003), which may be capable of coordinating neuronal activity on a network level 
(Bushong et al. 2002; Ogata and Kosaka 2002). In particular, the astrocytic cystine-
glutamate antiporter, system xc-, which exchanges one extracellular molecule of cystine  
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for one intracellular molecule of glutamate (Bannai and Kitamura 1980) has been 
implicated in maintaining the extrasynaptic pool of glutamate (Baker et al. 2002). 
Dysregulation of system xc- activity results in altered concentrations of extrasynaptic 
glutamate, altered neurotransmitter release, and upregulation of postsynaptic glutamate 
receptor clustering, which can lead to pathology (Augustin et al. 2007; Baker et al. 2008; 
Baker et al. 2003; De Bundel et al. 2011; Featherstone et al. 2002; Knackstedt et al. 2009; 
Kupchik et al. 2012; Moran et al. 2005). Moreover, excessive extrasynaptic glutamate 
concentrations, perhaps through system xc-, may also contribute to excitotoxic neuronal 
injury or death suggesting the regulation of this antiporter may be tightly regulated by the 
 
Figure 1.4. Schematic representation of a typical glutamatergic synapse. Glutamate (Glu) signaling 
occurs both within the synapse and extrasynaptically to regulate neuronal excitability, much of 
which is regulated by astrocytes through synaptic glutamate uptake (E; EAATs), glutamate release 
(via cystine (c-c)-glutamate antiporter), and the glutamate-glutamine (Glt) cycle responsible for 
replenishing glutamate availability in neurons that have only few glutamate reuptake transporters. 
M, metabotropic glutamate receptor; A, AMPA receptor; N, NMDA receptor. Figure adapted from 
Bridges et al.  2012. 
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synaptic environment (Buckingham et al. 2011; de Groot and Sontheimer 2011; Fogal et 
al. 2007; Jackman et al. 2010; Liu et al. 2014; Sontheimer 2011).  
 Importantly, PACAP also displays significant interactions with glia, especially 
astrocytes, with all three PACAP/VIP receptors showing astrocytic expression (Ashur-
Fabian et al. 1997; Grimaldi and Cavallaro 1999; Grimaldi and Cavallaro 2000; Jaworski 
2000; Suzuki et al. 2003; Tatsuno et al. 1991; Tatsuno et al. 1990; Tatsuno et al. 1996a). 
Remarkably, PACAP signaling on astrocytes involves many of the glutamatergic systems 
in place to regulate cell excitability and energy metabolism. For example, PACAP 
treatment of astrocytes appears to upregulate expression and function of the glial 
glutamate transporters GLT-1 and GLAST through activation of both PKA and PKC-
dependent pathways (Figiel and Engele 2000). PACAP has also been shown to play a 
role in glial glycogen metabolism (Cardinaux and Magistretti 1996; Magistretti et al. 
1998), and may mediate its neurotrophic role through protecting against oxidative stress 
and excitotoxicity by signaling on astrocytes (Brown 2000; Masmoudi-Kouki et al. 2011; 
Morio et al. 1996; Stumm et al. 2007; Zusev and Gozes 2004).  
Current Studies  
 This thesis continues to build upon the foundation of knowledge involving 
hypothalamic regulation of energy balance by investigating the role of PACAP signaling 
on feeding behavior and metabolism. Characterizing specific components of PACAP 
neurocircuitry and receptor signaling as they pertain to hypothalamic energy regulation 
could make great strides toward eventual therapeutic tools to treat obesity and diabetes. 
While the research field is aware of the potent effects of PACAP on feeding and 
metabolism, much of the data is marred by behavioral pharmacology based on non-
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specific central injections of the peptide or global gene knockout strategies. The current 
work begins to answer questions about the hypophagic and hypermetabolic effects 
observed following icv injections of PACAP by carefully restricting our injections to 
distinct hypothalamic nuclei.  
 Remarkably at the onset of this dissertation project, the PACAP neurocircuitry 
mediating its regulation of body weight was only speculative. Consequently, we set to 1) 
identify the site(s) of action responsible for the hypophagic response to PACAP in the 
hypothalamus, 2) determine if these "satiety centers" were also involved in other aspects 
of energy homeostasis such as controlling energy expenditure and glucose homeostasis, 
3) delineate the sources of endogenous PACAP signaling projecting into these nuclei, and 
4) investigate how PACAP modulates glutamatergic neurotransmission to produce 
behavioral and physiological effects. Through site-specific behavioral pharmacological 
analysis, retrograde tract tracing, and examination of the interaction between glutamate 
and PACAP both in vitro and in vivo, the resulting data from these experiments not only 
strongly suggests a critical role for PACAP in the regulation of feeding behavior and 
metabolism but also towards the modulation of glutamate neurotransmission.   
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CHAPTER II 
 
 
REGULATION OF FOOD INTAKE BY PACAP SIGNALING IN THE 
VENTROMEDIAL NUCLEI OF THE HYPOTHALAMUS 
 
 
Introduction 
 
 
 The ventromedial nuclei of the hypothalamus (VMN) are important regulators of 
feeding behavior. Temporary inhibition, with procaine (Berthoud and Jeanrenaud 1979; 
Yadav et al. 2009) and colchicine (Avrith and Mogenson 1978; Choi and Dallman 1999), 
or permanent lesion of the VMN result in hyperphagia (Brobeck et al. 1943), while 
electrical stimulation produces reduced feeding in rats (Beltt and Keesey 1975; Ruffin 
and Nicolaidis 1999; Stenger et al. 1991). Furthermore, many signaling molecules 
including norepinephrine (Shimazu et al. 1986), brain-derived neurotrophic factor 
(BDNF) (Wang et al. 2007), and leptin (Jacob et al. 1997) have been discovered to affect 
feeding behavior when administered into the VMN, however the effect of a particular 
transmitter on feeding behavior is dependent upon receptor expression within the VMN 
and whether the signal results in excitation or inhibition of VMN neurons. Understanding 
specific neurotransmitters and how they modulate VMN activity provides insight into the 
neurocircuitry controlling VMN-dependent behaviors and potential therapeutic targets for 
obesity.    
The neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) is 
positioned to have a significant role in hypothalamic regulation of feeding behavior, but 
its signaling specifically within the VMN has yet to be clearly characterized. 
Intracerebroventricular (icv) administration of PACAP robustly decreases food intake 
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(Dore et al. 2013; Hawke et al. 2009; Mizuno et al. 1998; Morley et al. 1992; Mounien et 
al. 2009). In addition, PACAP has been linked to both leptin and BDNF signaling 
(Fukuchi et al. 2005; Hammack et al. 2009; Hawke et al. 2009; Pellegri et al. 1998; Yaka 
et al. 2003), both of which decrease food intake when administered into the VMN (Jacob 
et al. 1997; Wang et al. 2007). Interestingly, PACAP mRNA expression decreases 
following fasting (Hawke et al. 2009; Mounien et al. 2009) while chronic high fat diet 
increases PACAP mRNA in the VMN (Hawke et al. 2009), suggesting that PACAP-
expressing neurons of the VMN are important energy sensors that monitor and regulate 
body weight. 
PACAP is a 38 amino acid neuropeptide that belongs to the secretin super family 
of peptides that also includes vasoactive intestinal polypeptide (VIP) (Hannibal et al. 
1995a; Vaudry et al. 2009). Because of their high sequence homology PACAP not only 
binds and activates the PACAP receptor (PAC1R), but also the VIP receptors VPAC1 
and VPAC2. All three receptors are G protein-coupled with PACAP demonstrating an 
approximate 2-fold higher affinity for the PACAP receptor (PAC1R) compared to the 
VIP receptors. Interestingly, PACAP and VIP display equal affinity for the VIP 
receptors, whereas VIP has a very low affinity for the PAC1R (Vaudry et al. 2009). All 
PACAP receptors stimulate adenylate cyclase activity, however the receptors, especially 
PAC1R, are heavily alternatively spliced and several variants have been shown to 
activate other secondary messenger pathways (Dickson and Finlayson 2009; Ushiyama et 
al. 2007).  
Much of the work thus far involving PACAP and feeding behavior has focused on 
icv injections or global knockouts, neither of which can speak to specific sites of action 
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by which PACAP induces its effects (Adams et al. 2008; Hawke et al. 2009; Morley et al. 
1992; Mounien et al. 2009; Nakata et al. 2004). PAC1R mRNA expression is reported to 
be widespread throughout the central nervous system, with abundant expression in the 
hypothalamus, specifically in areas known to regulate feeding behavior such as the 
paraventricular nuclei (PVN), VMN, and arcuate nuclei (ARC) (Hashimoto et al. 1996).  
Given its discrete and abundant expression within the VMN, PACAP and its 
receptor may yield novel mechanisms for the control of feeding behavior. To further 
investigate the importance of highly localized PAC1R signaling we microinjected 
PACAP site-specifically into the VMN and subsequently measured feeding behavior. We 
further confirmed that changes in feeding behavior were first, mediated through the 
PAC1R subtype, and second, not a product of malaise. Our studies demonstrate that 
PACAP signaling within the hypothalamic VMN promotes a negative energy balance by 
decreasing food intake.  
Materials and Methods 
Animals 
Male Sprague-Dawley rats (Harlan; Madison, WI) weighing 225-250 g were 
individually housed in a climate controlled room with a 12 hr light/dark cycle (lights on 
at 0500h). Animals had free access to Harlan standard diet (8604 formulation) and water 
unless stated otherwise in specific experiments. Food consumption was measured with a 
BioDAQ Food Intake Monitor (Research Diets; New Brunswick, NJ) or calculated by 
pre-weighing food in each bin and subtracting the weight of non-ingested and spilled 
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food at the end of each measurement period. All procedures using animals were approved 
by the Marquette University Institutional Animal Care and Use Committee. 
Surgery   
Animals were anesthetized with a ketamine/xylazine/acepromazine (77:1.5:1.5 
mg/ml/kg; ip) cocktail and placed in a stereotaxic apparatus. 26 gauge bilateral guide 
cannulae (Plastics One; Roanoke VA) were placed 3 mm dorsal to the hypothalamic 
ventromedial nuclei (VMN) in all animals, and secured to the surface of the skull with an 
acrylic resin. The stereotaxic coordinates for the VMN injection site were:  
anterior/posterior, -2.5 mm from bregma; medial/lateral, ±0.6 mm from midline; 
dorsal/ventral, -9.2 mm from surface of the skull based on The Rat Brain in Stereotaxic 
Coordinates, 6th Edition (Paxinos and Watson 2007). Injectors extended 3 mm past the 
ventral tip of the cannulae reaching an injection site of -9.2 mm ventral from the surface 
of the skull. The upper incisor bar was positioned -3.3mm below horizontal zero. A 
bilateral dummy stylet placed in the guide cannulae was used to maintain patency. The 
animals were given at least five days to recover after cannulae installation before 
receiving drug or vehicle injections. During this time the animals were handled and guide 
cannulae were removed and replaced daily to acclimate the animals to the physical 
handling necessary during the experiment. Correct cannulae placements were confirmed 
at the conclusion of each experiment by microscopic examination of Nissl stained 
sections and only those with correct placement were included in the studies. 
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Microinjections and Injection Spread 
In all experiments, 0.25 µl/side of PACAP (PACAP38; California Peptide 
Research; Napa, CA) or saline was microinjected through bilateral guide cannulae over 
approximately two minutes in awake animals. Following each injection an additional 
minute elapsed before removing injectors to minimize backflow of injected material. At 
the completion of each experiment, brains were collected following rapid decapitation for 
in situ hybridization or confirmation of cannulae placement. The optimal spread of 
injection within the VMN was determined using different volumes (0.1, 0.25 µl) of 
biotinylated PACAP (PACAP38-Biotin; Anaspec; Fremont, CA).  One hour following 
biotinylated PACAP injections animals were anesthetized with a 
ketamine/xylazine/acepromazine cocktail, and transcardially perfused with 0.9% NaCl 
and 4% paraformaldehyde in phosphate-buffered saline. Brains were removed, sucrose 
embedded, and sectioned on a freezing microtome at 30 µm and stored in cryoprotectant 
solution at -20° C. Brain sections containing the injection sites and surrounding areas 
were then immunohistochemically stained using a primary antibody against biotin. 
Immunohistochemical signal was then compared to the cresyl violet staining of adjacent 
sections to determine surgical accuracy and the spread of the biotinylated PACAP 
injection within the VMN. 
Experiments 
Feeding behavior   
Animals (n=4 per group) were acclimated to the BioDAQ Food Intake Monitor 
for at least 7 days before the onset of the experiment. Approximately 2 hours prior to 
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lights off rats were weighed and injected bilaterally with vehicle, 25, or 50 pmol PACAP. 
Feeding measurements were collected for the next 18 hours at which time body weights 
were measured again. Afterwards, brains were collected to confirm cannula placement as 
well as retroperitoneal (including perirenal; rWAT) and epididymal white adipose tissue 
(eWAT), and interscapular brown adipose tissue (iBAT). iBAT was cleaned of white 
adipose tissue for measurement of uncoupling protein 1 (UCP1) mRNA content. 
To examine effects of PACAP on feeding behavior following an overnight fast, a 
separate cohort of animals (n=10 per group) was used. Food was removed from all 
animals just prior to lights off (1700h) the day before the experiment. The following 
morning (approximately 16 hours later) animals received bilateral injections of vehicle or 
50 pmol PACAP. 10 minutes after the injection, food was returned and feeding was 
measured for the next hour. 
Conditioned flavor avoidance  
To determine whether PACAP-induced hypophagia in the VMN was a 
consequence of malaise, a conditioned flavor avoidance (CFA) behavioral paradigm was 
used (Deutsch and Hardy 1977; Rinaman and Dzmura 2007). A baseline experiment was 
performed by water depriving naïve rats for 22 hours, and giving the animals a two-bottle 
choice test with one bottle containing novel vanilla flavored water (0.5% McCormick 
vanilla extract) and the other bottle containing novel almond flavored water (0.5% 
McCormick almond extract). For the CFA test, rats (n=5 per group) were water deprived 
for 22 hours then allowed 30 minutes of access to novel almond flavored water (0.5% 
McCormick almond extract) or novel vanilla flavored water (0.5% McCormick vanilla 
extract).  Flavors were divided among each group. Following the ingestion of flavored 
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water animals received a bilateral injection of 50 pmol PACAP into the VMN. Normal 
water was returned 30 minutes later and rats were allowed ad libitum access to water for 
the next 24 hours. Afterwards, rats were again water deprived for 22 hours then allowed 
30-minute access to the opposite flavor as on day 1 (see Fig. 3A).  Subsequent to access 
to flavored water, animals received a bilateral vehicle injection into the VMN and water 
was again returned for the next 24 hours. After both pairing days the rats were water 
deprived a final time for 22 hours followed by the test day in which rats were given a 
two-bottle choice with both flavors for 30 minutes. A preference ratio was generated 
from the test day to determine if rats avoided the flavor paired with the VMN PACAP 
injection. As a CFA positive control, another group of animals (n=5 per group) was 
included using lithium chloride (LiCl; 0.15M; 2% body weight, ip), as LiCl is well 
known to induce malaise. This group of rats was treated similar to the PACAP treated 
animals, but receiving only vehicle injections into the VMN and an ip injection of either 
saline or LiCl.  
PACAP receptor antagonism   
Approximately 1 hour before dark, rats (n=6 per group) were weighed and given a 
bilateral VMN pretreatment of either vehicle or 2.2 nmol of the specific PACAP receptor 
(PAC1R) antagonist, PACAP6-38 (Anaspec; Fremont, CA). After five minutes, rats 
received a second bilateral VMN injection of either vehicle or 220 pmol of PACAP. Food 
intake was measured manually for the next three hours, followed by a final 24-hour post-
injection measurement of food intake and body weight. 
In addition to food intake and body weight, changes in hypothalamic arcuate 
nuclei (ARC) neuropeptide mRNA expression were measured. In a similar experimental 
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design, rats (n=4 per group) received either bilateral VMN injections of vehicle or 220 
pmol PACAP and after one hour the animals were euthanized via rapid decapitation. 
Brains were removed quickly and frozen for analysis using semi-quantitative in situ 
hybridization for pro-opiomelanocortin (POMC), neuropeptide Y (NPY), and agouti-
related polypeptide (AgRP) mRNA levels. 
In Situ Hybridization 
Brains were cryostat sectioned coronally at 12 µm, thaw-mounted onto 
electrostatically clean slides, and stored at -80°C until post-fixed. Prior to hybridization, 
sections were post-fixed in 4% paraformaldehyde, rinsed in 0.1 M PBS (pH 7.4), 
equilibrated in 0.1 M triethanolamine (pH 8.0), and acetylated in triethanolamine 
containing 0.25% acetic anhydride. Sections were dehydrated through graded ethanol 
concentrations, de-lipidated in chloroform, re-hydrated to 95% ethanol, and air-dried. 
Standard in vitro transcription methods were used to generate riboprobes against PAC1R 
(Choi; Milwaukee, WI), NPY (Sabol, Bethesda, MD), AgRP (Schwartz, Seattle, WA), 
and POMC (Wilkinson, Seattle, WA), which were subsequently diluted in hybridization 
cocktail (Amresco; Solon, OH) with tRNA. Sections were hybridized overnight at 55°C 
with each 33P-labeled riboprobe.  After hybridization, slides were rinsed in 2x SSC buffer 
(pH 7.0). They were treated with RNase A in a 0.5 M sodium chloride, 10 mM Tris, 1 
mM EDTA buffer for 30 min at 37°C and then washed in the same buffer without RNase 
A for 30 min at 37°C. After a subsequent 1x SSC wash for 15 min at room temperature, 
slides were stringently washed in 0.5x SSC for 30 min at 65°C (AgRP, NPY, PAC1R) or 
68°C (POMC). Slides were then coated with Kodak autoradiographic emulsion NTB 
(Rochester, NY) and exposed for 11-22 days depending on the specific riboprobe to 
37 
produce silver grains. Following standard autoradiography development, NTB emulsion-
dipped sections were counterstained with 0.5% cresyl violet. 
Image Analysis 
Semi-quantitative analysis of silver grains was conducted using dark field 
microscopy (Axioskop-2, Zeiss; Thornwood, NY) and Axiovision image analysis 
software (Zeiss; Thornwood, NY). Optical transmission (OT) was determined from the 
integration of scattered light captured with a 5x objective and analyzed for intensity of 
region of interest and total area of reflected light. Background values measured in 
adjacent areas of tissue not containing hybridized probe were subtracted from all 
measurements.  As such, the reported units are arbitrary and will vary based on the 
proportion of the area of transmitted light compared to the background.  Since the area of 
distribution for each population of mRNA varies relative to the size of the background, 
the arbitrary units do not represent relative differences between various brain regions but 
can be used to measure changes within the same brain region.  Analyses of hypothalamic 
cell groups include the following distances posterior to Bregma: the arcuate nuclei for 
NPY and AgRP analysis: -3.1mm to -3.6mm, and POMC analysis: -2.6mm to -3.8mm. 
Immunohistochemistry 
 Floating coronal sections were incubated in primary antibody against biotin (goat 
anti-biotin; 1:5,000,000; Vector labs; Burlingame, CA) or PACAP (rabbit anti-
PACAP38; 1:10,000; Bachem; Torrance, CA) for 48 hours at 4°C. After washes in PBS 
sections were incubated in biotinylated secondary antibody (1:600; Vector labs) for 1 
hour at room temperature. Next, sections were washed again and incubated in a 
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peroxidase-based avidin/biotin solution using the Vectastain Elite ABC kit (Vector labs) 
for 1 hour at room temperature. Finally, immunohistochemical staining was visualized 
using a 3,3'-diaminobenzidine (DAB) chromogen solution containing nickel.  
Statistics 
Data are presented as means ± standard errors of the mean, and were analyzed 
statistically by analysis of variance (with repeated measures when appropriate). Tukey 
HSD analysis was used for all post-hoc group comparisons. Statistical analyses were 
performed using JMP9 (SAS Institute; Cary, NC). P values less than 0.05 were 
considered statistically significant. 
Results 
Hypothalamic PAC1R mRNA expression and microinjection spread 
Figure 2.1A shows in situ hybridization for PAC1R in the rat brain, confirming 
high  levels of mRNA expression in the hypothalamus (Hashimoto et al. 1996). Note the 
most abundant mRNA expression is found in the medial cell groups of the hypothalamus, 
which include the dorsomedial nuclei (DMN), VMN, and arcuate nuclei (ARC; Fig 2.1B 
and C).  In Figure 2.2, immunohistochemical staining of biotinylated PACAP confirmed 
that the 0.25 µl microinjection spread was an optimal volume (Fig 2.2A), as it did not 
exceed the boundaries of the VMN (right panel) delineated in the adjacent nissl stained 
section (left panel). Figure 2.2B shows PACAP immunoreactivity within the VMN of 
both neuronal cell bodies and terminals suggesting endogenous PACAP 
neurotransmission in this region. 
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Figure 2.1.  In situ hybridization of hypothalamic PAC1R mRNA 
distribution. (a) Darkfield photomicrograph (1.25X) of PAC1R 
mRNA expression in the rat. (b and c) Schematic and darkfield 
photomicrograph (5X) of region highlighted in (a) illustrating the 
dense expression of PAC1R mRNA in the medial nuclei of the 
hypothalamus. DMN = dorsomedial nuclei, VMN = ventromedial 
nuclei, ARC = arcuate nuclei, f = fornix. Anterior/Posterior coordinate 
of section depicted is -3.0 mm relative to Bregma. 
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Feeding Behavior 
 PACAP injected into the VMN decreased normal feeding as demonstrated by 
significant main effects by repeated measures ANOVA (P < 0.05; Fig. 2.3A). At three 
hours post-injection both 25 and 50 pmol doses of PACAP significantly reduced 
cumulative food intake compared to saline controls, with 25 pmol reducing feeding by  
 
 
Figure 2.2.  Ventromedial nuclei injection spread of biotinylated PACAP and endogenous PACAP 
protein immunohistochemistry. Staining for biotin-labeled PACAP (a; far right panel; scale bar = 200 
µm) accompanied by adjacent cresyl violet staining (a; far left panel) shows that spread of injectate is 
contained within the boundaries of the VMN. Schematic image corresponding to the level of 
injection site is shown in the middle panel (a). PACAP immunoreactivity in the VMN is shown at 
low magnification (b; middle panel), with a left inset (b; far left panel) showing terminal labeling in 
the VMN (white arrows), and the right inset (b; far right panel) showing neuronal cell body 
immunoreactivity (white arrows). Anterior/posterior coordinate of section depicted is -2.76 mm 
relative to Bregma.  Scale bar = 30 µm. 
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52% (P < 0.05) and 50 pmol by 80% (P < 0.01).  Furthermore, the 50 pmol dose of 
PACAP continued to significantly decrease cumulative food intake at four hours (P < 
0.05) and six hours post-injection (P < 0.01).  18 hours after injections no significant 
 
Figure 2.3.  PACAP injections into the VMN dose dependently decrease feeding behavior and 
retroperitoneal white adipose tissue (rWAT). (a) Both 25 pmol and 50 pmol bilateral PACAP 
injections  (0.25 µl/side) result in significantly reduced cumulative food intake after three hours, 
while the effect of 50 pmol PACAP lasts for six hours post-injection. (b) PACAP injections 
specifically reduce rWAT mass after 18 hours. (c) 50 pmol PACAP reduces refeeding (1 hour after 
PACAP administration ) in animals following an overnight fast. Data are expressed as mean ± 
SEM, * = P < 0.05 compared to vehicle. 
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differences were observed across any groups for food intake, but fat pad analysis revealed 
significant reduction in rWAT weight in animals receiving bilateral 50 pmol PACAP 
infusion (P < 0.05; Fig. 2.3B). No significant changes in eWAT or iBAT weights were 
found.  
 PACAP also significantly reduced food intake following an overnight fast. 
Bilateral VMN-injected PACAP at a dose of 50 pmol decreased food intake compared to 
saline controls after one hour of refeeding during the light cycle (P < 0.05; Fig. 2.3C). 
 
 
 PACAP receptor antagonism 
Specific antagonism of PAC1R prior to injection of PACAP completely blocked 
PACAP-induced decreases in food intake and body weight. Rats received a bilateral 
pretreatment of saline or PACAP6-38 approximately five minutes prior to bilateral saline 
or PACAP injections into the VMN. Significant main effects were observed by repeated  
 
 
Figure 2.4.  PACAP effects on feeding are mediated by the PAC1 receptor. (a) PACAP-induced 
hypophagia (220 pmol), and (b) body weight loss (24 hours) are prevented by the PAC1R 
antagonist, PACAP6-38 (2.2 nmol). Data are expressed as mean ± SEM, * = P < 0.05 compared 
to vehicle.  
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measures ANOVA for food intake (P < 0.05; Fig. 2.4A). Animals receiving vehicle as a 
pretreatment prior to PACAP showed significantly reduced food intake compared to 
vehicle controls with a reduction in food intake by 85% (P < 0.05) over the first hour, 
76% (P < 0.05) over two hours, and 79% (P < 0.01) over three hours. Food intake levels 
in animals receiving pretreatment with PACAP6-38 prior to PACAP did not differ from 
vehicle controls. Body weight measurements 24 hours after injections showed a 
Figure 2.5.  Hypothalamic PACAP injections do not produce 
conditioned flavor avoidance. (a) Schematic of the conditioned flavor 
avoidance behavioral paradigm shows the procedural timeline of the 
experiment. (b) Preference ratios expressed as mean ± SEM for PACAP 
(50 pmol) and LiCl (0.15 M; 2% body weight, ip) treated animals show a 
clear avoidance of the LiCl-paired flavor, but not the PACAP-paired 
flavor.  There was no difference in baseline intake of either flavor.  * = 
P<0.01 compared to saline-paired flavor. 
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significant decrease in the vehicle/PACAP group compared to all other groups (P < 0.05; 
Fig. 2.4B).   
Conditioned flavor avoidance 
Baseline consumption of the two novel flavors were tested by giving water 
deprived naïve rats a two-bottle choice test for 30 minutes, and measuring intake of both 
almond and vanilla flavored water. There was no difference in intake volumes of the two 
flavors in the baseline experiment (52% almond, 48% vanilla; Fig. 2.5A). In the 
conditioned flavor avoidance experiment (CFA) bilateral infusion of 50 pmol PACAP on 
pairing day one was evenly distributed between the two flavors. Furthermore, intake 
volumes on both pairing days were measured, and rats drank at least 13 ml of flavored 
water on each pairing day demonstrating that every animal experienced both flavors prior 
to the test day. PACAP had no effect on the two-flavor choice test, with animals drinking 
similar volumes of both the PACAP-paired and vehicle-paired flavor (Fig. 2.5B). As a 
positive control, a separate group of animals receiving ip injections of LiCl showed 
significant avoidance of the LiCl-paired flavor compared to saline treated controls 
(P<0.01; Fig 2.5B). 
Neuropeptide mRNA expression changes 
Semi-quantitative in situ hybridization analyses of AgRP, NPY, and POMC 
mRNA in the hypothalamic arcuate nuclei following bilateral PACAP injections into the 
VMN were performed at one hour post-injection (Fig 2.6A). Quantification of the in situ     
hybridization revealed a significant increase in arcuate POMC mRNA expression by 52%  
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Figure 2.6.  In situ hybridization of hypothalamic arcuate nuclei neuropeptide mRNA 
expression levels following PACAP injection into the VMN. (a) Representative darkfield 
photomicrographs showing mRNA expression levels of POMC, NPY, and AgRP in the ARC 
from vehicle treated (left side of photo) and PACAP treated (220 pmol; right side of photo) 
animals. (b) Graphical representation of optical transmission from in situ hybridization signal 
for each neuropeptide. Data are expressed as mean ± SEM, * = P < 0.05 compared to vehicle. 
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(P < 0.05; Fig. 2.6B), while no significant differences were observed in either arcuate 
AgRP or NPY mRNA expression. 
Discussion 
Bilateral injections of PACAP into the VMN produce a marked reduction in 
feeding under both normal and food restricted conditions. Importantly, this reduction in 
feeding is not the result of malaise induced by PACAP administration, as there was no 
evidence of conditioned flavor avoidance. To diminish potential confounding 
contributions of PAC1R stimulation in surrounding hypothalamic cell groups, we made 
efforts to confine our PACAP injections within the boundaries of the VMN, which was 
clearly demonstrated by the biotinylated PACAP. 
Under normal feeding conditions, injections of either 25 pmol or 50 pmol PACAP 
per side into the VMN significantly decreased in cumulative feeding by three hours post-
injection, and lasting for up to six hours post-injection in animals receiving the higher 
dose of PACAP. The delayed effect on feeding behavior may be a result of injections 
administered approximately two hours prior to lights off, a time when normal food intake 
is still considerably low suggesting that PACAP-induced suppression of feeding behavior 
occurs when endogenous feeding behavior is actively stimulated.  This is further 
supported by results following an overnight fast, where PACAP injections effectively 
reduced feeding in food-deprived animals one hour post-injection, as well as in the 
PACAP receptor antagonist study where animals injected with PACAP more proximal to 
the onset of dark did significantly reduce feeding after one hour. In addition to 
influencing feeding behavior, we also observed a significant reduction in rWAT weight at 
18 hours post-injection with no differences in any of the other fat depots measured. While 
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the reduction in only rWAT is curious and the underlying mechanism still unknown, 
others have also found rWAT to be more labile during conditions of mild/moderate 
weight loss (Giordano et al. 2005; Li et al. 1998).  
Results obtained following PACAP injections into the VMN closely resemble 
reports of ventricular PACAP injections (Hawke et al. 2009; Morley et al. 1992; Mounien 
et al. 2009), which suggests that the medial hypothalamus may be an important site for 
PACAP signaling pertaining to energy homeostasis. This is further supported by the 
dense expression of PAC1R mRNA found in multiple subdivisions of the medial 
hypothalamus such as the dorsomedial (DMN), arcuate (ARC), and VMN, all of which 
are major contributors to the control of energy balance (Fig. 2.1).  Although resulting in 
different patterns in feeding behavior, lesions of all three hypothalamic subgroups 
produce obese rats (Choi and Dallman 1999). To begin identifying the circuitry involving 
PACAP signaling and energy regulation, we demonstrate that changes in feeding 
behavior following PACAP administration into the VMN are specifically mediated 
through the PAC1R. In addition, while our chosen dose of PAC1R antagonist did not 
produce significant differences in feeding from vehicle treated controls, food intake was 
elevated in these animals suggesting that a higher dose of PACAP6-38 may have 
produced a significant increase. Changing the timing of PAC1R antagonist injections to a 
period of minimal feeding behavior would aid in making conclusions about the role of 
endogenous PACAP signaling in the VMN and feeding behavior. As an initial point of 
observation, the VMN may function as an important, but not exclusive, site of action for 
mediating the behavioral effects of PACAP signaling.  For example, PACAP’s actions in 
the hypothalamus may also include direct or indirect activation of feeding and/or 
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metabolic circuitries involving other hypothalamic cell groups such as the PVN and 
ARC. As mentioned earlier, both the PVN and ARC have prominent roles in regulating 
energy balance and are both known to contain both PACAP receptors and PACAP 
protein, making these areas attractive targets for future studies.   
Previous reports have suggested PACAP-induced hypophagia following icv 
injection in mice may stimulate melanocortin signaling in the ARC, a well characterized 
system known to decrease feeding behavior (Mounien et al. 2009). Indeed, PACAP 
receptors have been found on both POMC and NPY containing neurons in the ARC 
through which activation leads to stimulation of POMC mRNA, c-fos expression and 
cytosolic Ca2+ concentrations (Mounien et al. 2006a; Mounien et al. 2006b; Mounien et 
al. 2009; Nakata et al. 2004).  However, the current results demonstrate that bilateral 
injections of PACAP directly into the VMN also increase mRNA expression of POMC in 
the ARC one hour after injection without affecting NPY or AgRP expression. Since the 
vast majority of neurons in the VMN are glutamatergic (Fu and van den Pol 2008), 
activation of PACAP receptors in the VMN could have an excitatory effect on VMN 
neurons through modulation of AMPA and NMDA currents, as seen in the hippocampus 
(Costa et al. 2009; Macdonald et al. 2005; Yaka et al. 2003), leading to VMN-mediated 
excitation of POMC neurons in the ARC (Sternson et al. 2005). Additionally, strong 
efferent connections from the VMN to the nucleus of the solitary tract (NTS) have been 
established, and it is possible that stimulation of the VMN by PACAP may cause 
increased POMC signaling in the NTS as well (Canteras et al. 1994). In support of the 
current data, increased POMC signaling in the NTS has also been associated with 
inhibition of food intake (Li et al. 2007; Zhang et al. 2010).  
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While there has been evidence for PACAP stimulation of NPY neurons in the 
ARC (Mounien et al. 2006a; Nakata et al. 2004), our data did not demonstrate any effect 
at one hour post-injection, possibly arguing for POMC-specific ARC activation by 
PAC1R expressing neurons from the VMN (Sternson et al. 2005).  Given the initial 
constellation of effects produced by icv or ex vivo application of PACAP such as 
hypophagia, thermogenesis, increased POMC and NPY signaling, further studies are 
needed to delineate PACAP’s integrated actions on multiple hypothalamic cell groups 
(Masuo et al. 1995; Mounien et al. 2009; Nakata et al. 2004; Resch et al. 2011). 
Although the VMN is known to express large amounts of PACAP, which appear 
to be responsive to varying nutritional conditions (Hawke et al. 2009; Mounien et al. 
2009), the origin of PACAP neurons synapsing onto VMN neurons is not known. In light 
of the current results, brain regions releasing PACAP into the medial hypothalamus that 
are sensitive to signals of nutritional status are likely sources of PACAP input into the 
VMN. One such candidate is the medial amygdala because of its dense PACAP mRNA 
expression, identified connections to the VMN, and its glucose sensing capability (Anand 
et al. 1964; King 2006a; Sakaguchi and Bray 1987; Sudo et al. 1991; Zhou et al. 2010). 
In addition to extra-hypothalamic regions of PACAP input, paracrine/autocrine signaling 
from VMN neurons themselves may also provide a notable source of PACAP signaling, 
especially since the VMN are well known to have extensive intrinsic and contralateral 
VMN-VMN synaptic circuitry (Kiss et al. 2011; Nishizuka and Pfaff 1989). Further 
anatomical studies are needed to identify hypothalamic circuitry involving PACAP 
signaling. 
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CHAPTER III 
 
MULTIPLE SITES OF ACTION FOR PACAP-INDUCED HYPOPHAGIA IN THE 
HYPOTHALAMUS: FOCUS ON GLUTAMATERGIC CELL GROUPS 
 
 
Introduction 
 
 
Pituitary adenylate cyclase-activating polypeptide (PACAP) is a key regulator of 
several hypothalamic systems, including stress (Agarwal et al. 2005), osmoregulation 
(Gillard et al. 2006), thermoregulation (Gray et al. 2002), and body weight (Hawke et al. 
2009). PACAP was first discovered to influence energy homeostasis through inhibition of 
feeding in mice following a single intracerebroventricular (icv) injection of the peptide 
(Morley et al. 1992). These results combined with reports of diet-specific alterations of 
PACAP mRNA expression in the hypothalamic ventromedial nuclei (VMN) suggest that 
PACAP neurons are responsive to nutritional status and directly tied to the regulation of 
feeding (Hawke et al. 2009; Mounien et al. 2009).  
As a ligand, PACAP binds to three different G protein-coupled receptors (GPCR), 
the PAC1 receptor (PAC1R), and the receptors originally discovered as targets of 
vasoactive intestinal polypeptide (VIP), VPAC1R and VPAC2R (Dickson and Finlayson 
2009). Although PACAP stimulates all three receptor subtypes it has the highest affinity 
for the PAC1R, whereas VIP is less likely to utilize the PAC1R due to its low binding 
affinity compared to the VPACRs (Gottschall et al. 1990; Lam et al. 1990).  
Due to the limited availability of conditional PACAP transgenic models, site-
specific injections of PACAP and related pharmacological agents directly into discrete 
hypothalamic nuclei are necessary to selectively investigate the role of PACAP signaling 
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within the hypothalamus. Recently, we reported that site-specific injections of PACAP 
isolated to the VMN reduce food intake via PAC1R signaling (Resch et al. 2011). Despite 
abundant PACAP receptor expression in several different hypothalamic nuclei, little 
attention has been given to other hypothalamic cell groups with regard to PACAP’s 
effects on food intake and body weight. In the few studies that have examined PACAP 
signaling in the hypothalamus, the paraventricular nuclei (PVN) are reported to show 
PACAP terminal immunoreactivity (Das et al. 2007; Legradi et al. 1998), and following 
direct administration of PACAP into the PVN changes in grooming behavior (Norrholm 
et al. 2005) and hepatic glucose production (Yi et al. 2010). However, these studies did 
not report on PACAP-induced changes in feeding or body weight.  Given that PVN 
lesion studies demonstrate an imperative role for this area of the hypothalamus in the 
regulation of energy balance (Leibowitz et al. 1981), and both the PVN and PACAP have 
been linked to melanocortin signaling involved in control of body weight (Balthasar et al. 
2005; Mounien et al. 2009), further examination of the relationship between PACAP 
signaling and PVN-mediated energy homeostasis is warranted. In order to examine the 
effects of PACAP signaling in the hypothalamus on food intake we have executed site-
specific PACAP injections in two separate hypothalamic nuclei, the PVN and VMN.  
Materials and Methods 
Animals 
Male Sprague-Dawley rats (Harlan; Madison, WI) weighing 225-250 g were 
individually housed in a climate controlled room with a 12 hr light/dark cycle. Animals 
had free access to Harlan standard diet (8604 formulation) and water. Food consumption 
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was measured with a BioDAQ Food Intake Monitor (Research Diets; New Brunswick, 
NJ) or calculated by pre-weighing food in each bin and subtracting the weight of non-
ingested and spilled food at the end of each measurement period. All procedures using 
animals were approved by the Marquette University Institutional Animal Care and Use 
Committee. 
Surgery   
Animals were anesthetized with a ketamine/xylazine/acepromazine (77:1.5:1.5 
mg/ml/kg; ip) cocktail and placed in a stereotaxic apparatus. 26 gauge bilateral guide 
cannulae (Plastics One; Roanoke VA) were placed 3 mm dorsal to the target site in all 
animals, and secured to the surface of the skull with an acrylic resin. The stereotaxic 
coordinates for the PVN injection site were anterior/posterior, -1.7 mm from bregma; 
medial/lateral, ±0.5 mm from midline; dorsal/ventral, -4.9 mm, and for the VMN 
anterior/posterior, -2.5 mm from bregma; medial/lateral, ±0.6 mm from midline; 
dorsal/ventral, -6.2 mm from surface of the skull based on The Rat Brain in Stereotaxic 
Coordinates, 6th Edition (Paxinos and Watson 2007). Injectors extended 3 mm past the 
ventral tip of the cannulae reaching an injection site of -7.9 mm for PVN and -9.2 mm for 
VMN ventral from the surface of the skull. The upper incisor bar was positioned -3.3 mm 
below horizontal zero. A bilateral dummy stylet placed in the guide cannulae was used to 
maintain patency. The animals were given at least five days to recover after cannula 
installation before receiving drug or vehicle injections during which time the animals 
were handled and dummy stylets were removed and replaced daily in order to acclimate 
the animals to the physical handling necessary during experiments. Correct cannulae 
placements were confirmed at the conclusion of each experiment by microscopic 
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examination of Nissl stained sections and only those with correct placement were 
included in the studies. 
Microinjections and Injection Spread 
In all experiments, PACAP  (50 pmol/0.25 µl/side; PACAP38; California Peptide 
Research; Napa, CA), PACAP6-38 (500 pmol/0.25 µl/side; Anaspec; Fremont, CA), 
VIP6-28 (500 pmol/0.25 µl/side; Bachem; Torrance, CA), or saline vehicle was 
microinjected through bilateral guide cannulae over approximately two minutes in awake 
animals while gently restrained. Following each injection an additional minute elapsed 
before removing injectors to minimize backflow of injected material. The optimal 
injection volume and subsequent spread within the VMN was determined previously 
(Resch et al. 2011), and the same procedure was used for PVN injection spread analysis. 
Briefly, biotinylated PACAP (50 pmol/0.25 µl/side; PACAP38-Biotin; Anaspec; 
Fremont, CA) was injected into the PVN or VMN.  One hour following biotinylated 
PACAP injections animals were perfused with 0.9% NaCl and 4% paraformaldehyde in 
phosphate-buffered saline, and brains were removed. Brain sections containing the 
injection sites and surrounding areas were then immunohistochemically stained using a 
primary antibody against biotin. Immunohistochemical signal was then compared to the 
cresyl violet staining of adjacent sections to determine surgical accuracy and the spread 
of the biotinylated PACAP injection within the target injection site. 
Feeding Behavior 
Animals were weighed daily and acclimated to the BioDAQ Food Intake Monitor 
for at least 7 days before the onset of the experiment. On the experiment day, 
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approximately 1 hour prior to lights off rats were injected bilaterally with vehicle or 50 
pmol PACAP. Feeding measurements were collected for the next 24 hours, as well as a 
final measurement of body weight at 24 hours post-injection. For BioDAQ meal pattern 
analysis the data were analyzed over the first six hours post-injection to determine 
latency to meal onset, meal amount, duration, and eating rate. Meals were defined as food 
intake of 0.2 g or more with less than 15 minutes elapsing between feeding bouts (Dunn-
Meynell et al. 2009; Farley et al. 2003). For studies involving antagonism of PACAP 
receptors, rats were bilaterally pretreated with saline, PACAP6-38  (500 pmol/0.25 
µl/side; Anaspec; Fremont, CA), or VIP6-28 (500 pmol/0.25 µl/side; Bachem; Torrance, 
CA).  PACAP6-38 is a widely used PAC1R antagonist however it also has antagonistic 
properties at the VPAC2R (Gourlet et al. 1995; Hawke et al. 2009; Mounien et al. 2009; 
Robberecht et al. 1992), while VIP6-28 is reported to be a potent nonselective VPAC 
receptor antagonist (Fishbein et al. 1994; Mohney and Zigmond 1998; Shoge et al. 1998) 
shown to be effective in the hypothalamus (Hermes et al. 2009). Five minutes after 
administering the antagonist rats received a second bilateral injection of either saline or 
50 pmol of PACAP followed by subsequent physiological and behavioral measurements.  
In Situ Hybridization 
Brains were sectioned coronally at 12 µm using a cryostat, thaw-mounted onto 
electrostatically clean slides, and stored at -80°C until post-fixed. Prior to hybridization, 
sections were post-fixed in 4% paraformaldehyde, rinsed in 0.1 M PBS (pH 7.4), 
equilibrated in 0.1 M triethanolamine (pH 8.0), and acetylated in triethanolamine 
containing 0.25% acetic anhydride. Standard in vitro transcription methods were used to 
generate both sense and antisense riboprobes recognizing VPAC2R and PAC1R 
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transcripts (Choi; Milwaukee, WI), which were subsequently diluted in hybridization 
cocktail (Amresco; Solon, OH) with tRNA. Sections were hybridized overnight at 55°C 
with either digoxigenin (DIG) or fluorescein isothiocyanate (FITC) labeled riboprobes.  
After hybridization, slides were treated with RNase A, and stringently washed in 0.5x 
SSC at 65°C (VPAC2R and PAC1R) for 30 minutes. Slides were then incubated with an 
antibody against DIG or FITC conjugated to horseradish peroxidase (HRP; Roche; 
Indianapolis, IN) overnight at 4° C. Riboprobe signal was further enhanced using the 
TSA-plus fluorophore system with either fluorescein or Cy3 (Perkin Elmer; Waltham, 
MA). Image capture was performed using fluorescent microscopy (Axioskop-2, Zeiss; 
Thornwood, NY) and Axiovision image analysis software (Zeiss; Thornwood, NY). 
Biotinylated PACAP injection spread was visualized following standard free-
floating immunohistochemical techniques. Floating coronal sections were incubated in 
primary antibody against biotin for 24 hours at 4°C. After washing in PBS, sections were 
incubated in biotinylated secondary antibody (Vector labs; Burlingame, CA) for 1 hour at 
room temperature. Following a second wash, sections were incubated in a peroxidase-
based avidin/biotin solution using the Vectastain Elite ABC kit (Vector labs; Burlingame, 
CA) for 1 hour at room temperature. Immunohistochemical staining was visualized using 
a nickel enhanced 3,3'-diaminobenzidine (DAB) chromogen solution.  
Statistics 
Data are presented as means ± standard errors of the mean, and were analyzed 
statistically by analysis of variance (with repeated measures when appropriate). Fischer 
LSD analysis was used for all post-hoc group comparisons. Statistical analyses were 
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performed using Sigma Plot 11 software (Systat Software Inc.; San Jose, CA). P < 0.05 
were considered statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results  
 To assess diffusion of PACAP microinjections into our target nuclei we injected a 
biotinylated PACAP peptide to simulate behavioral experiments followed by histological 
analysis of injection sites. Following immunohistochemical detection of the biotinylated 
PACAP (Fig. 3.1) we confirmed that peptide injection volumes were appropriate and did 
not diffuse outside of the borders of the PVN or VMN. Our prior studies have indicated 
that bilateral PACAP injections of 50 pmol into the VMN significantly decreased food  
 
Figure 3.1.  Injection spread of biotin-labeled PACAP within the PVN and 
VMN. Staining for biotin-labeled PACAP (far right panel) accompanied by 
adjacent cresyl violet staining (far left panel) shows that spread of injectate is 
contained within the boundaries of the PVN (A; Bregma -1.8 mm) or VMN (B; 
Bregma -3.0 mm). Schematic image corresponding to the level of injection site 
is shown in the middle panel adapted from The Rat Brain in Stereotaxic 
Coordinates 6th Edition (Paxinos and Watson 2007). PVN, paraventricular 
nuclei; AHA, anterior hypothalamic area; VMN, ventromedial nuclei  
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intake (Resch et al. 2011), but the effects of PACAP injections into the PVN on food 
intake had yet to be reported. We performed feeding behavior experiments under free-
feeding conditions starting at approximately 1 hour prior to lights off following saline or 
PACAP injections into the PVN and compared subsequent responses to PACAP-induced 
 
 
Figure 3.2.  PACAP injections into the PVN and VMN both decrease feeding behavior and 
body weight. 50 pmol bilateral PACAP injections (0.25 µl/side) into the PVN (A) or VMN (B) 
result in significantly reduced cumulative food intake at 3 and 5 hours post-injection (left), 
accompanied by a reduction in body weight 24 hours later (right). Data are expressed as mean 
± SEM, * = P < 0.05 compared to saline. 
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hypophagia in the VMN. Feeding behavior in both PVN and VMN animals treated with 
PACAP showed significant main effects by two-factor repeated measures ANOVA  
(treatment P < 0.01; time P < 0.001; interaction P < 0.05). Multiple comparison analysis 
performed at 1, 3, and 5 hours post-injection resulted in significant differences at 3 (PVN,  
P < 0.001; VMN, P < 0.01) and 5 hours (PVN, P < 0.001; VMN, P < 0.001) compared to 
controls (Fig 3.2). Body weight following the injection day was also significantly 
decreased (Fig. 3.2) with PVN-PACAP treated animals losing 3% (P < 0.001) and VMN-
PACAP treated animals losing 2 % (P < 0.05) of their pre-injection body weight 
compared to saline injections which left body weight unchanged. 
 
Table 3.1. Meal pattern analysis following PACAP treatment in the PVN and VMN 
 PVN VMN 
  Saline PACAP Saline PACAP 
Latency to 1st meal (min) 47.9 ± 12.8   105.9 ± 25.1*     29.6 ±  6.8     89.3 ± 27.5* 
Latency to 2nd meal (min)     93.9 ± 13.1     75.6 ± 15.6     62.8 ± 10.1     60.2 ± 11.6 
Duration of 1st meal (min)      42.6 ±  7.6     14.5 ±   4.0*     37.4 ±  5.8     48.8 ±   7.1 
Duration of 2nd meal (min)     31.9 ±  4.8     15.4 ±   1.8*     28.8 ±  4.5     22.9 ±   3.6 
Amount of 1st meal (g)       2.8 ±  0.7       1.0 ±   0.2*       2.8 ±  0.4       2.1 ±   0.3 
Amount of 2nd meal (g)       3.0 ±  0.4       1.4 ±   0.3*       3.1 ±  0.5       2.5 ±  0.5 
Average meal size (g)       3.1 ±  0.3       1.5 ±  0.2*       2.8 ±  0.2       2.3 ±  0.3 
Meal Frequency       2.6 ±  0.2       2.5 ±  0.4       3.7 ±  0.3       3.3 ±  0.3 
Total time spent eating (min)     91.2 ±  8.4     56.3 ± 14.5*   107.2 ±  6.9   104.6 ± 10.6 
% of total time spent eating     25.3 ±  2.3     15.6 ±   4.0*     30.5 ±  1.7     29.1 ±  3.0 
Rate of eating (mg/min)     22.0 ±  1.8     13.1 ±   2.7*     27.6 ±  1.1     21.0 ±  2.2* 
24 hr intake (g)     19.4 ±  1.2     16.9 ±   1.0     21.7 ±  0.8     19.3 ±  1.1 
Meal patterns were analyzed for six hour post-injection. Data are mean ± SEM. * = P < 0.05 
compared to appropriate anatomical control 
  
 In order to better characterize the hypophagia produced by hypothalamic PACAP 
signaling we evaluated meal patterns from the experiment shown in Figure 3.2 (Table 
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3.1). PVN injections of PACAP significantly decreased meal size (1st meal, P < 0.05; 2nd 
meal, P < 0.01), meal duration (1st meal, P < 0.01; 2nd meal, P < 0.01), average meal size 
(P < 0.01), time spent eating (total time, P < 0.05; % time, P < 0.05), and rate of eating (P 
< 0.01), while also increasing the time it took to initiate the first meal (1st meal, P < 0.05; 
2nd meal, P = 0.375). In contrast, PACAP administration into the VMN only produced a 
decrease in the rate of eating (P < 0.05), and increased the latency to initiate the first meal 
(1st meal, P < 0.05; 2nd meal, P = 0.863). While PACAP treated animals ate less, neither 
PVN nor VMN injected animals showed significantly altered 24-hour intake.  
 
 
The diversity of effects that PACAP produces physiologically and behaviorally 
may be due to its multiple receptor subtypes, and the anatomical distribution of specific 
receptor expression. Fluorescent in situ hybridization revealed that the VPAC2R and  
 
Figure 3.3.  In situ hybridization of hypothalamic PACAP receptor mRNA. mRNA expression of the 
VPAC2R (middle panel) and PAC1R (far right panel) in the hypothalamic paraventricular (A; 
Bregma -1.8 mm), and ventro/dorsomedial nuclei (B; Bregma -3.0 mm) accompanied by adjacent 
sections stained with cresyl violet depicting the corresponding hypothalamic anatomy in the far left 
panel. 
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PAC1R in the hypothalamus each have distinctive expression patterns (Fig. 3.3). 
VPAC2R mRNA expression was abundant in the central dorsomedial nuclei (DMN) and 
the medial PVN, while VPAC2R expression in the VMN was not detected. On the other 
hand, PAC1R mRNA expression was much more widely distributed, with abundant 
expression found throughout the hypothalamic nuclei, including PVN, DMN, VMN, and 
 
Figure 3.4.  PACAP effects on feeding are mediated by PAC1R in both the PVN and VMN. In both 
the PVN (A) and VMN (B), PACAP-induced hypophagia (50 pmol/side) is prevented by the 
PAC1R antagonist, PACAP6-38 (500 pmol/side; right), but not the VPACR antagonist VIP6-28 
(500 pmol/side, left). Data are expressed as mean ± SEM, * = P < 0.05 compared to saline.  
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ARC nuclei. Furthermore, the wide distribution of PAC1R mRNA expression may 
represent expression in both glial and neuronal cell types (Figiel and Engele 2000). 
Hybridization with sense probes to control for nonspecific binding did not show any 
signal for either receptor probe (data not shown). 
 Due to the expression of multiple PACAP receptors in the hypothalamus, we 
assessed the involvement of PAC1 and VPAC receptors in the regulation of feeding 
behavior by administering receptor antagonists prior to PACAP injections. Pretreatment 
with VIP6-28 did not alter the suppression of feeding behavior produced by PACAP in 
either the PVN or VMN compared to controls (Fig. 3.4). However, administration of 
PACAP6-38 completely reversed the effects of PACAP administration into the PVN at 
both 3 (P < 0.05) and 5 hr (P < 0.01) time points (Fig 3.4A). Similarly, pre-treatment with 
PACAP6-38 blocked the effects of PACAP administration into the VMN at both 3 (P < 
0.05) and 5 hrs (P < 0.001) post-injection (fig 3.4B).  
Discussion 
The current study demonstrates that site-specific PACAP injections into either the 
ventromedial (VMN) or paraventricular nuclei (PVN) of the hypothalamus both produce 
long-lasting reductions in food intake, as well as changes in meal patterns, altered 
glucose homeostasis, and significant body weight loss 24 hours post-injection. 
Importantly, site-specific hypothalamic injections do not cause malaise (Resch et al. 
2011) that can sometimes arise following exogenous peptide administration. Although 
there are multiple PACAP receptor subtypes expressed in the hypothalamus, the 
reduction in feeding behavior appears to be mediated primarily by the PAC1R subtype 
which is in agreement with prior feeding studies (Hawke et al. 2009; Mounien et al. 
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2009; Resch et al. 2011).  Specifically, in both the PVN and VMN, the effects of PACAP 
could be blocked by the VPAC2R/PAC1R antagonist PACAP6-38, but not by the 
VPAC1R/VPAC2R antagonist VIP6-28.  
To specifically address the impact of PACAP signaling on feeding behavior we 
placed site-specific microinjections of PACAP into both the PVN and VMN, which 
produced significant reductions in feeding.  However, there were differences in PACAP-
mediated meal pattern changes in the PVN versus the VMN. PACAP injected into the 
PVN produced several alterations in meal patterns, including increased latency to meal 
initiation, decreased meal size, decreased meal duration, decreased time spent eating, and 
decreased rate of eating. In contrast, PACAP injected into the VMN only produced an 
increase in the latency to meal initiation, and a decrease in the rate of eating. Taken 
together with the cumulative food intake data, PACAP’s functional role in the PVN may 
be more specific to the regulation of feeding behavior compared to its actions in the 
VMN. These results are consistent with loss of function studies involving the PVN and 
VMN where there is a pronounced hyperphagia in PVN-lesioned animals, while loss of 
function following VMN-lesions produces a more modest hyperphagia often restricted to 
the light period (Choi and Dallman 1999). In light of the current data, combined with 
anatomical and biochemical reports involving PACAP, stress, and the hypothalamus 
(Agarwal et al. 2005; Choi et al. 1996; Dore et al. 2013; Hammack et al. 2010) it is 
plausible that central stress pathways may play a substantial role in the anorectic response 
caused by PACAP within these hypothalamic nuclei. Further investigation of stress and 
satiety mechanisms utilizing PACAP signaling will be important to the understanding of 
the role of this pleiotropic neuropeptide.  
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Due to the heterogeneous PACAP receptor population in the hypothalamus, and 
in particular the PVN, it was necessary to determine which PACAP receptor subtype 
mediated the effects on food intake. The most abundant and widely distributed PACAP 
receptor in the hypothalamus is the PAC1R, with high mRNA expression in all 
hypothalamic mediobasal cell groups. There is little evidence for any appreciable 
expression of VPAC1R mRNA in the hypothalamus, however the VPAC2R is expressed 
in several hypothalamic areas including the suprachiasmatic nuclei (SCN), PVN, and 
dorsomedial nuclei (DMN) (Usdin et al. 1994). Expression of multiple PACAP receptor 
subtypes in the hypothalamus suggests PACAP is a multifunctional neuropeptide signal 
that contributes to several behavioral and physiological systems. Feasibility of this 
concept is supported by reports linking PACAP to stress (Ressler et al. 2011), anxiety 
(Hammack et al. 2009), feeding (Hawke et al. 2009; Mounien et al. 2009; Resch et al. 
2011), and glucose mobilization (Yi et al. 2010), all systems that may work 
synergistically, and converge on PACAP-enriched anatomical areas, such as the 
hypothalamus and amygdala (Hannibal et al. 1995a).  
We examined both the VPAC2R/PAC1R antagonist PACAP6-38 and the 
VPAC1R/VPAC2R antagonist VIP6-28 (Fishbein et al. 1994) on their ability to inhibit 
the affects of PACAP on feeding. Even though there is no data to support VPAC1R 
expression in the hypothalamus, we used VIP6-28 to antagonize both the VPAC1R and 
VPAC2R subtypes to fully eliminate the participation of the VPAC receptors (Usdin et 
al. 1994). Furthermore, because PACAP6-38 has antagonistic activity at the VPAC2 
receptor, VIP6-28 was utilized to rule out possible contributions of VPAC2R antagonism 
by PACAP6-38. Our findings were clear that, in both the PVN and VMN, pretreatment 
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with PACAP6-38 prior to PACAP injection completely abolished the effects of PACAP 
on feeding. While we had reported previously that the PAC1R was important for the 
feeding phenotype observed following PACAP injection into the VMN (Resch et al. 
2011), it is worthy to note that VIP6-28 did not alter the effects of PACAP in the PVN on 
feeding behavior despite recent reports demonstrating the importance of PVN VPAC2Rs 
for the regulation of PACAP-induced hepatic glucose production (Yi et al. 2010). 
Additionally, PAC1R antagonist treatment alone caused increased feeding in the PVN, 
however the results were not significant, which suggests a dose-response of PACAP6-38 
at higher concentrations may result in significantly increased food intake and provide 
stronger evidence for endogenous PACAP signaling. Taken together there may be 
anatomical and receptor specific roles for PACAP in the PVN with PAC1R governing the 
feeding behavior response, while VPAC2R may govern the sympathetic-driven glycemic 
response to PACAP.  
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CHAPTER IV 
 
 
SITE-SPECIFIC ACTIVATION OF ENERGY EXPENDITURE WITHIN THE 
HYPOTHALAMUS BY PACAP 
 
 
Introduction 
 
 
  PACAP signaling is an important regulator of feeding behavior (Chance et al. 
1995; Hawke et al. 2009; Morley et al. 1992; Mounien et al. 2009; Resch et al. 2011; 
Resch et al. 2013). Yet, pair-feeding experiments demonstrate that body weight loss from 
PACAP injections is not solely due to decreased food intake, suggesting that PACAP 
may also increase energy expenditure (Hawke et al. 2009). In fact, icv injections of 
PACAP increase core body temperature, oxygen consumption, and locomotor activity 
(Hawke et al. 2009; Masuo et al. 1995; Mizuno et al. 1998), as well as increases in 
sympathetic nerve activity and heart rate (Tanida et al. 2010).  
In contrast to pharmacological data, PACAP knockout mice are not metabolically 
insufficient nor are they overweight. Instead, PACAP and PAC1R knockout mice are 
lean, temperature sensitive, and have impaired glucose homeostasis (Adams et al. 2008; 
Gray et al. 2002; Hamelink et al. 2002; Jamen et al. 2000; Tomimoto et al. 2008). Given 
the disparity between phenotypes of PACAP knockout mice and pharmacological data 
from central injections, and reports of PACAP and PAC1R knockout mice exhibiting 
complications that result in early lethality (Gray et al. 2001; Otto et al. 2004), a more 
specific approach to investigate the regulation of metabolism by PACAP is needed.  
 PACAP and PAC1R expression is abundant in the hypothalamus (Hannibal 2002; 
Hannibal et al. 1995a; Hashimoto et al. 1996; Resch et al. 2011; Resch et al. 2013), and 
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PACAP signaling exerts control over the autonomic nervous system in order to regulate 
glycemia and metabolism.  Recently we reported that intrahypothalamic injection of 
PACAP into the PVN or VMN reduces food intake and body weight (Resch et al. 2011; 
Resch et al. 2013), however each of these nuclei are also involved in regulation of energy 
expenditure and glucose homeostasis.  The VMN are particularly important for the 
counterregulatory response to hypoglycemia, stimulating hormonal release that drives 
glucose production in times of low blood glucose (Borg et al. 1997; Borg et al. 1994; 
Borg et al. 1995; Fioramonti et al. 2010; Levin et al. 2008). Similarly, the PVN play a 
role in sympathetic activation of hepatic glucose production, which is reported to involve 
PACAP signaling (Kalsbeek et al. 2004; Yi et al. 2010). Furthermore, both the PVN and 
VMN may regulate brown adipose tissue (BAT) thermogenesis, a critical means of heat 
generation and energy expenditure for rodents, however findings arguing for and against 
this notion have been described (Amir 1990a; Amir 1990b; Bamshad et al. 1999; Kim et 
al. 2011; Madden and Morrison 2009; Oldfield et al. 2002; Perkins et al. 1981; Sakaguchi 
and Bray 1987; Yoshimatsu et al. 1993). To assess the affects of PACAP on indices of 
energy expenditure and glucose homeostasis within the hypothalamus we did site-specific 
PACAP injections into the PVN and VMN similar to the feeding experiments (see 
Chapter 2 and 3). In these studies, we assessed the responses of temperature, locomotor 
activity, blood glucose, and pancreatic hormones following central PACAP injections. 
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Materials and Methods 
Animals 
Male Sprague-Dawley rats (Harlan; Madison, WI) weighing 225-250 g were 
individually housed in a climate controlled room with a 12 hr light/dark cycle. Animals 
had free access to Harlan standard diet (8604 formulation) and water. Food consumption 
was calculated by pre-weighing food in each bin and subtracting the weight of non-
ingested and spilled food at the end of each measurement period. All procedures using 
animals were approved by the Marquette University Institutional Animal Care and Use 
Committee. 
Surgery   
Animals were anesthetized with a ketamine/xylazine/acepromazine (77:1.5:1.5 
mg/ml/kg; ip) cocktail and placed in a stereotaxic apparatus. 26 gauge bilateral guide 
cannulae (Plastics One; Roanoke VA) were placed 3 mm dorsal to the target site in all 
animals, and secured to the surface of the skull with an acrylic resin. The stereotaxic 
coordinates for the PVN injection site were anterior/posterior, -1.7 mm from bregma; 
medial/lateral, ±0.5 mm from midline; dorsal/ventral, -4.9 mm, and for the VMN 
anterior/posterior, -2.5 mm from bregma; medial/lateral, ±0.6 mm from midline; 
dorsal/ventral, -6.2 mm from surface of the skull based on The Rat Brain in Stereotaxic 
Coordinates, 6th Edition (Paxinos and Watson 2007). Injectors extended 3 mm past the 
ventral tip of the cannulae reaching an injection site of -7.9 mm for PVN and -9.2 mm for 
VMN ventral from the surface of the skull. The upper incisor bar was positioned -3.3 mm 
below horizontal zero. A bilateral dummy stylet placed in the guide cannulae was used to 
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maintain patency. The animals were given at least five days to recover after cannula 
installation before receiving drug or vehicle injections during which time the animals 
were handled and dummy stylets were removed and replaced daily in order to acclimate 
the animals to the physical handling necessary during experiments. Correct cannulae 
placements were confirmed at the conclusion of each experiment by microscopic 
examination of Nissl stained sections and only those with correct placement were 
included in the studies. 
Microinjections and Injection Spread 
 In all experiments, PACAP  (50 pmol/0.25 µl/side; PACAP38; California Peptide 
Research; Napa, CA), VIP (50 pmol/0.25 µl/side; California Peptide Research; Napa, 
CA), maxadilan (50 pmol/0.25 µl/side; a generous gift from Dr. Ethan Lerner), PACAP6-
38 (500 pmol/0.25 µl/side; Anaspec; Fremont, CA), or saline vehicle was microinjected 
through bilateral guide cannulae over approximately two minutes in awake animals while 
gently restrained. Following each injection an additional minute elapsed before removing 
injectors to minimize backflow of injected material. The optimal injection volume and 
subsequent spread within the PVN and VMN was determined previously (Resch et al. 
2011; Resch et al. 2013).    
Thermogenesis and activity  
At the time of cannulation surgery animals were also implanted intraperitoneally 
with telemetry probes (Mini-Mitter Inc.; Sunriver, OR). Animals were allowed to recover 
for five days before initiation of experiments. For telemetry experiments, rats received 
bilateral VMN injections of vehicle or 50 pmol PACAP during the light cycle, when 
69 
temperature and activity are at their circadian trough, and placed back into their home 
cages positioned over a telemetry receiver platform. Telemetric data for core body 
temperature and spontaneous locomotor activity were collected every 5 minutes. Core 
body temperature data were averaged by the hour, and spontaneous locomotor activity 
data was either summed into one-hour bins or summed to give cumulative activity over a 
specified amount of time. 
Isolation of Total RNA and Quantitative PCR 
Total RNA was isolated from interscapular brown adipose tissue (iBAT) by 
TRIzol extraction (Invitrogen; Carlsbad, CA). Subsequently, cDNA was constructed with 
1 µg of total RNA using the Reverse Transcription System (Promega; Madison, WI). 
Quantitative PCR was performed using a StepOne Real-Time PCR System (Applied 
Biosystems; Carlsbad, CA), and PerfeCTa SYBR Green FastMix with ROX (Quanta 
Biosciences; Gaithersberg, MD) according to the manufacturer’s protocol. Quantification 
of UCP1 expression was done using a relative standard curve and normalized to the 
housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH).  Primers for 
each gene were designed to span an exon-exon junction and had efficiencies of approximately 
95%. Product sizes for each primer set were 126 bp for UCP1 and 126 bp for GAPDH. Melt 
curve analysis of experiments confirmed a single product for each reaction. Primers for UCP1 
were 5’-GGTCAGAATGCAAGCACAAA-3’ and 5’-TTAGGAGTCGTCCCTTTCCA-
3’, and primers for GAPDH were 5’-CTCCCATTCTTCCACCTTTGA-3’ and 5’-
ATGTAGGCCATGAGGTCCAC-3’.  
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Glucose, pancreatic hormone, and BAT triglyceride measurements 
 Blood was collected via tail vein before and after injections of saline or PACAP 
into the PVN or VMN in tubes containing EDTA, and then immediately chilled on ice 
until centrifugation. Plasma was then collected and stored at -20°C until analyzed. 
Glucose measurements were performed via a glucose oxidase colorimetric assay (Sigma-
Aldrich; St. Louis, MO). Insulin and glucagon levels were measured by 
radioimmunoassay (Millipore; Billerica, MA). For triglyceride measurements, 
interscapular brown adipose tissue (BAT) was harvested three hours after PACAP 
injections into the VMN and snap frozen in liquid nitrogen. BAT was homogenized in 
radioimmunoassay buffer (Boston BioProducts Inc; Ashland, MA) containing protease 
inhibitor cocktail (Roche; Indianapolis, IN). Triglyceride content of BAT was measured 
using a colorimetric assay (Sigma-Aldrich; St. Louis, MO) and normalized to protein 
concentration using the DC protein assay (Bio-Rad; Hercules, CA). 
Statistics 
Data are presented as means ± standard errors of the mean, and were analyzed 
statistically by analysis of variance (with repeated measures when appropriate). Fischer 
LSD analysis was used for all post-hoc group comparisons. Statistical analyses were 
performed using Sigma Plot 11 software (Systat Software Inc.; San Jose, CA). P < 0.05 
were considered statistically significant. 
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Results 
Glucose and pancreatic hormones  
 Both the PVN and VMN are hypothalamic regions known to regulate peripheral 
glucose as well as feeding behavior (Choi and Dallman 1999; Kalsbeek et al. 2004; 
Tokunaga et al. 1986; Tong et al. 2007). Similarly, central PACAP has been implicated in 
glucose homeostasis (Yi et al. 2010). The effect of PACAP infusion into the PVN or 
VMN on plasma glucose was assessed in animals fasted overnight (Table 4.1). PACAP 
administration in both the PVN and VMN produced significant increases in plasma 
glucose concentrations one hour post-injections (PVN, P < 0.05; VMN, P < 0.05). 
Next, in non-fasted animals, we analyzed insulin and glucagon levels to assess the effects 
of PACAP on pancreatic hormone secretion. Neither PVN nor VMN injections of 
PACAP significantly altered pancreatic hormone levels, although insulin did show a 
trend to decrease with PACAP injections into the VMN (P = 0.11).  
 
 
 
 
 
Table 4.1. Change in levels of glucose and pancreatic hormones 60 minutes following PACAP 
treatment 
 PVN VMN 
    Saline PACAP Saline PACAP 
Glucose ∆ (fasted; mg/dl)      19.1 ±  2.2      29.8 ± 4.5*        9.2 ±  2.5      17.5 ± 2.0* 
Insulin ∆ (ng/ml)      0.03 ±  0.18     -0.06 ±  0.13     -0.01 ±  0.21     -0.55 ±   0.18 
Glucagon ∆ (pg/ml)       -6.6 ±  6.2        5.5 ±  6.5       -2.9 ±  4.2     -13.2 ±   13.1 
Data are mean ± SEM. * = P < 0.05 as compared to appropriate anatomical control 
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Figure 4.1.  VMN injections of PACAP increase 
thermogenesis and activity. (a) Core body temperature and (b) 
spontaneous locomotor activity (averaged into 1 hour bins) 
increase significantly following PACAP injections (50 pmol) 
into the VMN. Data are expressed as mean ± SEM, * = P < 
0.05 compared to vehicle. 
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Thermogenesis and activity 
 We began telemetry experiments first with bilateral infusions of PACAP into the 
VMN. These telemetric experiments were similar to our previous feeding studies except 
they were performed at the onset of the light phase, when core body temperature is at its 
circadian trough. PACAP injections induced increases in core body temperature with 
significant main effects of time and treatment by repeated measures ANOVA (P < 0.01; 
Fig. 4.1A), and the increase in thermogenesis was sustained for up to 7 hours after a 
single injection (P < 0.05). In addition to core body temperature, spontaneous locomotor 
activity was also increased in PACAP treated animals, again showing significant main 
effects of time and treatment by repeated measures ANOVA (P < 0.05; Fig. 4.1B).  
Specifically, activity was significantly increased in PACAP-treated animals from 2-5 
hours following injections (P < 0.05). 
 To gain further insight as to how hypothalamic PACAP signaling impacts energy 
expenditure we expanded our injection sites in order to compare temperature and activity 
responses from animals administered PACAP into the PVN vs. VMN. Surprisingly, 
PACAP infusion into the PVN had no effect on either core body temperature (Fig. 4.2A 
& B) or activity (Fig. 4.2C & D) compared to saline treated controls. By contrast, animals 
that were injected with PACAP into the VMN again displayed marked and long-lasting 
increases in both temperature (Fig. 4.1A & B, P < 0.05) and activity (Fig. 4.2C & D, P < 
0.01) compared to saline-treated controls.  
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 In the VMN, PACAP6-38 significantly attenuated the increased thermogenesis 
produced by PACAP administration alone from 2-5 hours post-injection (Fig 4.3A and B; 
P < 0.05).  A separate cohort of animals was used to assess UCP1 mRNA expression via 
qPCR in iBAT one and three hours following PACAP injection into the VMN. The 
results of the qPCR analysis showed a trend to increase iBAT UCP1 mRNA at one hour 
and a significant increase at three hours post-injection (P < 0.05; Fig 4.3C). Additionally,  
 
 
Figure 4.2.  VMN but not PVN injections of PACAP increase thermogenesis and activity. (A) 
Timecourse of core body temperature and (B) 3 hour temperature change (∆) show a significant 
increase following PACAP injections (50 pmol) into the VMN, however injections into the PVN do 
not affect temperature. (C) Timecourse for cumulative activity and (D) area under the curve (AUC) 
analysis depict a similar significant increase only in animals receiving injections of PACAP into the 
VMN. Data are expressed as mean ± SEM, * = P < 0.05 compared to saline. 
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interscapular brown adipose tissue (iBAT) triglyceride content per mg protein at 3 hours 
post-injection into the VMN was significantly decreased (Fig. 4.3C, P < 0.05). Although  
PACAP6-38 only attenuated the effects of PACAP-induced thermogenesis, we used 
agonists for the VPAC and PAC1 receptors, VIP and maxadilan respectively, to confirm 
the specific involvement of PAC1R receptors. As predicted, VIP injections into the VMN 
did not affect body temperature (Fig. 4.3D & 4.3F), whereas the PAC1R-specific agonist, 
maxadilan, produced a large and long-lasting increase in core body temperature (Fig. 
4.3E & 4.3F, P < 0.001) similar to PACAP-induced thermogenesis. 
Figure 4.3.  PACAP-mediated increases in temperature by the VMN are PAC1R-dependent. (A & B) 
The PAC1R antagonist PACAP6-38 (500 pmol/side) attenuates the timecourse and 3 hour temperature 
change (∆) of PACAP-induced thermogenesis (50 pmol/side). (C) Interscapular brown adipose tissue 
(iBAT) UCP1 mRNA and triglyceride (TG) content was analyzed. Quantitative PCR of iBAT UCP1 
mRNA showed a significant increase at three hours following injections of PACAP into the VMN. At 
the same timepoint iBAT TG content was significantly reduced. (D) VMN injections of the VPACR 
agonist VIP (50 pmol/side) did not alter the timecourse of core body temperature, while the PAC1R 
specific agonist maxadilan (50 pmol/side) caused significant increases in the (E) timecourse and (F) 3 
hour temperature change (∆) in core body temperature similar to PACAP injections. Data are expressed 
as mean ± SEM. * = P < 0.05 compared saline group, and # = P < 0.05 compared to PACAP group. 
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 The PAC1 receptor also mediates the increased activity following PACAP 
infusion into the VMN. PACAP6-38 blocked the PACAP-induced increase in 
spontaneous locomotor activity (Fig. 4.4A & B, P < 0.05) unlike the effect on 
temperature, which was only partially inhibited. Further investigation with VIP and 
maxadilan confirmed the increase in locomotor activity induced by PACAP is dependent 
on the PAC1R. VIP did not alter activity compared to controls (Fig. 4.4C & E), while 
maxadilan produced large increases in cumulative activity compared to saline treated 
controls (Fig. 4.4D & E, P < 0.05). 
 
 
Figure 4.4.  PACAP-mediated increases in activity by the VMN are PAC1R-dependent. (A) The 
timecourse of PACAP-induced spontaneous locomotor activity (50 pmol/side) is blocked by the 
PAC1R antagonist, PACAP6-38 (500 pmol/side), shown by (B) area under the curve (AUC) analysis. 
(C) VMN injections of the VPACR agonist VIP (50 pmol/side) did not alter the timecourse of 
activity, while the (D & E) PAC1R specific agonist maxadilan (50 pmol/side) caused significant 
increases in the timecourse of locomotor activity shown by AUC analysis similar to PACAP 
injections. Data are expressed as mean ± SEM. * = P < 0.05 compared saline group. 
 
77 
Discussion 
The current study establishes the PVN and VMN as important targets for PACAP 
signaling likely involved in autonomic nervous system regulation of glucose homeostasis 
and metabolism. Following intrahypothalamic PACAP injections, both the PVN and 
VMN produced increases in blood glucose availability without altering insulin and 
glucagon levels one-hour post-injections. Although the physiological relevance is still 
unknown, PACAP has previously been shown to stimulate hepatic glucose production 
through activation of VPAC2 receptor-expressing neurons of the PVN, which regulate 
hepatic sympathetic nerve activity by sending efferent projections to the intermediolateral 
column of the thoracic spinal cord (Yi et al. 2010). Less is known about glucose 
responses emanating from VMN activation by PACAP leaving the mechanism involved 
in driving glucose production unclear, however the VMN have been associated with 
catecholaminergic and glucagon responses to hypoglycemia (Borg et al. 1997; Borg et al. 
1994; Borg et al. 1995).  
Numerous other studies have linked PACAP with autonomic activation including 
those showing PACAP synapsing onto PVN neurons, which are known to control 
autonomic nervous system activity (Das et al. 2007; Grinevich et al. 1997; Legradi et al. 
1998; Yi et al. 2010). Also, icv injection of PACAP in anesthetized rats alters autonomic 
nerve activity (Tanida et al. 2010), some of which can be blocked by the melanocortin 
receptor antagonist SHU9119 (Tanida et al. 2011b), further supporting that PACAP-
mediated effects on energy are at least partially dependent on melanocortin signaling 
(Mounien et al. 2009; Resch et al. 2011). Interestingly, PACAP knockout mice are highly 
thermosensitive and require higher ambient temperatures to survive into adulthood, 
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adding to the evidence that PACAP plays a necessary role in thermoregulation (Adams et 
al. 2008; Gray et al. 2001; Gray et al. 2002).   
Reduction in body weight is consistently found following central PACAP 
injections (Dore et al. 2013; Hawke et al. 2009; Resch et al. 2011), however pair-feeding 
studies suggest that the body weight loss is not entirely due to decreased feeding, but 
rather an increased metabolic rate (Hawke et al. 2009). Here we find that PACAP 
signaling in the VMN augments core body temperature and spontaneous locomotor 
activity, both of which requiring PAC1R signaling. While pretreatment of the VMN with 
the PAC1R antagonist only attenuated the increased thermogenesis and activity produced 
by PACAP it is likely that a higher dose of PACAP6-38 would fully inhibit these effects, 
as injections of the specific PAC1R agonist maxadilan in the VMN produced the same 
pattern of behaviors demonstrated by PACAP administration, while VIP injections had 
no effect on either temperature or activity. By contrast, stimulation of the PVN by 
PACAP did not significantly alter these measures of energy expenditure, despite evidence 
of PVN regulation of sympathetic outflow to BAT (Amir 1990b; Oldfield et al. 2002), 
and its control over the sympathetically driven PACAP-induced glycemic response (Yi et 
al. 2010). However, these results are in agreement with reports that populations of PVN 
neurons inhibit sympathetic activity to BAT (Kong et al. 2012; Madden and Morrison 
2009).  
Sympathetic thermogenesis independent of physical activity or shivering behavior 
can be positively correlated with UCP1 content in BAT (Himms-Hagen 1990). At one 
hour following PACAP administration into the VMN, increases in iBAT UCP1 mRNA 
expression did not reach statistical significance (data not shown), but by 3 hours the 
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increase in UCP1 mRNA was significant. Furthermore, VMN injected animals exhibiting 
increased thermogenesis and activity also displayed decreased BAT triglyceride stores, 
which is consistent with increased sympathetic nerve activation and lipolysis but not 
pyrogenic action (Cannon and Nedergaard 2004; Okamatsu-Ogura et al. 2007). While 
transynaptic retrograde tracing studies from the interscapular brown adipose tissue often 
fail to detect VMN neurons (Bamshad et al. 1999; Oldfield et al. 2002), there is ample 
evidence supporting VMN activation of BAT thermogenesis, including both VMN-
specific microinjection and genetic studies (Amir 1990a; Kim et al. 2011; Perkins et al. 
1981). It is feasible that the VMN exerts its influences over hypothalamic structures that 
are labeled by transynaptic tracers from BAT such as the medial preoptic area, 
dorsomedial nuclei, or lateral hypothalamus (Oldfield et al. 2002; Zhang et al. 2011) 
allowing for indirect and downstream effects on BAT thermogenesis that are not 
observed in more proximal polysynaptic tracing experiments. Future studies are needed 
to reconcile the discrepancy between the anatomical and functional studies regarding 
VMN-mediated BAT thermogenesis.  
The elevation of spontaneous locomotor activity observed after PACAP injections 
into the VMN is in contrast to previous reports of ventricular injections in mice where no 
increases in activity were noted (Hawke et al. 2009), however increased activity has been 
observed in rats (Masuo et al. 1995). This may reflect that direct or specific stimulation 
of the VMN is necessary to alter locomotor circuits, similar to reports showing that direct 
injection of GABAA receptor antagonists or kainate into the VMN produces running 
activity (Narita et al. 1993; Yokawa et al. 1989). Moreover, VMN lesion studies have 
consistently demonstrated diminished locomotor activity and delayed onset of normal 
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diurnal running activity. Such evidence is congruous with the current study and 
contributes to the notion that locomotor activity pathways involve the VMN (Challet et 
al. 1995; Challet et al. 1996; Choi et al. 1998). 
PACAP neurocircuitry mediating energy homeostasis is not well defined, 
however the present results suggest at least partially distinct circuits of PACAP 
innervation between the PVN and VMN. Analysis of PACAP expression suggests several 
strong candidate brain regions that may provide afferent input of PACAP into the 
hypothalamic regions under study including the medial amygdala and perhaps the VMN 
itself (Hannibal 2002; Nishizuka and Pfaff 1989). Future directions should address this 
gap in knowledge through functional mapping studies of PACAP-expressing PVN and 
VMN circuits, and by overlaying this information in terms of the role of PACAP in the 
regulation of feeding and metabolism.  
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CHAPTER V 
 
 
HYPOTHALAMIC AFFERENTS EXPRESSING PACAP: POTENTIAL CIRCUITS 
MODULATING FEEDING BEHAVIOR AND METABOLISM 
 
 
Introduction 
 
 
 The hypothalamus contains the highest concentration of PACAP protein 
expression within the brain (Hannibal et al. 1995a). Given the high expression of PACAP 
and its receptors in the hypothalamus, it's signaling is likely vital to normal hypothalamic 
function. This is supported by the large deficits in temperature regulation and glycemic 
control exhibited by PACAP knockout mice (Adams et al. 2008; Gray et al. 2001; Gray 
et al. 2002; Hamelink et al. 2002; Tomimoto et al. 2008), and the robust changes in food 
intake and energy expenditure observed following central injections of PACAP (Chance 
et al. 1995; Hawke et al. 2009; Morley et al. 1992; Mounien et al. 2009; Resch et al. 
2011; Resch et al. 2013). Remarkably, the hypothalamic neurocircuitry regulating 
feeding and metabolism through PACAP signaling has not been characterized.  
 Many hypothalamic nuclei contain some expression of PACAP mRNA, but the 
majority of PACAP-expressing neurons reside within the VMN and mammillary bodies 
(Hannibal 2002). Importantly, fasting causes a decrease in hypothalamic PACAP mRNA 
expression indicating a relationship between feeding behavior and PACAP signaling 
(Mounien et al. 2009). Moreover, decreased PACAP mRNA expression following fasting 
is specifically found in the VMN, and by contrast, mice chronically fed a high energy diet 
display increased expression (Hawke et al. 2009). Yet, the efferent targets of 
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hypothalamic PACAP neurons, specifically emanating from the VMN, that are 
potentially responsible for body weight regulation, are not known.  
 In addition to intrahypothalamic sites of PACAP mRNA expression, there are 
several extrahypothalamic regions that express PACAP and have a role in maintaining 
energy homeostasis, including the amygdala and areas of the brainstem (Hannibal 2002). 
Both the amygdala and brainstem possess heavy bidirectional connectivity with the 
hypothalamus, and are critical for regulation of many homeostatic systems including 
feeding, temperature, glucose, and stress regulation (Hammack et al. 2010; King 2006a; 
Kong et al. 2012; Ulrich-Lai et al. 2011; Wu et al. 2009; Zhou et al. 2010; Ziegler et al. 
2012). 
 The PVN and VMN were previously shown to decrease food intake, while 
increasing peripheral glucose levels in response to PACAP injections. Furthermore, 
PACAP signaling specifically in the VMN causes augmented thermogenesis and activity 
(Resch et al. 2013). In order to initiate the functional mapping of PACAP circuits in the 
hypothalamus that drive these behaviors we performed retrograde neuronal tract tracing 
from the PVN and VMN to examine PACAP-expressing circuits that project to these 
regions of the hypothalamus. Retrograde signal from the PVN or VMN was then co-
labeled with PACAP mRNA signal using fluorescent in situ hybridization to define 
afferent circuits expressing PACAP that may control feeding behavior and metabolism. 
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Materials and Methods 
Animals 
Male Sprague-Dawley rats (Harlan; Madison, WI) weighing 225-250 g were 
individually housed in a climate controlled room with a 12 hr light/dark cycle. Animals 
had free access to Harlan standard diet (8604 formulation) and water. All procedures 
using animals were approved by the Marquette University Institutional Animal Care and 
Use Committee. 
Surgery   
Animals were anesthetized with a ketamine/xylazine/acepromazine (77:1.5:1.5 
mg/ml/kg; ip) cocktail and placed in a stereotaxic apparatus. The stereotaxic coordinates 
for the PVN injection site were anterior/posterior, -1.7 mm from bregma; medial/lateral, 
±0.5 mm from midline; dorsal/ventral, -7.9 mm, and for the VMN anterior/posterior, -2.5 
mm from bregma; medial/lateral, ±0.6 mm from midline; dorsal/ventral, -9.2 mm from 
surface of the skull based on The Rat Brain in Stereotaxic Coordinates, 6th Edition 
(Paxinos and Watson 2007). The upper incisor bar was positioned -3.3 mm below 
horizontal zero. Correct injection sites were confirmed by microscopic examination of 
Nissl stained sections and immunohistochemical signal for the retrograde tracer at the 
injection site. Only those with correct placement were included in the analysis. 
In Situ Hybridization 
Brains were sectioned coronally at 12 µm using a cryostat, thaw-mounted onto 
electrostatically clean slides, and stored at -80°C until post-fixed. Prior to hybridization, 
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sections were post-fixed in 4% paraformaldehyde, rinsed in 0.1 M PBS (pH 7.4), 
equilibrated in 0.1 M triethanolamine (pH 8.0), and acetylated in triethanolamine 
containing 0.25% acetic anhydride. Standard in vitro transcription methods were used to 
generate both sense and antisense riboprobes recognizing VGLUT2 (Cullinan; 
Milwaukee, WI) and PACAP transcripts (Choi; Milwaukee, WI), which were 
subsequently diluted in hybridization cocktail (Amresco; Solon, OH) with tRNA. 
Sections were hybridized overnight at 55°C with either digoxigenin (DIG) or fluorescein 
isothiocyanate (FITC) labeled riboprobes.  After hybridization, slides were treated with 
RNase A, and stringently washed in 0.1x SSC at 65°C for 30 minutes. Slides were then 
incubated with an antibody against DIG or FITC conjugated to horseradish peroxidase 
(HRP; Roche; Indianapolis, IN) overnight at 4° C. Riboprobe signal was further 
enhanced using the TSA-plus fluorophore system with either fluorescein or Cy3 (Perkin 
Elmer; Waltham, MA). For dual fluorescent in situ hybridization, following the first 
probe visualization the remaining HRP activity was quenched with 30% H2O2. Following 
the peroxide quench, slides were treated for visualization of the second probe. Image 
capture was performed using fluorescent microscopy (Axioskop-2, Zeiss; Thornwood, 
NY) and Axiovision image analysis software (Zeiss; Thornwood, NY). 
Tract tracing and Immunohistochemistry 
 For PVN and VMN tract tracing experiments, 0.1 µl (PVN) or 0.2 µl (VMN) of 
biotinylated cholera toxin subunit B was stereotaxically microinjected over 10 minutes, 
and injectors were left in place for an additional 5 minutes before removal. 7 days later 
animals were euthanized and brains were collected. Brains were sectioned by cryostat at 
12 µm and prepared for PACAP or VGLUT2 fluorescent in situ hybridization as 
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described above. Following in situ hybridization, slides were then probed with a primary 
antibody against CTB (goat anti-CTB; List Biological Laboratories; Campbell, CA) 
overnight at 4° C, and the antibody signal was visualized using a donkey anti-goat 
Alexafluor 594 conjugated secondary antibody (Life Technologies; Grand Island, NY). 
Upon completion of fluorescent staining, representative sections from regions containing 
both PACAP signal from in situ hybridization and CTB immunolabeling were counted 
for total number of CTB positive cells and the number of CTB positive cells also 
expressing PACAP mRNA. 
 
 
 
 
 
Figure 5.1.  PACAP and Vglut2 mRNA are co-expressed in the VMN. In situ hybridization for PACAP 
(FITC) and Vglut2 (Cy3) mRNA in the dorsal thalamus, habenula (A-C), and ventromedial nuclei of 
the hypothalamus (D-F) shows minimal co-expression in the dorsal thalamic region (C), but extensive 
co-labeling in the ventromedial hypothalamus (F). 3V, third ventricle; ARC, arcuate nuclei; dTHAL, 
dorsal thalamus; mHAB, medial habenula; VMN, ventromedial nuclei. 
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Results  
 To characterize VMN neuron mRNA expression of PACAP and the vesicular 
glutamate transporter 2 (Vglut2) dual fluorescent in situ hybridization was used. Analysis 
of PACAP and Vglut2 expression was done in the dorsal thalamus and VMN. The dorsal 
thalamus was almost completely devoid of PACAP mRNA expression. However, within 
the same habenular area expression of PACAP mRNA was very robust, especially in the 
medial portion (PACAP = green fluorescence; Fig. 5.1A). In contrast, Vglut2 mRNA 
expression was abundant in the dorsal thalamus with little expression in the medial 
habenula, and no cells were observed to express both PACAP and Vglut2 in this region 
(Vglut2 = red fluorescence; Fig. 5.1B & C). Conversely, the VMN contain rich 
expression of both PACAP and Vglut2 mRNA, with almost all PACAP positive 
(PACAP+) neurons co-expressing Vglut2 (~95%; Fig. 5.1D-F). However, there were a 
few PACAP neurons residing in the lateral portions of the arcuate (ARC) that were not 
co-labeled with Vglut2 (Arrow; Fig. 5.1F).  
  
 
 
Figure 5.2.  Cholera toxin subunit B injection site for the PVN. For retrograde labeling of PVN 
afferent circuits the neuronal tracer cholera toxin subunit B (CTB) was injected site-specifically into 
the PVN. Boundaries of PVN are denoted by Vglut2 mRNA signal (green; A), with CTB injection 
signal (red; B) found to be confined within the PVN (C). 
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 PACAP signaling in the hypothalamus drives several behaviors leading to 
reduced body weight, however PACAP-expressing afferent circuits of the PVN and 
VMN are not well defined. We performed tract tracing with the neuronal tracer cholera 
toxin subunit B (CTB), coupled with fluorescent in situ hybridization for PACAP and 
VGLUT2 mRNA (Fig. 5.2 and 5.6). VGLUT2 fluorescent in situ hybridization was used 
as an anatomical marker for both the PVN and VMN. One week following unilateral 
stereotaxic injections of CTB into the PVN and VMN, we examined the distribution of 
both the neuronal tracer and PACAP mRNA. CTB retrograde signal from the PVN (Fig. 
5.3-5.5) co-localized with PACAP mRNA most notably in the anterior medial bed 
nucleus of the stria terminalis (BNST), VMN, and lateral parabrachial nucleus (LPB).  
Figure 5.3.  PACAP-expressing cells of the bed nucleus of the stria terminalis project to the PVN. 
Left column: fluorescent in situ hybridization for PACAP mRNA, middle column: 
immunofluorescence for CTB, and right column: merged images. Approximately 50% of cells 
identified projecting from the bed nucleus of the stria terminalis (BNST) to the PVN were positive 
for PACAP mRNA. Anterior medial BNST at 10X (A, B, C) and 40X (D, E, F). Box within the left 
panels represent the area of subsequent high magnification pictures. Arrows indicate representative 
dual-labeled cells. ac, anterior commissure; BNST, bed nucleus of the stria terminalis; CTB, cholera 
toxin subunit B. 
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Figure 5.4.  PACAP-expressing cells of the VMN project to the PVN. Left column: fluorescent in situ 
hybridization for PACAP mRNA, middle column: immunofluorescence for CTB, and right column: 
merged images.  The majority of cells (~90%) in the VMN that project to the PVN were positive for 
PACAP. VMN at 10X (A, B, C) and 40X (D, E, F). Box within the left panels represent the area of 
subsequent high magnification pictures. Arrows indicate representative dual-labeled cells. 3V, third 
ventricle; CTB, cholera toxin subunit B; VMN, ventromedial nucleus. 
 
Figure 5.5.  PACAP-expressing cells of the lateral parabrachial nuclei project to the PVN. Left 
column: fluorescent in situ hybridization for PACAP mRNA, middle column: immunofluorescence for 
CTB, and right column: merged images.  The majority of cells (~90%) in the lateral parabrachial nuclei 
(LPB) projecting to the PVN were positive for PACAP. LPB at 10X (A, B, C) and 40X (D, E, F).  Box 
within the left panels represent the area of subsequent high magnification pictures. Arrows indicate 
representative dual-labeled cells. CTB, cholera toxin subunit B; LPB, lateral parabrachial nucleus. 
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Few dual labeled cells were also found in the medial amygdala (MeA; data not shown). 
With the exception of the BNST, which had 56% of CTB positive cells co-expressing 
PACAP mRNA, the vast majority of CTB cells in the VMN (95%) and LPB (92%) co-
Figure 5.6.  Cholera toxin subunit B injection site for the VMN. For retrograde labeling of VMN 
afferent circuits the neuronal tracer cholera toxin subunit B (CTB) was injected site-specifically into 
the VMN. Boundaries of VMN are denoted by Vglut2 mRNA signal (green; A), with CTB injection 
signal (red; B) found to be confined within the VMN (C). 
 
Figure 5.7.  PACAP-expressing cells of the medial amygdala project to the VMN. Left column: 
fluorescent in situ hybridization for PACAP mRNA, middle column: immunofluorescence for CTB, 
and right column: merged images. The majority of cells projecting to the VMN from the medial 
amygdala (MeA) were positive for PACAP (~85-90%). MeA at 10X (A, B, C) and 40x (D, E, F). Box 
within the left panels represent the area of subsequent high magnification pictures. Arrows indicate 
representative dual-labeled cells. CTB, cholera toxin subunit B; opt, optic tract. 
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expressed PACAP mRNA. Retrograde CTB tracing from the VMN (Fig. 5.7-5.8) was 
abundantly co-localized with PACAP mRNA in the MeA (85%) ipsilateral to the 
injection site, as well as in the LPB (90%).   
 
 
Discussion 
PACAP signaling within the hypothalamus and at downstream extrahypothalamic 
sites is critical for the control of feeding behavior and metabolism. The VMN possess a 
high degree of PACAP mRNA expression (Hannibal 2002), and are comprised of 
predominantly glutamatergic neurons that express Vglut2 (Fu and van den Pol 2008; 
Tong et al. 2007; Ziegler et al. 2002). While PACAP and glutamate have been reported to  
Figure 5.8.  PACAP-expressing cells of the lateral parabrachial nuclei project to the VMN. Left 
column: fluorescent in situ hybridization for PACAP mRNA, middle column: immunofluorescence for 
CTB, and right column: merged images. The majority of cells projecting to the VMN from the lateral 
parabrachial nuclei (LPB) were positive for PACAP (~85-90%). LPB at 10x (A, B, C) and 40X (D, E, 
F). Box within the left panels represent the area of subsequent high magnification pictures. Arrows 
indicate representative dual-labeled cells. CTB, cholera toxin subunit B; LPB, lateral parabrachial 
nucleus. 
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be co-stored within the same cell previously (Engelund et al. 2010; Fahrenkrug and 
Hannibal 2004; Hannibal et al. 2000), we found evidence of co-storage of PACAP and 
glutamate in VMN neurons using Vglut2 as a marker of glutamate releasing neurons (Fig. 
5.1D-F). Importantly, not all PACAP-expressing neurons co-express Vglut2, as there are 
PACAP+ neurons in the lateral portions of the ARC that do not express Vglut2. 
Interestingly, these ARC PACAP neurons may also express POMC and acetylcholine 
(Durr et al. 2007), yet whether these ARC PACAP neurons are still glutamatergic is 
unknown. Moreover, analysis of habenular neurons revealed no co-labeling of PACAP 
and Vglut2 signal. It should be noted, however, that PACAP+ neurons of the habenula are 
also likely glutamatergic but express Vglut1 instead of Vglut2 (Barroso-Chinea et al. 
2007).    
Hypothalamic PACAP mRNA is predominantly expressed in the VMN (Hannibal 
2002; Hawke et al. 2009), suggesting that a prominent source of PACAP release in the 
PVN may originate from the VMN. In fact, much work has been done to characterize 
PACAP-containing afferents of the PVN.  PACAP immunolabeling of synaptic terminals 
(Legradi et al. 1998) and expression of PACAP receptor subtypes have been identified 
within the PVN (Hashimoto et al. 1996; Resch et al. 2013; Sheward et al. 1995; Usdin et 
al. 1994). Furthermore, retrograde tracing from the PVN demonstrates co-labeling of 
neurons with PACAP immunoreactivity (Das et al. 2007), however results using PACAP 
immunohistochemistry are often difficult to interpret since available PACAP antibodies 
typically have low sensitivity and require the use of colchicine and antigen retrieval 
methods to obtain even low numbers of immunoreactive labeling of neuronal cell bodies  
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(Das et al. 2007).  The current study demonstrates that a number of known PVN afferent 
pathways utilize PACAP signaling including an input from the VMN. Taking into 
consideration the similar feeding behavior responses following stimulation of the VMN 
and PVN by PACAP injections (Resch et al. 2013), the established circuitry of  
glutamatergic VMN neurons projecting to the PVN (Ulrich-Lai et al. 2011), and the 
extremely high PACAP mRNA expression found in the VMN (Hannibal 2002), it is not 
surprising that the VMN may contribute functionally important PACAP-expressing 
afferent inputs to the PVN. However, other significant sources of PACAP innervation to 
the PVN were also found in the anterior medial bed nucleus of the stria terminalis 
(BNST), the lateral parabrachial nucleus (LPB), and sparse dual labeling in the medial 
amygdala (MeA) (Figure 5.9). Although PACAP containing cells from the LPB and MeA 
appear to project more extensively to the VMN, the BNST is well characterized to be a 
critical regulator of stress and anxiety with known inputs to the PVN, which could 
suggest a potential role of PACAP-mediated hypophagia during times of stress (Dong 
and Swanson 2006; Hammack et al. 2009; Hammack et al. 2010). 
 In contrast to the PVN, the circuitry of PACAP-containing afferents to the VMN 
are far less studied, with no prior published reports to date.  While the possibility of 
contralateral and intrinsic PACAP signaling within the VMN still exists (Kiss et al. 2011; 
Nishizuka and Pfaff 1989), cholera toxin subunit B retrograde tracing following 
injections into the VMN robustly co-labeled with fluorescent in situ hybridization signal 
for PACAP mRNA in two distinct regions, the MeA and LPB (Figure 5.9). Both brain 
regions have been strongly implicated in energy balance, suggesting that the MeA and 
LPB may be two distinct central pathways that converge on the PVN and VMN to 
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manage both feeding behavior and metabolic systems. Lesions to the MeA produce 
hyperphagia and obesity, especially in female rats (King 2006a). Moreover, the MeA is 
also a glucose-sensing area of the brain that may respond to states of hypoglycemia 
further strengthening a connection with the well-characterized glucostatic role of the 
VMN (Zhou et al. 2010). The LPB also contributes to body weight regulation as 
demonstrated by the loss of GABAergic signaling to the parabrachial nuclei from agouti-
related polypeptide (AGRP) neurons of the arcuate leading to starvation (Wu et al. 2009). 
Given their effect on feeding, the PVN and VMN may be significant efferent targets of 
the LPB whereby, LPB disinhibition could lead to increased excitation of these areas and 
anorexia. Furthermore, the LPB are critical structures in the thermoregulation pathway 
(Nakamura and Morrison 2008; Nakamura and Morrison 2010), thereby positioning the 
VMN as potential downstream targets of LPB signaling that, in turn, could modulate 
thermogenic responses.   
 The differential response to PACAP signaling within the PVN and VMN 
regarding feeding, temperature, and locomotor activity may reflect an anatomical 
divergence segregating the PVN as the predominant sight of action for PACAP-mediated 
hypophagia, while PACAP stimulation of the VMN may primarily serve to stimulate 
energy expenditure. The distinct and widespread population of PACAP receptors in the 
hypothalamus enables functionally diverse signaling by PACAP. Thus, it would be 
intriguing to determine if multiple subtypes of PACAP receptors are expressed on the 
same cell, or more importantly at the same synapse.  
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Figure 5.9.  Sagittal schematic of PACAP-expressing afferent circuits of the paraventricular (PVN) 
and ventromedial (VMN) nuclei. (A) Afferents of the PVN that may regulate energy homeostasis 
through PACAP signaling originate from the bed nucleus of the stria terminalis (BNST), lateral 
parabrachial nuclei (LPBN), and VMN. (B) Afferents of the VMN that potentially regulate energy 
balance through PACAP signaling originate from the LPBN and medial amygdala (MeA). 
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CHAPTER VI 
 
 
PACAP MODULATION OF GLUTAMATE: REGULATION OF ASTROCYTIC 
CYSTINE-GLUTAMATE EXCHANGE 
 
 
Introduction 
 
 
The inhibition of feeding behavior in response to PACAP signaling in the 
hypothalamus is mediated by the PAC1 receptor (Hawke et al. 2009; Mounien et al. 
2009; Resch et al. 2013). Because the PAC1 receptor is G protein-coupled, the exact 
mechanism driving excitation of cells in the hypothalamus by PACAP is not clear. Given 
evidence that PACAP receptor activation potentiates glutamate signaling in several brain 
regions (Chen et al. 1999; Cho et al. 2012; Costa et al. 2009; Kopp et al. 2001; 
Macdonald et al. 2005; Martin et al. 1995; Pellegri et al. 1998; Yaka et al. 2003), it is 
probable that PACAP modulates glutamate signaling to increase the excitation of 
hypothalamic neurons. However, glutamate signaling can be enhanced not only by 
conventional means, such as increased presynaptic release and potentiation of 
postsynaptic receptor currents, but also through nonconventional mechanisms including 
decreased synaptic clearance via glutamate transporters or glutamate release from 
astrocytes. Often overlooked, nonconventional modulation of glutamate signaling by 
astrocytes is critical to CNS function, which is especially relevant since astrocytes are 
heavily targeted by PACAP signaling (Figiel and Engele 2000; Magistretti et al. 1998; 
Tatsuno et al. 1991; Tatsuno et al. 1990; Tatsuno et al. 1996a; Tatsuno et al. 1996b). 
Identifying novel aspects of glutamate modulation by PACAP will be valuable towards 
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understanding more complex aspects of PACAP signaling that affect physiology and 
behavior.   
In the central nervous system (CNS) astrocytic cystine-glutamate exchange is 
critical for both protection against reactive oxygen species (ROS) (Kranich et al. 1998; 
Sagara et al. 1993b), as well as the maintenance of extracellular glutamate concentrations 
(Baker et al. 2002; Moran et al. 2005; Murphy and Baraban 1990). The cystine-glutamate 
antiporter, system xc-, composed of the light chain xCT and heavy chain 4F2hc subunits, 
is a sodium independent amino acid transporter that exchanges one molecule of 
extracellular cystine for one molecule of intracellular glutamate (Bannai 1986; Bannai 
and Kitamura 1980; Sato et al. 1999). System xc- is the principal mode of cystine entry 
into the cell (Sagara et al. 1993a), which is immediately reduced to cysteine, the rate-
limiting substrate for glutathione (GSH) production (Sagara et al. 1993b). Maintaining 
sufficient levels of GSH is paramount to the cellular defense against oxidative stress, 
which is thought to significantly impact the development of several disease states 
including cancer, diabetes, and numerous neurodegenerative diseases (Bridges et al. 
2012; Lewerenz et al. 2013).  
Nonvesicular extrasynaptic glutamate release by system xc- may be important for 
activation of extrasynaptic NMDA and group II/III metabotropic glutamate receptors 
that, in turn, affect neuronal excitability (Kupchik et al. 2012; Moran et al. 2005; Pow 
2001).  In support, nonvesicular glutamate released by the cystine-glutamate antiporter is 
reported to be an essential regulator of extrasynaptic glutamate concentrations in the CNS 
(Baker et al. 2002).  Moreover, dysregulation of extrasynaptic glutamate concentrations 
resulting from altered system xc- activity has been implicated in glutamate excitotoxicity 
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(Piani and Fontana 1994) and psychiatric disorders (Baker et al. 2008; Baker et al. 2003). 
With the large array of pathological states in the CNS stemming from both insufficient 
glutathione synthesis and dysfunctional glutamate homeostasis, system xc- is positioned 
to heavily influence a variety of pathologies ranging from compulsive disorders to 
neurodegenerative disease (Berman et al. 2011; de Groot and Sontheimer 2011; Grant et 
al. 2007; Grant et al. 2009; Knackstedt et al. 2009; Park et al. 2004; Sontheimer 2011; 
Zhou and Kalivas 2008). Unfortunately, the regulation of this heterodimeric amino acid 
transporter is poorly understood.  
PACAP is a pleiotropic neuropeptide with widespread expression throughout the 
central nervous system (CNS) and periphery (Vaudry et al. 2009). PACAP regulates 
multiple aspects of astrocyte signaling (Magistretti et al. 1998; Masmoudi-Kouki et al. 
2007; Tatsuno et al. 1991; Tatsuno et al. 1996a; Watanabe et al. 2006) including 
transcriptional activation of the glial glutamate transporters GLT-1 and GLAST (Figiel 
and Engele 2000). Three receptors have been identified for this peptide including the VIP 
receptors VPAC1 and VPAC2, and PAC1R, which PACAP binds to with the highest 
affinity (Dickson and Finlayson 2009). All of the PACAP receptors are expressed on 
astrocytes to some degree (Ashur-Fabian et al. 1997; Grimaldi and Cavallaro 1999; 
Grimaldi and Cavallaro 2000; Masmoudi-Kouki et al. 2007; Suzuki et al. 2003; Tatsuno 
et al. 1991) suggesting a significant role for PACAP signaling in the regulation of 
astrocyte function. Moreover, PACAP synthesis and transmission may be exclusively 
released from glutamate neurons in the CNS (Engelund et al. 2010; Fahrenkrug and 
Hannibal 2004; Hannibal et al. 2000) allowing PACAP to have a potential modulatory 
role on glutamate signaling at both the neuron as well as on the surrounding glia.  
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While PACAP appears to be a critical signal for astrocytes (Masmoudi-Kouki et 
al. 2007), as well as a key modulator of glutamate signaling (Magistretti et al. 1998), the 
affects of PACAP signaling on system xc- function are unknown. However, evidence of 
the neuroprotective actions of PACAP under conditions of both oxidative stress and 
excitotoxicity (Masmoudi-Kouki et al. 2011; Morio et al. 1996; Shintani et al. 2005) 
suggests these effects could be mediated through activation of system xc-, a mechanism 
that alters both GSH production and glutamate signaling. To test this hypothesis, we 
treated primary cortical cultures with PACAP and found a potentiation of system xc- 
activity. Subsequent experiments were performed to determine the specific mechanism 
mediating the increased cystine-glutamate exchange produced by PACAP application in 
these cultures. 
Materials and Methods 
Materials 
 Timed pregnant female Swiss Webster mice (Charles River Laboratories; 
Wilmington, DE) were housed in a climate controlled room with a 12 hr light/dark cycle. 
Animals had free access to standard diet (Harlan 8604 formulation) and water until 
preparation of cell cultures. All procedures using animals were approved by the 
Marquette University Institutional Animal Care and Use Committee. PACAP was 
obtained from California Peptide Research (Napa, CA), PACAP6-38 from Anaspec 
(Fremont, CA), and VIP, VIP6-28, PG 97-269, PG 99-465 from Bachem (Torrance, CA). 
(S)-4-carboxyphenyglycine (CPG) was purchased from Tocris Bioscience (R&D 
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Systems; Minneapolis, MN), and H89 from Sigma (St. Louis, MO). All other common 
chemicals were purchased from Sigma (St. Louis, MO). 
Cortical cell cultures   
Primary mixed cortical cultures containing both neurons and glia were prepared 
from embryonic day 15-16 mouse pups as previously described (Lobner 2000). 
Dissociated cortical cells suspended in Eagles’ Minimal Essential Medium (MEM, 
Earle’s salts, supplied glutamine-free) supplemented with 5% heat-inactivated horse 
serum (Atlanta Biologicals; Lawrenceville, GA), 5% fetal bovine serum (Atlanta 
Biologicals), 2 mM glutamine and glucose (total 21 mM) were plated on 24-well plates 
coated with poly-D-lysine and laminin. Neuronal-enriched cultures were prepared in an 
identical manner with the addition of 10 µM cytosine arabinoside 48 hours after plating 
cultures in order to inhibit glial replication. Neuronal-enriched cultures using this method 
have astrocyte levels of <1% of the total cell population (Dugan et al. 1995; Rush et al. 
2010). Astrocyte-enriched cultures were prepared using a similar protocol to that of the 
mixed cortical culture, however cortices were obtained from postnatal day 1-3 mouse 
pups (Choi et al. 1987; Rush et al. 2010; Schwartz and Wilson 1992). To obtain 
microglial cultures, microglia were collected after shaking astrocyte-enriched cultures 
and then plated in media containing 10 ng/ml colony stimulating factor (CSF) (Barger 
and Basile 2001). All cultures were maintained in humidified 5% CO2 incubators at 
37°C. 
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Radiolabeled cystine uptake 
 Radiolabeled cystine uptake was measured as previously described (Liu et al. 
2012b). Briefly, prior to treatment on in vitro day 15, cultures were washed in serum-free 
media and incubated for a specified period with or without drug.  Following incubation, 
cultures were then washed with HEPES buffered saline solution and immediately 
exposed to 0.3 µM 14C-cystine (Perkin Elmer; Waltham, MA) for 20 minutes. Following 
14C-cystine exposure the cultures were washed with HEPES buffered saline solution and 
dissolved in 250 µl of 0.1% sodium dodecyl sulfate. Of the 250 µl sample, 200 µl were 
used for scintillation counting, with the remaining sample used for protein quantification 
using the Bio-Rad DC protein assay (Hercules, CA). Counts were normalized to 14C-
cystine uptake in controls on the same experimental plate. To inhibit system xc- activity, 
200 µM CPG was added to the 14C-cystine solution during the uptake experiment. 
Quantitative reverse transcription PCR 
 Cultures used for qRT-PCR were treated identically to those used for radiolabeled 
cystine uptake assays.  However, following drug incubation, cells were harvested for total 
RNA extraction using TRiZOL (Life Technologies; Grand Island, NY). Single-stranded 
cDNA synthesis was performed with 1 µg total RNA using the Promega Reverse 
Transcription System (Madison, WI). Real-time quantitative PCR was performed with 
the StepOne real-time PCR system (Applied Biosystems; Carlsbad, CA) using PerfeCTa 
SYBR Green FastMix containing ROX (Quanta Biosciences; Gaithersberg, MD). 
Relative quantification of xCT transcripts was analyzed via the ∆∆Ct method normalized 
to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Primers for each gene were 
designed to span an exon-exon junction and had efficiencies of approximately 95%. Product sizes 
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for each primer set were 88 bp for xCT and 116 bp for GAPDH. Melt curve analysis of 
experiments confirmed a single product for each reaction. Primer sequences were as follows: 
xCT forward – AGG GCA TAC TCC AGA ACA CG; xCT reverse – GAC AGG GCT 
CCA AAA AGT GA; GAPDH forward – AAG GGC TCA TGA CCA CAG TC; and 
GAPDH reverse – GGA TGC AGG GAT GAT GTT CT.  
Statistics 
Data are presented as means ± standard errors of the mean, and were analyzed 
statistically by analysis of variance. Fischer LSD analysis was used for all post-hoc group 
comparisons. Statistical analyses were performed using Sigma Plot 11 software (Systat 
Software Inc.; San Jose, CA). P < 0.05 were considered statistically significant. 
 
 
 
Figure 6.1.  PACAP increases cystine uptake through system xc- in a dose-dependent manner. (A) Dose 
response of 24-hour PACAP treatment on primary mixed cortical cultures on radio-labeled cystine 
uptake. (B) Inhibition of system xc- with (S)-4-carboxyphenylglycine (CPG; 200 µM) blocks cystine 
uptake in both control and PACAP (1 nM) treated primary mixed cortical cultures. Data are expressed 
as mean ± SEM. * = P < 0.05 compared to control group. 
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Results 
 The effect of PACAP on radiolabeled cystine uptake was initially tested in 
primary mixed cortical cultures using doses ranging from 0.01 and 10 nM PACAP.  By 
24 hours post-treatment, 1 nM PACAP showed a significant increase in radiolabeled 
cystine uptake (Fig. 6.1A; P < 0.01). Consequently, we used the 1 nM dose of PACAP 
for all future experiments examining cystine uptake following PACAP treatment. To 
determine whether the increased cystine uptake induced by PACAP was attributed to 
system xc- activity, we applied the system xc- inhibitor CPG (200 µM) during uptake 
experiments. CPG inhibited approximately 90% of radiolabeled cystine uptake in control 
cells as well as the increase in system xc- activity following 24-hour PACAP treatment 
(Fig. 6.1B). 
 
  
Figure 6.2.  Time course of cystine uptake and quantitative PCR for xCT mRNA expression 
following PACAP treatment. (A) A time course revealed a delayed effect of PACAP (1nM) on 
cystine uptake in primary mixed cortical cultures. PACAP treatment for 6, 12, and 24 hours yielded 
significant increases in radiolabeled cystine uptake. (B) Quantitative PCR from RNA isolated from 
control and 24-hour PACAP (1 nM) treated primary mixed cortical cultures. Data are expressed as 
mean ± SEM. * = P < 0.05 compared to control group. 
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 Subsequently, mixed cortical cultures were incubated with 1 nM PACAP for 1, 3, 
6, 12, and 24 hours prior to the radiolabeled cystine uptake assay to determine the 
optimal incubation period for PACAP treatment needed to augment system xc- activity. 
PACAP treatment produced significant increases in cystine uptake following incubation 
times ranging from 6-24 hours (Fig 6.2A; P < 0.05). The necessity for long-term 
treatment with PACAP to significantly increase cystine uptake in primary mixed cortical 
cultures suggests that PACAP may be involved with the transcriptional regulation of the 
cystine-glutamate antiporter. Using quantitative real-time PCR (qPCR) we measured 
mRNA expression of the unique functional subunit of system xc-, xCT. Relative 
quantification for xCT mRNA was performed on total RNA extracted from control or 24-
hour PACAP treated primary mixed cortical cultures normalized to the housekeeping 
 
Figure 6.3.  PACAP increases cystine uptake via a PKA-
dependent pathway. 10 µM of the PKA inhibitor H89 
completely blocked increases in cystine uptake induced by 
24-hour PACAP (1 nM) treatment in primary mixed 
cortical cultures. Data are expressed as mean ± SEM. * = P 
< 0.05 compared to control group. 
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gene GAPDH. In primary mixed cortical cultures, 24-hour treatment with PACAP 
produced significantly increased xCT mRNA levels (Fig. 6.2B; P < 0.01).  
 PACAP signaling through its G protein-coupled receptors often utilizes Gαs to 
increase adenylyl cyclase, a process leading to cyclic AMP formation and increased 
activation of protein kinase A (PKA) (Dickson and Finlayson 2009). To determine 
whether the PKA pathway contributed to the augmentation of system xc- activity, mixed 
cortical cultures were treated with 10 µM H89 (Figiel and Engele 2000), a PKA inhibitor, 
during 24-hour PACAP treatment. Inhibition of PKA activity by H89 completely blocked 
the increase in radiolabeled cystine uptake induced by 24-hour PACAP treatment  (Fig. 
6.3).  
To identify the PACAP receptor type mediating the effects on cystine-glutamate 
exchange, cortical cultures were co-incubated with antagonists for the PAC1 receptor and 
VPAC receptors. Inhibition of the PAC1R with 100 nM PACAP6-38 did not block 
PACAP facilitated radiolabeled cystine uptake, but instead potentiated the effects of 
PACAP treatment alone (Fig 6.4A; P < 0.05 compared to PACAP treatment). The 
nonspecific VPAC receptor antagonist VIP6-28 at a dose of 100 nM was effective in 
attenuating the increased cystine uptake following 24 hour 1 nM PACAP treatment (Fig. 
6.4B). To further investigate which VPAC receptors were involved in the augmentation 
of system xc- activity, primary mixed cortical cultures were pre-treated with specific 
antagonists for VPAC1R and VPAC2R. A 100 nM concentration of the VPAC1R 
antagonist PG 97-269 blocked the increased cystine uptake produced by 24 hour PACAP 
(1 nM) treatment in mixed cortical cells (Fig. 6.4C), while similar treatment with the 
VPAC2R antagonist PG 99-465 had no effect (Fig. 6.4D). Finally, a dose response using  
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Figure 6.4.  Increases in cystine uptake induced by PACAP are mediated by VPAC1 receptors. (A) 
The PAC1R antagonist PACAP6-38 (100 nM) caused a potentiation of 1 nM PACAP on cystine 
uptake. (B) The VIP receptor antagonist VIP6-28 (100 nM) significantly attenuated the increased 
cystine uptake caused by PACAP treatment. (C) Treatment with 100 nM PG 97-269 (specific 
VPAC1R antagonist) abolished the 1 nM PACAP effect on cystine uptake, while (D) 100 nM PG 
99-465 (VPAC2R antagonist) had no effect. (E) A dose response of 24-hour VIP treatment showed 
that VIP increases cystine uptake at a similar dose to PACAP, as well as at the higher dose ranges 
where PACAP was ineffective. Data are expressed as mean ± SEM. * = P < 0.05 compared to 
control group. # = P < 0.05 compared to PACAP group. 
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VIP concentrations ranging from 1, 10, and 100 nM also produced significant increases 
in radiolabeled cystine uptake (Fig. 6.4E; P < 0.05). 
To isolate which cell type in a mixed cortical preparation primarily contributed to 
the increased radiolabeled cystine uptake following incubation with PACAP or VIP, we 
applied similar measures to neuronal, astrocyte, and microglia-enriched cultures. Optimal 
concentrations determined from previous dose response experiments in mixed cortical 
cultures resulted in the use of 1 nM PACAP (Fig. 6.1A) and 10 nM VIP (Fig. 6.4E) 
doses. Incubation with either PACAP or VIP produced significant increases in 
radiolabeled cystine uptake in astrocyte-enriched cultures only (Fig. 6.5B; P < 0.01), with 
no changes detected in neuronal or microglia-enriched cultures. 
 
 
Discussion 
 Previous reports have indicated that both neuropeptides and growth factors may 
be potential regulators of the cystine-glutamate antiporter, system xc- (Johnson and 
Johnson 1993; Liu et al. 2012b). The present study demonstrates that the pleiotropic 
Figure 6.5.  Cell type specific analysis of PACAP and VIP treatment on cystine uptake. (A) Cystine 
uptake was unaffected following PACAP (1 nM) and VIP (10 nM) treatment in neuronally-enriched 
cultures. (B) Both PACAP and VIP significantly increased cystine uptake in astrocyte-enriched 
cultures. (C) There was no affect of PACAP or VIP on microglial cystine uptake. Data are expressed 
as mean ± SEM. * = P < 0.05 compared to control group. 
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neuropeptide PACAP is a novel regulator of system xc- activity. 24-hour PACAP 
treatment of primary cortical cultures significantly increased radiolabeled cystine uptake.  
Inhibition of cystine uptake following CPG treatment indicated that PACAP facilitated 
cystine uptake was mediated specifically through system xc-. Furthermore, the increases 
in cystine-glutamate exchange appear to be mediated, in part, by increased transcription 
of the specific light chain subunit of system xc-, xCT. This induction of cystine-glutamate 
exchange activity appears to be driven primarily via VPAC1R signaling through a PKA-
dependent pathway that appears to be specific to astrocytes in our primary cortical culture 
models.  
 Cell culture models have shown that overexpression of xCT yields increased 
glutathione content and neuroprotection against toxicity induced by glutamate and 
reactive oxygen species (Shih et al. 2006), thus suggesting that signals such as PACAP or 
VIP may achieve their neuroprotective effects via increased expression and activity of the 
cystine-glutamate antiporter. In addition, spontaneous deletion of the xCT gene 
characterized in sut/sut mutant mice results in significant brain atrophy (Shih et al. 2006). 
However, it should be noted that genetically engineered xCT knockout mice do not 
appear to have significant behavioral or morphological deficits (Lewerenz et al. 2013), 
and increased system xc- activity may produce excitotoxicity under certain circumstances 
such as in primary brain tumors (de Groot and Sontheimer 2011) and interleukin-1β 
mediated hypoxic neuronal injury (Fogal et al. 2007; Jackman et al. 2010). 
Alterations in system xc- activity and expression have been implicated in various 
disease states such as gliomas, schizophrenia, and drug abuse (Baker et al. 2008; Baker et 
al. 2003; Ye et al. 1999). Oxidative stress and glutamate dysfunction lead to the 
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development of numerous pathologies, demonstrating that system xc- may be an attractive 
target for drug development. Similarly, the potential therapeutic value of PACAP as a 
neuroprotective drug is high, and others have begun the task of designing drugs targeting 
PACAP and its receptors for the treatment of neurodegenerative disorders (Bourgault et 
al. 2011). Thus, PACAP/VIP signaling on astrocytes may be a critical regulator of 
cystine-glutamate exchange mediating neurotrophic effects in the central nervous system. 
PACAP and VIP are neurotrophic factors that have numerous effects on both 
astrocyte function and glutamate homeostasis (Arimura et al. 1994; Brenneman et al. 
1998; Figiel and Engele 2000; Hannibal et al. 2000; Magistretti et al. 1998; Martin et al. 
1995; Masmoudi-Kouki et al. 2011; Morio et al. 1996; Seaborn et al. 2011; Yuhara et al. 
2001). As an excitatory neuropeptide expressed in glutamatergic neurons, PACAP 
enhances both NMDA and AMPA currents in the hippocampus through PAC1R 
signaling (Costa et al. 2009; Hannibal et al. 2000; Macdonald et al. 2005; Yaka et al. 
2003). Moreover, PACAP ameliorates glutamate toxicity and oxidative stress suggesting 
that its signaling mechanism contributes to multiple aspects of glutamate modulation and 
cell survival. One such mechanism of protection may be the result of enhanced sodium-
dependent glial excitatory amino acid transporter (EAAT) expression following PACAP 
treatment, leading to an increase in synaptic glutamate clearance following high intensity 
neurotransmitter release (Figiel and Engele 2000). In addition, VIP and PACAP also 
regulate astrocytic glycogen metabolism through cAMP-dependent activation of the 
transcription factor CCAAT/enhancer binding protein (Cardinaux and Magistretti 1996; 
Magistretti et al. 1998; Sorg and Magistretti 1991). Thus, increases in cystine-glutamate 
exchange activity is yet another mechanism enabling PACAP/VIP to exert its 
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neuroprotective potential by increasing cystine/cysteine availability for glutathione 
production to decrease free reactive oxygen species, as well as increasing extrasynaptic 
glutamatergic tone on the presynaptic group II/III metabotropic glutamate autoreceptors, 
dampening the potentially harmful excessive synaptic release of neurotransmitter.  
Twenty-four hour treatment of primary mixed cortical cultures with PACAP 
produced a dose-dependent increase in cystine uptake, at an optimal dose of 1 nM, while 
an elevated dose of 10 nM PACAP did not produce any changes in cystine uptake (Fig. 
6.1A). The physiological relevance of prolonged neuropeptide treatment in vitro is still 
somewhat unclear as there is no rapid clearance mechanism for neuropeptides, and 
diffusion is not an applicable process when neuropeptide concentrations are uniform in 
the cell culture media. Furthermore, the slow degradation of neuropeptides by 
aminopeptidases likely result in peptide fragments that are commonly used as 
neuropeptide receptor antagonists in pharmacology experiments. In the case of PACAP, 
PACAP6-38 is likely generated a few hours after application, and the consequences of 
this process may be reflected in some of our data, such as the inverted U-shape curve of 
cystine uptake observed at high doses of PACAP. Additionally, this increase in cystine 
uptake in primary mixed cortical cultures at 1 nM PACAP was relatively modest 
compared to the increases observed in astrocyte-enriched cultures (Fig. 6.5B) suggesting 
that PACAP-mediated regulation of system xc- is primarily driven by signaling on 
astrocytes, and PACAP stimulation of neurons may evoke other signaling mechanisms 
that inhibit increases in cystine uptake via system xc-. Interestingly, the PAC1R 
antagonist, PACAP6-38, actually potentiated the effect of 1 nM PACAP treatment in 
mixed cultures on cystine uptake (Fig. 6.4A), perhaps demonstrating a role for neuronal 
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PAC1R activation in reducing cystine-glutamate exchange.  Furthermore, a dose-
response of VIP treatment did not produce the same U-shaped profile for cystine uptake 
in primary mixed cortical cultures as PACAP (Fig. 6.4E), indicating that VIP-neuron 
interactions do not suppress system xc- activity.  
Surprisingly, the nonspecific VIP receptor antagonist VIP6-28 and the VPAC1R 
antagonist PG 97-269 both blocked PACAP-induced increases in cystine uptake 
suggesting that regulation of system xc- in mixed cortical cells is achieved through 
VPAC1R signaling and not VPAC2R or the PACAP-specific PAC1R. Importantly, 
primary cortical neurons express PAC1 and VPAC2 receptor subtypes, while primary 
cortical astrocytes express all three receptor subtypes including VPAC1 (Grimaldi and 
Cavallaro 1999). The expression of the VPAC1R is distributed throughout the central 
nervous system, with very high levels of immunoreactivity reported in cortical layers 
(Joo et al. 2004). Since, regulation of feeding behavior by hypothalamic PACAP 
signaling is dependent upon PAC1R and central VIP injections have little effect on food 
intake (Mounien et al. 2009), it appears unlikely that control of feeding behavior by 
PACAP is mediated by system xc- activity. However, the current studies have not 
addressed the possible rapid regulation of cystine-glutamate exchange by PACAP which 
could significantly affect behavior, and similar in vitro studies using cultured 
hypothalamic cells may be necessary to examine whether the mechanisms of glutamate 
modulation by PACAP receptors is anatomically specific.   
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 The current study identifies a novel neuropeptide signal that regulates the function 
of the cystine-glutamate antiporter (Figure 6.6). PACAP/VIP signaling may critically 
modulate system xc- activity throughout the central nervous system conveying signals to 
astrocytes of increased activity and oxidative stress at the synapse. Future studies are 
needed to examine the potentially harmful affects of abnormal PACAP/VIP signaling on 
system xc- function, as well as the therapeutic potential of targeting these neuropeptide 
signals in order to drive system xc- activity for the treatment of disease. 
 
 
 
 
Figure 6.6. Modulation of astrocytic system xc- activity by PACAP. PACAP released from 
Glutamate neurons targets astrocytic receptors altering glutamate signaling by regulating EAATs 
and system xc-. C-C, cystine; mGr, metabotropic glutamate receptor; A, AMPA receptor; N, 
NMDA receptor. 
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CHAPTER VII 
 
 
PACAP MODULATION OF GLUTAMATE: HYPOPHAGIA INDUCED BY PACAP 
IN THE VENTROMEDIAL NUCLEI OF THE HYPOTHALAMUS IS MEDIATED BY 
NMDA RECEPTORS 
 
 
Introduction 
 
 
 Hypothalamic glutamate neurotransmission is crucial to energy regulation 
(Fuente-Martin et al. 2012; Liu et al. 2012a; Sternson et al. 2005; Tong et al. 2007; Xu et 
al. 2013a; Xu et al. 2013b), in part, through the regulation of feeding behavior (Guyenet 
et al. 2013; Stanley et al. 1993a; Takaki et al. 1992). This is in contrast to classical views 
of hypothalamic signaling that have focused on the importance of neuropeptides for 
homeostatic regulation. However, recent investigation into mechanisms of neuropeptide 
function has indicated that modulation of the fast-acting amino acid neurotransmitters, 
glutamate and GABA, in addition to effects on cell morphology and gene expression, 
may be the primary role for neuropeptide signaling (van den Pol 2012). This is 
demonstrated by neuropeptides, such as orexin or neuropeptide Y, that potently increase 
feeding behavior through glutamate receptor-dependent pathways (Doane et al. 2007; Lee 
and Stanley 2005).  
 The hypothalamic ventromedial nuclei (VMN) are critical regulators of body 
weight and possess both high levels of glutamate and all glutamate receptor subtypes (Fu 
and van den Pol 2008; Meeker et al. 1994; Tong et al. 2007; Ziegler et al. 2002). 
Stimulation of these nuclei produces reductions in food intake and increased metabolic 
rate (Amir 1990a; Beltt and Keesey 1975; Ruffin and Nicolaidis 1999; Takaki et al. 1992; 
Yoshimatsu et al. 1993). Likewise, microinjection of PACAP into the VMN also inhibits 
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feeding behavior through activation of PAC1 receptors even after food deprivation 
(Resch et al. 2011), however, the signaling downstream of the PAC1R-expressing 
neurons of the VMN that results in decreased food intake is not clear. Still, previous 
demonstration of synergy between PACAP and glutamate (Hannibal et al. 2000; 
Harrington et al. 1999; Macdonald et al. 2005) suggests that PACAP-PAC1R signaling in 
the VMN may result in augmented glutamate neurotransmission.  
 Co-localization of PACAP and glutamate immunoreactivity in retinal ganglion 
cells, as well as in nerve terminals located in the suprachiasmatic nuclei (SCN) support a 
mechanism of co-release at synapses of the retinohypothalamic tract (Engelund et al. 
2010; Fahrenkrug and Hannibal 2004; Hannibal et al. 2000). Functionally, PACAP 
application to SCN slices produces dose-dependent phase shifts in circadian rhythms 
through modulation of NMDA receptor activity (Harrington et al. 1999). Moreover, 
PACAP enhances NMDA receptor activity in the hippocampus, reportedly by two 
separate mechanisms involving Src tyrosine kinase signaling. The first of which involves 
cAMP/PKA-dependent activation of Fyn, a member of the Src tyrosine kinase family, 
leading to phosphorylation of multiple tyrosine residues on the GluN2B subunit of the 
NMDA receptor (Yaka et al. 2003). The second was shown to occur via PAC1R 
activation of a phospholipase C pathway leading to Src tyrosine kinase activation and 
augmented hippocampal NMDA receptor function (Macdonald et al. 2005). Both 
PACAP-mediated signaling pathways suggest that modulation of NMDA receptors can 
occur through Src kinase activity, which has been implicated in the regulation of feeding 
behavior by lateral hypothalamic neurons (Khan et al. 2004). 
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 Glutamate is also substantially regulated by astrocytes, which are major targets of 
PACAP signaling (Masmoudi-Kouki et al. 2007; Tatsuno et al. 1996a; Tatsuno et al. 
1996b), yielding another potentially important mechanism for glutamate modulation by 
PACAP. Astrocytes impact glutamate neurotransmission most notably through removal 
of synaptic glutamate by sodium-dependent excitatory amino acid transporters (EAATs) 
(Asztely et al. 1997; Diamond and Jahr 2000; Zheng et al. 2008) and glutamate release 
from astrocytes themselves (Baker et al. 2002; Kupchik et al. 2012; Moran et al. 2005; 
Parpura and Haydon 2000; Ye et al. 2003). Given that a single astrocyte can interact with 
numerous synapses (Bushong et al. 2002; Ogata and Kosaka 2002), their influence over 
glutamate signaling and overall network activity is immense. Therefore, investigation 
into how glutamate neurotransmission is influenced by astrocytes may reveal new 
insights into signaling mechanisms that are unique to glutamatergic synapses and the 
manner by which they influence behavior. In terms of PACAP signaling, this 
neuropeptide stimulates expression of both GLAST and GLT-1 (EAAT1 and EAAT2 
respectively) in primary cortical astrocyte cultures (Figiel and Engele 2000) and 
augments cystine-glutamate exchange through increasing system xc- activity (Resch et al. 
2014 under review), illustrating that separate mechanisms driven by the same 
neuropeptide signal can increases both uptake and release of glutamate by astrocytes. 
Despite the extensive study of how astrocytic control of glutamate affects hypothalamic 
function (Fuente-Martin et al. 2012; Gordon et al. 2009; Oliet et al. 2001; Potapenko et 
al. 2012) and knowledge that PACAP potently regulates feeding behavior (Hawke et al. 
2009; Morley et al. 1992; Mounien et al. 2009; Resch et al. 2013), whether or not 
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modulation of astrocytic glutamate signaling by PACAP influences food intake has yet to 
be investigated. 
 In order to determine whether modulation of glutamate signaling underlies the 
regulation of feeding behavior by PACAP in the hypothalamus we measured food intake 
following administration of pharmacological inhibitors of system xc- or NMDA receptor 
function within the VMN prior to PACAP injection. Our results suggest that PACAP 
interacts with and possibly potentiates both system xc- and NMDA receptor activity, 
however only modulation of NMDA receptors significantly altered PACAP-induced 
hypophagia in the VMN.    
Methods 
Animals 
Male Sprague-Dawley rats (Harlan; Madison, WI) weighing 225-250 g were 
individually housed in a climate controlled room with a 12 hr light/dark cycle. Animals 
had free access to Harlan standard diet (8604 formulation) and water. Food consumption 
was measured with a BioDAQ Food Intake Monitor (Research Diets; New Brunswick, 
NJ) or calculated by pre-weighing food in each bin and subtracting the weight of non-
ingested and spilled food at the end of each measurement period. All procedures using 
animals were approved by the Marquette University Institutional Animal Care and Use 
Committee. 
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Surgery   
Animals were anesthetized with a ketamine/xylazine/acepromazine (77:1.5:1.5 
mg/ml/kg; ip) cocktail and placed in a stereotaxic apparatus. Bilateral guide cannulae (26 
gauge; Plastics One; Roanoke VA) were placed 3 mm dorsal to the target site in all 
animals, and secured to the surface of the skull with an acrylic resin. The stereotaxic 
coordinates for the VMN were anterior/posterior, -2.5 mm from bregma; medial/lateral, 
±0.6 mm from midline; dorsal/ventral, -6.2 mm from surface of the skull based on The 
Rat Brain in Stereotaxic Coordinates, 6th Edition (Paxinos and Watson 2007). Injectors 
extended 3 mm past the ventral tip of the cannulae reaching a VMN injection site of -9.2 
mm ventral from the surface of the skull. The upper incisor bar was positioned -3.3 mm 
below horizontal zero. A bilateral dummy stylet placed in the guide cannulae was used to 
maintain patency. All animals were given at least five days to recover after cannula 
installation before receiving drug or vehicle injections, during which time the animals 
were handled and dummy stylets were removed and replaced daily in order to acclimate 
the animals to the physical handling necessary during experiments. Correct cannulae 
placements were confirmed at the conclusion of each experiment by microscopic 
examination of Nissl stained sections and only those with correct placement were 
included in the studies. 
Feeding Behavior Experiments 
Animals were weighed daily and acclimated to the BioDAQ Food Intake Monitor 
for at least 7 days before the onset of the experiment. In all experiments, approximately 1 
hour prior to lights off rats received bilateral microinjections of an antagonist, which 
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included sulfasalazine (SSZ; 10 - 10,000 pmol in 10 % dimethylsulfoxide (DMSO)/0.25 
µl/side; Anaspec; Fremont, CA), (S)-4-carboxyphenylglycine (CPG; 10 - 10,000 pmol in 
saline/0.25 µl/side; Tocris Bioscience; Minneapolis, MN), D-(-)-2-amino-5-
phosphonopentanoic acid (AP5; 10 - 10,000 pmol in saline/0.25 µl/side; Tocris 
Bioscience), 1-(1,1-Dimethylethyl)-1-(4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
amine (PP1; Src kinase inhibitor; 1 - 100 pmol in 10 % DMSO/0.25 µl/side; 1 nmol in 
25% DMSO/0.25 µl/side; Tocris Bioscience), or vehicle alone over approximately two 
minutes in awake animals while gently restrained. When necessary, DMSO was used as a 
vehicle for water insoluble substances such as SSZ and PP1, as it has been previously 
verified to be suitable for such feeding experiments, causing no significant alterations in 
food intake when administered alone, even with solutions at concentrations as high as 
75% (Blevins et al. 2002; Khan et al. 2004). Upon completion of antagonist injections an 
additional minute elapsed before removing injectors to minimize backflow of injected 
material. Five minutes later (15 minutes for PP1 studies) rats received a second bilateral 
injection of either saline or PACAP (50 pmol/0.25 µl/side; PACAP38; California Peptide 
Research; Napa, CA) followed by subsequent feeding measurements. The optimal 
injection volume of 0.25 µl and subsequent spread within the VMN was determined 
previously (Resch et al. 2011). Feeding measurements were collected for the next 24 
hours, with the greatest emphasis placed on the first 3-5 hours after microinjections were 
delivered.  
Quantitative reverse transcription PCR  
Three hours post-injection of saline or PACAP (50 pmol/0.25 µl/side) into the 
VMN, bilateral dissections of the VMH were collected and snap frozen in liquid nitrogen. 
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Total RNA was isolated from VMH punches by TRIzol extraction (Invitrogen; Carlsbad, 
CA). Subsequently, cDNA was constructed with 1 µg of total RNA using the Reverse 
Transcription System (Promega; Madison, WI). Quantitative PCR was performed using a 
StepOne Real-Time PCR System (Applied Biosystems; Carlsbad, CA), and PerfeCTa 
SYBR Green FastMix with ROX (Quanta Biosciences; Gaithersberg, MD) according to 
the manufacturer’s protocol. Quantification of xCT expression was done using the ΔΔCT 
method normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression. 
Primers for each gene were designed to span an exon-exon junction and had efficiencies of 
approximately 95%. Product sizes for each primer set were 112 bp for xCT and 126 bp for 
GAPDH. Melt curve analysis of experiments confirmed a single product for each reaction. 
Primers were as follows: xCT - AGGGCATACTCCAGAACACG and ATGCTCGTACC 
CAATTCAGC; GAPDH - CTCCCATTCTTCCACCTTTGA and 
ATGTAGGCCATGAGGTCCAC.  
Western blot analysis of GluN2B tyrosine phosphorylation   
 Thirty minutes following saline or PACAP (50 pmol/0.25 µl/side) injections into 
the VMN, bilateral dissections of the ventromedial hypothalamus (VMH) were collected. 
VMH tissue was homogenized in ice-cold homogenization buffer (320 mM sucrose, 10 
mM Tris-HCl, pH 7.4, 10mM EDTA, 10mM EGTA) containing Halt protease and 
phosphatase inhibitor cocktail (Pierce; Rockfork, IL) with a Teflon homogenizer (10 
strokes), followed by 3-4 seconds of sonication. Homogenates were centrifuged at 1000 
X g for 2 minutes at 4° C to remove nuclei and large debris. The resulting supernatant 
was further centrifuged at 10,000 X g for 30 minutes at 4° C to obtain a crude membranal 
pellet that was resuspended in solubilization buffer (1% Triton x-100, 150 mM NaCl, 
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10nM Tris-HCl pH 7.4, 1 mM EDTA, 1 mM EGT, protease & phosphatase inhibitor 
cocktail). Protein quantification of samples was determined using a bicinchoninic (BCA) 
assay (Pierce). Membrane protein (20 µg) was run on an 8% gel by SDS-PAGE and 
transferred to a polyvinylidine fluoride (PVDF) membrane. Membranes were blocked 
with 5% bovine serum albumin (BSA) in tris-buffered saline containing 0.1 % Tween-20 
(TBS-T). Blots were then probed with rabbit anti-pY1336 GluN2B antibody (Rockland 
Immunochemicals; Gilbertsville, PA) overnight at 4° C, followed by washes with TBS-T 
and incubation with an HRP-conjugated mouse anti-rabbit secondary antibody (Jackson 
Immunoresearch; West Grove, PA) at room temperature for 2 hours. Band intensities for 
pY1336 were developed using SuperSignal West Femto chemiluminescent substrate 
(Pierce) and visualized using the Kodak Image Station 4000MM. After visualization of 
pY1336 signal, blots were stripped and reprobed in an identical fashion for total GluN2B 
expression using mouse anti-GluN2B (Rockland Immunochemicals) and HRP-
conjugated goat anti-mouse (Jackson Immunoresearch) antibodies. Band densities were 
measured using Kodak Molecular Imaging Software v4.0. 
Radiolabeled cystine uptake from VMN punches 
 Brain punches containing the ventromedial hypothalamus (VMH) which included 
the VMN and other nearby hypothalamic regions were collected using a blunt 16 gauge 
needle and incubated in 95% O2: 5% CO2 slice buffer (118 mM NaCl, 3 mM KCl, 1.4 
mM KH2PO4, 2.7 mM MgSO4, 26 mM NaHCO3, 3.2 mM CaCl2, and 7.8 mM glucose) 
for 20 minutes for acclimation. Punches were then treated with 1 µM 14C-Cystine and 10 
µM TBOA for 20 minutes ±500 µM sulfasalazine (SSZ) or 1 mM S-(4)-
carboxyphenylglycine (CPG). Following radiolabeled cystine incubation punches were 
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washed three times with ice-cold PBS, and dissolved with 1N NaOH. Radioactivity was 
measured using a scintillation counter and normalized for protein content using the Bio-
Rad DC protein assay (Hercules, CA). Data are presented as % radiolabeled cystine 
uptake of control VMH punches. 
Statistics 
Data are presented as means ± standard errors of the mean, and were analyzed 
statistically by analysis of variance (with repeated measures when appropriate). Fischer 
LSD analysis was used for all post-hoc group comparisons. Statistical analyses were 
performed using Sigma Plot 11 software (Systat Software Inc.; San Jose, CA). P < 0.05 
were considered statistically significant. 
Results 
 Prior to determining the affects of cystine-glutamate exchange on feeding 
behavior, we first tested for functional system xc- activity in the hypothalamus by 
assessing radiolabeled cystine uptake in ventromedial hypothalamus (VMH) punches ex 
vivo. VMH punches were incubated with or without a system xc- inhibitor, 500 µM 
sulfasalazine (SSZ) or 1 mM 4-(S)-carboxyphenylglycine (CPG), in the presence of 
radiolabeled cystine for 20 minutes. Both SSZ and CPG dramatically reduced 
radiolabeled cystine uptake in VMH punches to approximately 30% of controls (Fig. 
7.1A; P < 0.05). Although PACAP modulates both system xc- activity and mRNA 
expression in primary cortical cultures (Resch et al. 2014 under review), there are no 
reports of similar mechanisms in the hypothalamus. In order to assess whether PACAP 
signaling affects in vivo system xc- expression in the hypothalamus we measured  
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radiolabeled cystine uptake in VMH punches treated with PACAP and xCT mRNA three 
hours following microinjections of saline or PACAP into the VMN. PACAP increased 
cystine uptake by approximately 20% above controls, although, it was not a statistically 
significant increase. By contrast, PACAP-treated VMH samples demonstrated a 
significant increase in xCT mRNA compared to saline treatment (Fig. 7.1B; P < 0.05). 
  After confirming system xc- activity and PACAP-induced stimulation of xCT 
mRNA expression in the VMN, we examined whether impairment of cystine-glutamate 
exchange in the VMN altered feeding behavior using the system xc- inhibitor 
sulfasalazine (SSZ). No concentration of SSZ (50 pmol, 500 pmol, or 5 nmol/side) 
injected into the VMN injections altered food intake (Fig. 7.2A) nor did SSZ (500  
 
Figure 7.1.  Demonstration of system xc- activity in the ventromedial hypothalamus and its regulation 
by PACAP. (A) Radiolabeled cystine uptake in ex vivo VMH punches was significantly reduced with 
the system xc- inhibitors sulfasalazine (SSZ) and 4-(S)-carboxyphenylglycine (CPG). (B) Radiolabeled 
cystine uptake from ex vivo VMH punches treated with 1 nM PACAP was increased compared to 
controls.(C) Quantitative PCR demonstrates that PACAP injections into the VMN result in increased 
xCT mRNA expression 3 hours post-injection. Levels of xCT expression were normalized to GAPDH 
using the ∆∆Ct method. Data are expressed as mean ± SEM. * = P < 0.05 compared to control group. 
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pmol/side) attenuate PACAP-mediated decreases in food intake (Fig. 7.2B). However, to 
be certain that the lack of effects on feeding were not due to the choice of system xc- 
inhibitor used, we also tested a second cystine-glutamate antiporter inhibitor, CPG, to 
determine whether it would attenuate the effects of PACAP on feeding behavior. 
Multiple doses of CPG (10 pmol - 1 nmol/side) were injected into the VMN prior to 
PACAP administration, however, like SSZ none of the CPG treatments were effective in 
blocking the hypophagic response to PACAP in the VMN (Fig. 7.3).  
 Considering that inhibition of cystine-glutamate antiporter function did not affect 
feeding behavior or attenuate hypophagia induced by PACAP, we proceeded to test 
whether glutamate signaling via the NMDA receptor was necessary for PACAP-mediated 
reductions in food intake. Initially, the NMDA receptor antagonist AP5 was administered 
into the VMN at multiple doses ranging from 10 pmol to 10 nmol to investigate its  
 
Figure 7.2.  Inhibition of the cystine-glutamate antiporter in the VMN with sulfasalazine has no 
effect on food intake. (A) Dose response of SSZ injections into the VMN shows no differences in 
food intake. (B) Bilateral pretreatment with 500 pmol of SSZ into the VMN does not attenuate 
decreased food intake caused by PACAP. Data are expressed as mean ± SEM. * = P < 0.05 
compared to control group. 
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contribution to normal feeding behavior. Surprisingly, only bilateral injections of 10 
nmol AP5 significantly altered feeding behavior by decreasing food intake (Fig. 7.4A; P 
< 0.05). An unexpected result considering inhibition of the VMN produces increased 
feeding behavior (Berthoud and Jeanrenaud 1979), however, administration of AP5 at 
concentrations of 10 nmol/side into the VMN also dramatically reduced locomotor 
activity, which may explain the reduction in food intake (data not shown). To determine 
whether NMDA receptor function is necessary for PACAP-mediated decreased food 
intake animals received AP5 (10 pmol/side) injections into the VMN prior to PACAP (50 
pmol/side). Although AP5 treatment alone again had no effect on feeding, it did 
successfully block the effects of PACAP injections into the VMN on food intake (Fig. 
7.4B; P < 0.05).  
Figure 7.3.  Inhibition of system xc- activity with 4-(S)-
carboxyphenylglycine (CPG) does not block PACAP-
mediated hypophagia. Data are expressed as mean ± SEM. 
* = P < 0.05 compared to control group. 
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 With the evidence that NMDA receptor function appeared to be necessary for 
decreased food intake induced by PACAP, we examined whether similar mechanisms of 
NMDA receptor potentiation by PACAP were at play in the hypothalamus as have been  
 
 
 
reported in the hippocampus. PACAP treatment of hippocampal slices was found to 
produce increased phosphorylation of tyrosines 1252, 1336, and 1472 specifically on the  
GluN2B subunit of NMDA receptors (Yaka et al. 2003). To test for tyrosine 
phosphorylation in our feeding behavior model we performed microinjections of saline or 
PACAP in a similar manner to prior feeding behavior experiments but then collected 
VMH tissue 30 minutes post-injection for GluN2B tyrosine phosphorylation analysis. In 
western blot experiments we examined phosphorylation levels of tyrosine 1336 (pY1336) 
on the GluN2B subunit of the NMDA receptor and normalized band intensities to total  
Figure 7.4.  NMDA receptor antagonism attenuates the hypophagic effects of PACAP administration 
into the VMN. (A) Feeding responses to a dose-response of bilateral AP5 microinjections into the 
VMN. (B) Bilateral injection of 10 pmol AP5 into the VMN blocks the inhibitory effect of PACAP 
on feeding behavior. Data are expressed as mean ± SEM. * = P < 0.05 compared to control group.  
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GluN2B expression. Indeed, semi-quantitative analysis demonstrated that VMN PACAP 
treatment increased pY1336 expression by approximately 25% (Fig. 7.5A & B; P < 0.05). 
 Tyrosine phosphorylation of the NMDA receptor mediated by PACAP signaling 
has been shown to be a result of increased Src family kinase activity (Macdonald et al. 
2005; Yaka et al. 2003). This pathway has also been implicated in the regulation of  
feeding behavior by the lateral hypothalamus (Khan et al. 2004), and in support of studies 
conducted in the hippocampus (Yaka et al. 2003), the phosphorylation appears to be 
 
Figure 7.5.  PACAP administration into the VMN results in increased 
tyrosine phosphorylation of the GluN2B subunit of the NMDA receptor. 
(A) Representative VMH protein samples from saline or PACAP (50 
pmol/side) microinjections into the VMN probed for phosphorylation of 
tyrosine 1336 of the GluN2b subunit (pY1336) and total GluN2B protein 
expression. (B) Semi-quantitative analysis of band densities for pY1336 
normalized to total GluN2b expression expressed as a percent of saline 
treatment. Data are expressed as mean ± SEM. * = P < 0.05 compared to 
control group. 
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specific to the GluN2B subunit of the NMDA receptor. We confirmed increased GluN2B 
tyrosine phosphorylation following PACAP administration into the VMN, however, 
analysis of other NMDA receptor subunits was not performed in our studies. Taken 
together it is probable that PACAP-PAC1R signaling results in tyrosine phosphorylation 
of the GluN2B subunit of the NMDA receptor in the VMN through activation of an Src 
kinase similar to prior reports. To assess this possibility the Src kinase inhibitor PP1 (1 - 
1000 pmol/0.25 µl/side) was injected into the VMN followed by measurements of food 
intake. No concentration of PP1 used in these studies significantly altered food intake 
when injected into the VMN alone (Fig. 7.6A). However, pretreatment with PP1 (10 
pmol/side) in the VMN prior to PACAP injections did significantly attenuate the 
hypophagic effects of PACAP (Fig. 7.6B; P < 0.05). 
 
 
Figure 7.6.  Inhibition of Src kinase activity with PP1 attenuates PACAP-induced decreases in 
food intake in the VMN. (A) Feeding response to PP1 injections into the VMN. (B) Pretreatment of 
the VMN with PP1 prior to PACAP injections prevents PACAP-mediated hypophagia. Data are 
expressed as mean ± SEM. * = P < 0.05 compared to control group. 
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 Discussion 
 By inhibiting aspects of glutamatergic signaling we were able to examine the 
contribution of cystine-glutamate exchange as well as NMDA receptor activity to 
PACAP-mediated decreases in food intake in the VMN. While functional system xc- 
activity was detected within the VMN, in addition to transcriptional regulation of xCT by 
PACAP signaling, inhibition of system xc- through SSZ or CPG administration failed to 
mitigate the effects of PACAP on feeding behavior. In contrast, pretreatment with the 
NMDA receptor antagonist AP5 successfully attenuated the hypophagic response to 
PACAP administration into the VMN. These data build upon previous findings indicating 
that PACAP-PAC1R signaling may potentiate postsynaptic NMDA receptor activity 
(Figure 7.7), perhaps through phosphorylation of the GluN2B subunit (Yaka et al. 2003). 
Upon examination of GluN2B phosphorylation following in vivo VMN PACAP 
injections, we detected an increase in phosphorylation at tyrosine 1336, a previously 
identified site of PACAP-induced tyrosine phosphorylation on the GluN2B subunit of the 
NMDA receptor (Yaka et al. 2003). This Src family of non-receptor tyrosine kinases was 
previously described to facilitate NMDA receptor phosphorylation mediated by PACAP 
(Macdonald et al. 2005; Yaka et al. 2003), and hypothalamic Src activity plays a role in 
controlling feeding behavior (Khan et al. 2004). These findings led us to test whether Src 
may be a downstream mediator of PACAP-induced hypophagia in the VMN. Inhibition 
of Src family tyrosine kinases with PP1 effectively blocked the effects of PACAP on 
feeding behavior, further supporting PACAP-mediated potentiation of NMDA receptors 
via an Src-dependent pathway.    
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 Although we did not detect an effect feeding behavior following inhibition of 
system xc- activity, altered cystine-glutamate exchange significantly impacts memory, 
psychosis, and motivated behaviors (Baker et al. 2008; Baker et al. 2003; De Bundel et 
al. 2011; Knackstedt et al. 2009; Zhou and Kalivas 2008). Furthermore, under certain 
conditions it is possible that augmented glutamate release from the cystine-glutamate 
antiporter may lead to increased excitation of VMN neurons and decreased feeding 
through activation of extrasynaptic NMDA or metabotropic glutamate receptors. Indeed, 
our dose-response of SSZ injections into the VMN showed alterations in feeding 
behavior at higher doses, and while not significant this suggests an endogenous 
glutamatergic signal at extrasynaptic NMDA and metabotropic glutamate receptors in the 
VMN. In addition, our current studies focused only on natural nocturnal feeding 
behavior, so while PACAP does appear to regulate cystine-glutamate exchange, under 
our experimental conditions changes in system xc- activity does not contribute 
significantly to PACAP-mediated decreases in food intake in the VMN, but may under 
different circumstances.  
 Given that system xc- is predominantly found on astrocytes, and astrocytes are 
critical to both glutamate and glucose homeostasis in the hypothalamus (Fuente-Martin et 
al. 2012; Gordon et al. 2009; Potapenko et al. 2012), a more likely role for system xc- in 
energy balance may exist in glycemic regulation. In support of this hypothesis, both the 
VMN and third ventricle tanycytes are critical to hypothalamic glucose sensing (Borg et 
al. 1997; Garcia et al. 2003; Sanders et al. 2004; Tong et al. 2007) and express xCT 
mRNA (Sato et al. 2002). Furthermore, stimulating cystine-glutamate exchange via 
systemic administration of the cysteine prodrug N-acetylcysteine improves glucose 
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tolerance and attenuates weight gain from a high sucrose diet (Novelli et al. 2009; Souza 
et al. 2008). Although the current experiments did not examine glucose regulation, there 
is evidence that PACAP administration increases both blood glucose (Resch et al. 2013) 
and system xc- activity (Resch et al. 2014 under review) suggesting that activation of 
system xc- by PACAP in the VMN may impact peripheral glucose availability. 
 Similar to our current data combining NMDA receptor antagonists with PACAP 
injections into the VMN, inhibition of NMDA receptors also blocks hyperphagia induced 
by orexin and neuropeptide Y in the lateral hypothalamus (Doane et al. 2007; Lee and 
Stanley 2005). Furthermore, AMPA/kainate and NMDA glutamate receptor agonists 
produce robust feeding in sated rats, and AP5 significantly reduces refeeding following a 
fast when administered into the lateral hypothalamus (Stanley et al. 1993a; Stanley et al. 
1996; Stanley et al. 1993b). Although treatment with AP5 in the VMN did not produce 
increased feeding behavior as expected in our experiments, AP5 was administered at a 
time when feeding behavior was naturally at its peak, possibly reducing our ability to 
detect AP5-induced alterations in feeding behavior. Moreover, we unexpectedly observed 
significant decreases in food intake following high doses of AP5 (10 nmol/0.25 µl/side), 
however, high doses of AP5 appeared to concomitantly produce immobility in animals 
post-injection (data not shown) likely due to VMN regulation of physical activity (Challet 
et al. 1995; Challet et al. 1996; Choi et al. 1998; Narita et al. 2002; Narita et al. 1993; 
Resch et al. 2013; Yokawa et al. 1989). In light of our current findings that VMN 
PACAP injections produce NMDAR-dependent hypophagia and GluN2B tyrosine 
phosphorylation, GluN2B containing NMDA receptors may significantly regulate 
feeding behavior. Interestingly, GluN2B expression is widespread throughout the 
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hypothalamus including in the VMN. In the lateral hypothalamus, antagonism of GluN2B 
containing NMDA receptors with ifenprodil attenuates the feeding response to both 
fasting and microinjection of NMDA into the lateral hypothalamus, although ifenprodil 
concentrations used in these studies may have also antagonized GluN2A containing 
NMDA receptors (Khan et al. 1999; Khan et al. 2000). Furthermore, the phosphorylation 
state of the GluN2B subunit may be critical for augmenting NMDA receptor activity 
induced by PACAP signaling, and appears to be regulated by the Src family of tyrosine 
kinases (Macdonald et al. 2005; Yaka et al. 2003), a family of kinases which have also  
been reported to reduce GluN3A trafficking to the synaptic membrane (Chowdhury et al. 
2013). Importantly, inhibition of Src family tyrosine kinases by PP1 has previously been 
reported to block NMDAR-dependent feeding behavior in the lateral hypothalamus 
(Khan et al. 2004), similar to our data regarding PACAP signaling in the VMN.  
 Although our investigations of PACAP-mediated feeding behavior in the VMN 
cannot directly demonstrate potentiation of postsynaptic NMDA receptors by PACAP 
signaling, extensive biochemical and electrophysiological analysis of glutamate signaling 
in the hippocampus has demonstrated this modulatory pathway. PACAP application 
yields enhancement of field excitatory postsynaptic potentials, brain derived neurotrophic 
factor mRNA expression, and tyrosine phosphorylation of the GluN2B subunit of the 
NMDA receptor by Fyn tyrosine kinase, which is a member of the Src family of tyrosine 
kinases (Yaka et al. 2003). Further coupling PACAP to glutamate signaling, PACAP 
augments NMDA currents following Schaffer collateral stimulation through a PAC1R-
dependent pathway that activates Src tyrosine kinase (Macdonald et al. 2005). While two 
different mechanisms of NMDA receptor potentiation by PACAP have been identified,  
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Figure 7.7.  Modulation of NMDA receptor signaling by PACAP. (A) Conventional 
glutamatergic synapse showing no modulation of glutamate neurotransmission leading to 
lesser excitatory postsynaptic potential (EPSP). (B) Proposed potentiation of EPSP 
following modulation of glutamate receptors by PACAP released from glutamate and 
PACAP co-expressing neurons or PACAPergic neurons. 
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both occur as a result of tyrosine phosphorylation of NMDA receptors by a member of 
the Src family of tyrosine kinases (Fyn and Src).   
 PACAP signaling may also modulate other aspects of glutamate signaling 
including the AMPA receptor, as PAC1R-dependent potentiation of AMPA receptors at 
low PACAP concentrations and VPAC2R-mediated depression of AMPA receptors at 
high concentrations of PACAP have been reported in the hippocampus (Costa et al. 
2009). Furthermore, excitatory transmission from the basolateral amygdala to the central 
amygdala is augmented through PACAP-VPAC1R increases in AMPA receptor activity 
(Cho et al. 2012). However, without further behavioral pharmacology examining 
glutamate receptor-mediated properties of PACAP-induced hypophagia in combination 
with the appropriate electrophysiology, the role of other modes of glutamatergic 
neurotransmission cannot be ascertained. Nevertheless, our experiments using AP5 and 
PP1 attenuated the effects of PACAP on feeding suggesting a similar mechanism of 
NMDA receptor modulation by PACAP likely exists in the hypothalamus as it does in the 
hippocampus.  
133 
CHAPTER VIII 
 
 
General Discussion 
 
 
Summary  
 The studies described in this thesis highlight some of the first experiments 
investigating site-specific effects of PACAP signaling on feeding and metabolism in the 
hypothalamus. This dissertation demonstrates that PACAP administration either into the 
PVN or VMN produced hypophagia mediated by the PAC1R, while increases in energy 
expenditure via elevated activity and core body temperature were only observed 
following PACAP administration into the VMN. Retrograde tracing from the PVN and 
VMN combined with fluorescent in situ hybridization for PACAP mRNA suggest 
partially overlapping PACAP circuits innervating these two hypothalamic nuclei, 
however, distinct efferent circuits could easily account for the dichotomy in energy 
expenditure (Chapter IV), as well as the perceived increased potency of PACAP-induced 
decreases in feeding from PVN administration (Chapter III).  
 While the effects of icv and hypothalamic PACAP administration on body weight 
regulation appear to be consistent across studies (Chance et al. 1995; Dore et al. 2013; 
Hawke et al. 2009; Masuo et al. 1995; Mizuno et al. 1998; Morley et al. 1992; Mounien 
et al. 2009; Pataki et al. 2000; Resch et al. 2011; Resch et al. 2013), the mechanisms by 
which PACAP modulates neurotransmission to affect feeding and metabolism are still 
unclear. In a number of brain regions, PACAP is co-expressed with glutamatergic 
markers (Figure 5.1) (Engelund et al. 2010; Hannibal et al. 2000) and has been implicated 
to regulate glutamate signaling (Cho et al. 2012; Figiel and Engele 2000; Macdonald et 
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al. 2005), leading us to investigate potential mechanisms of glutamate modulation by 
PACAP both in vitro and in vivo. Expanding on previous reports of astrocytic glutamate 
transport regulation (Figiel and Engele 2000), we found PACAP to significantly increase 
astrocytic glutamate signaling via the cystine-glutamate antiporter, system xc-, both in 
vitro and in vivo (Chapters VI and VII). Despite the stimulatory effects of PACAP on 
system xc- function, augmenting glutamate signaling via PACAP-mediated increases in 
cystine-glutamate exchange did not appear to contribute to changes in feeding behavior 
as demonstrated by the ineffectiveness of intra-VMN sulfasalazine (SSZ) or (4)-(S)-
carboxyphenylglycine (CPG) to block PACAP-induced hypophagia. On the other hand, 
potentiation of postsynaptic glutamate receptor signaling by PACAP has been reported in 
areas of the brain such as the hippocampus and amygdala (Cho et al. 2012; Harrington et 
al. 1999; Macdonald et al. 2005; Yaka et al. 2003) suggesting that PACAP may augment 
NMDA or AMPA receptor activity in the hypothalamus. Indeed, NMDA receptor 
antagonism blocked the effects of PACAP on feeding behavior in the VMN corroborating 
PAC1R-NMDAR signaling pathways proposed earlier (Chapter VII). Overall these 
results indicate that PACAP acts as a modulator of glutamate neurotransmission, thereby, 
augmenting excitatory signaling, which in the case of the VMN leads to decreased food 
intake and increased metabolism, while maintaining an optimal synaptic environment 
through astrocytic regulation of glutamate homeostasis. The following sections discuss 
the importance of the results described within this thesis, as well as remaining questions 
that should be addressed in the future to further understand hypothalamic PACAP 
signaling.   
 
135 
What is the endogenous role of PACAP signaling in terms of energy balance? 
 Central PACAP signaling appears to function as a significant satiety factor, as 
well as a stimulator of metabolism (Chance et al. 1995; Hawke et al. 2009; Mizuno et al. 
1998; Morley et al. 1992; Mounien et al. 2009; Resch et al. 2011; Resch et al. 2013). 
Unfortunately, the circumstances under which PACAP becomes important for the 
regulation of energy balance remain unclear. While neuropeptides such as oxytocin and 
vasopressin are released dendritically and only from brief high-frequency action 
potentials (Kombian et al. 1997; Leng and Ludwig 2008), data characterizing the release 
dynamics of PACAP is lacking. Furthermore, in vivo estimates of neuropeptide diffusion 
and rates of degradation within the hypothalamus are very difficult to predict, but the 
long duration of PACAP-induced effects may suggest that the neuropeptide is active in 
some form for quite some time following its release.   
 Clues to PACAP's physiological importance have emerged in recent years, linking 
it to several critical hypothalamic signals such as leptin, corticotropin-releasing factor 
(CRF), and melanocortin signaling (Dore et al. 2013; Hawke et al. 2009; Mounien et al. 
2009; Tanida et al. 2013; Tanida et al. 2011a). However, many of these studies 
administer antagonists along with agonists into the brain's ventricular system, which 
often results in effective attenuation of agonistic properties (Dore et al. 2013; Hawke et 
al. 2009; Mounien et al. 2009; Tanida et al. 2013; Tanida et al. 2011a). Experimental 
designs utilizing ventricular injection routes cannot account for separate but parallel 
circuits involving PACAP and other neuromodulators. For example, Hawke et al. 
reported that the PAC1R antagonist PACAP6-38 completely blocked the effects of leptin 
on feeding and metabolism, which leads to the assumption that PACAP neurons mediate 
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leptin signaling. Yet, there are several other neuronal populations, not just in the 
hypothalamus but throughout the brain, that express leptin receptors and affect energy 
balance independent of PACAP signaling (Balthasar et al. 2004; DiLeone 2009; Elmquist 
et al. 2005; Kong et al. 2012; Leinninger et al. 2009; Zhang et al. 2011). It is more likely 
that PACAP6-38 and leptin merely have separate but opposing effects that result in 
neutralization of the signals leading to false interpretations. Furthermore, PACAP 
neurons are almost exclusively glutamatergic and leptin regulation of body weight is 
predominantly mediated through GABAergic neurons (Vong et al. 2011). Therefore, 
instead of presuming that PACAP has a specific physiological role similar to CRF and 
stress, it may be more accurate to suggest that PACAP is simply pleiotropic in nature, 
acting within multiple neural systems as a modulator of glutamate signaling. The pattern 
of PACAP expression in the brain corroborates this notion, with PACAP mRNA 
expression found in several brain regions (Hannibal 2002) with a wide range of functions, 
regulating affect (Dore et al. 2013; Hammack et al. 2009), fear (Ressler et al. 2011; 
Stevens et al. 2014), and body weight (Hawke et al. 2009; Krashes et al. 2014; Mounien 
et al. 2009; Resch et al. 2013) among others.  
Significance of afferent PACAP circuits to the hypothalamus  
 The PVN and VMN are both glutamatergic cell populations in the hypothalamus 
(Ziegler et al. 2002) that produce obesity when lesioned (Choi and Dallman 1999; 
Tokunaga et al. 1986). Given that icv PACAP administration results in decreased feeding 
behavior we hypothesized that these two nuclei are likely targets for PACAP-mediated 
hypophagia. Site-specific PACAP injections into the PVN and VMN did indeed produce 
decreased feeding similar to icv administration, but alterations to thermogenesis stemmed 
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from PACAP injections only into the VMN. With this in mind we began to map the 
PACAP-containing circuits that mediate satiety using retrograde tracing from the PVN 
and VMN combined with in situ hybridization for PACAP mRNA (Figure 8.1). These 
anatomical studies identified the lateral parabrachial nuclei (LPB) to contain PACAP-
expressing neurons that project to both the PVN and VMN indicating that the LPB are 
prominent sources of PACAP release into these structures. LPB neurons are activated by 
the satiety signals cholecystokinin (CCK) and amylin (Becskei et al. 2007), as well as by 
substances that are perceived to be toxic such as LiCl or lipopolysaccharide (LPS) (Carter 
et al. 2013) producing hypophagia through signaling downstream of the LPB. In addition, 
activation of ascending fibers carrying cutaneous thermosensory information excite LPB 
neurons in order to regulate body temperature, thereby identifying this circuit as 
potentially relevant to VMN induction of BAT thermogenesis by PACAP. More studies 
investigating the stimuli necessary for activation of PACAP-expressing LPB neurons are 
needed to understand the specific physiological role of these neurons with respect to 
feeding and metabolism.  
 VMN-specific afferents expressing PACAP originated from the medial amygdala 
(MeA), a brain region less familiar to the study of body weight regulation. While the 
MeA does possess a small population of glucose-sensing neurons (Zhou et al. 2010) and 
produces obesity when lesioned, especially in females (King 2006a), its main function 
appears to be involved in the processing of olfaction, as the MeA receives considerable 
input from the olfactory bulb (Park et al. 2013) leading to activation of its neurons in the 
presence of pheromones or predator odors (Bian et al. 2008; Butler et al. 2011; Kondo 
1992; Masini et al. 2009; Staples et al. 2008). Therefore, this vomeronasal pathway may 
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involve the VMN in the activation of the sympathetic fight or flight response and/or 
dampen parasympathetic activity in times of psychosocial stress, as the VMN have been 
implicated in mating behaviors and aggression (Yang et al. 2013). 
 PVN-specific afferents expressing PACAP included the anteromedial bed nucleus 
of the stria terminalis (BNST), a well-characterized region of the brain regulating stress 
and anxiety-related behaviors. This PACAP-expressing circuit may be responsible not 
only for regulation of the hypothalamic-pituitary-adrenal (HPA) axis by the PVN, but 
also the hypophagia that often corresponds with stressful and anxiogenic stimuli.  
Interestingly, we found a PACAP-expressing neuronal population in the anteromedial 
BNST that projects to the PVN that we propose regulates feeding behavior in some 
fashion, however, a recent study by Kocho-Schellenberg et al. reports that PACAP 
administration into the posterior BNST produces significant decreases in feeding 
behavior and body weight, while the the anterior BNST did not (Kocho-Schellenberg et 
al. 2014). Though these findings appear to be in contradiction, PACAP injections into 
areas of the BNST stimulate neurons expressing PACAP receptors, and not necessarily 
the neurons expressing PACAP mRNA that we propose inhibit feeding by projecting to 
the PVN.    
 Finally, a subset of PACAP neurons of the VMN project to the PVN, perhaps to 
the preautonomic subpopulation, providing a connection that allows VMN neurons to 
produce hypophagia or activation of glucose production in response to hypoglycemia. 
VMN PACAP neurons also project to pro-opiomelanocortin (POMC) neurons of the 
hypothalamic arcuate nuclei (ARC) (Krashes et al. 2014) suggesting that stimulation of 
the VMN by PACAP contributes to additional routes that inhibit feeding behavior.  
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Figure 8.1.  Review of PACAP-expressing afferent circuits of the paraventricular (PVN) and 
ventromedial (VMN) nuclei. (A) Afferents of the PVN that may regulate energy homeostasis through 
PACAP signaling originate from the bed nucleus of the stria terminalis (BNST), lateral parabrachial 
nuclei (LPBN), and VMN. (B) Afferents of the VMN that potentially regulate energy balance through 
PACAP signaling originate from the LPBN and medial amygdala (MeA). 
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Notably, PACAP administration into the PVN did not affect indices of energy 
expenditure in our experiments, perhaps suggesting that ARC POMC neuron activation 
by VMN neurons are responsible for these effects, as they are known to project to and 
stimulate preganglionic sympathetic neurons of the intermediolateral spinal cord 
coordinating aspects of sympathetic nervous system activity (Elias et al. 1998).  
Significance of efferent PACAP circuits from the hypothalamus  
  Decades of research focusing on hypothalamic regulation of feeding behavior 
have referred to both the PVN and VMN as "satiety centers" following demonstrations of 
stimulation-induced hypophagia and lesion-induced hyperphagia and obesity (Beltt and 
Keesey 1975; Choi and Dallman 1999; Kennedy 1950; Leibowitz et al. 1981; Ruffin and 
Nicolaidis 1999; Stenger et al. 1991; Tokunaga et al. 1986). Despite this wealth of data, 
remarkably little is known about the downstream circuitry that produces satiety, as both 
of these nuclei have considerable efferent targets making it difficult to isolate the feeding 
circuits from circuits controlling other aspects of physiology. The utilization of gene 
targeting approaches allowing for the examination of function within distinct circuits will 
provide giant steps towards providing a wiring diagram for hypothalamic feeding circuits.  
 Nonetheless, there are some known efferents that produce satiety involving these 
nuclei including PACAP projections from the VMN to ARC POMC, but not AgRP/NPY 
neurons (Krashes et al. 2014; Resch et al. 2011; Sternson et al. 2005), and projections to 
the PVN (Resch et al. 2013). Efferents from the PVN to areas such as the nucleus tractus 
solitarius (NTS) have been shown to inhibit brown adipose tissue thermogenesis without 
effects on satiety (Kong et al. 2012). Recently, however, a pro-feeding circuit was 
recently discovered involving a subpopulation of PVN neurons that express PACAP 
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and/or thyrotropin-releasing hormone (TRH). These neurons project specifically to ARC 
AgRP neurons and provide intense excitatory stimulation under fasting conditions 
thereby completely transforming our presumptions about PACAP and PVN function 
(Krashes et al. 2014). 
What hypothalamic cell populations express PACAP receptors? 
 As the organization of the ARC and PVN alone demonstrate, hypothalamic 
neurocircuitry is extraordinarily complex, often with multiple cell populations within the 
same nuclei having completely opposing or seemingly unrelated functions. This 
demonstrates the importance of understanding which specific cell populations are 
mediating the effects of PACAP signaling on feeding and metabolism. This point is 
exemplified by PACAP receptor expression in the PVN, which when activated by 
PACAP injections decrease feeding behavior and increase peripheral glucose levels 
(Resch et al. 2013). Though we were able to attribute the hypophagic effect of PACAP to 
activation of the PAC1 receptor we did not identify the receptor involved in modulating 
glucose availability, although another research group has indicated that VPAC2 receptors 
are important for stimulation of hepatic glucose production following PACAP injections 
into the PVN (Yi et al. 2010). It is unclear whether the same PVN cells express both 
types of PACAP receptors yielding those effects, or if distinct PACAP circuits target 
different cell populations within the PVN. Currently, expression patterns of PAC1 and 
VPAC receptors are not well characterized amongst the many cell phenotypes of the 
PVN, or in any of the other hypothalamic nuclei outside of the ARC where the PAC1 
receptor has been linked to feeding and to show expression on both POMC and 
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NPY/AgRP neurons (Krashes et al. 2014; Mounien et al. 2006a; Mounien et al. 2006b; 
Mounien et al. 2009).  
Glutamate modulation by PACAP 
 Our results from Chapters VI and VII demonstrate a relationship between PACAP 
and glutamate signaling that results in increased astrocytic system xc- activity, as well as 
apparent potentiation of NMDA receptor activity in the VMN. Furthermore, our findings 
demonstrate that tyrosine phosphorylation of the GluN2B subunit of the NMDA receptor 
in the VMN stimulated by PACAP injections and the attenuation of PACAP-induced 
hypophagia by inhibition of Src kinases agree with prior reports that an Src-dependent 
pathway resulting in NMDA receptor potentiation is driven by PACAP (Macdonald et al. 
2005; Yaka et al. 2003). However, without evidence of PAC1R signaling acting directly 
on the NMDA receptor through electrophysiological investigation we cannot completely 
rule out the possibility of indirect modulation of the NMDA receptor through other 
PACAP-related mechanisms. While pharmacological inhibition of the NMDA receptor 
with AP5 and Src with PP1 both attenuated the effects of PACAP on feeding behavior, 
we acknowledge that eliminating such essential components of cell signaling may render 
VMN neurons nonfunctional independent of PAC1R signaling pathways. Although we 
do not believe this is the case, as pharmacological inhibition of NMDA receptors or Src 
kinase alone did not produce behavioral effects, and others have used similar means to 
examine NMDA receptor (Stanley et al. 1996) and Src kinase (Khan et al. 2004) activity 
with regard to feeding behavior.  
 Modulating other aspects of glutamate signaling to affect feeding behavior is also 
a viable possibility. As with NMDA receptors, PACAP has been shown to augment 
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AMPA receptor activity in the hippocampus and amygdala suggesting that multiple 
second messenger signals with numerous targets could be stimulated by PACAP receptor 
activation (Cho et al. 2012; Costa et al. 2009). In addition to postsynaptic localization of 
the PAC1 receptor with ionotropic glutamate receptors (Cho et al. 2012; Costa et al. 
2009; Harrington et al. 1999; Macdonald et al. 2005; Shioda et al. 1997; Yaka et al. 
2003), PACAP receptors also exist presynaptically on mossy fibers of the hippocampus 
and cerebellum likely having a significant impact on presynaptic neurotransmitter release 
(Otto et al. 1999). While postsynaptic mechanisms of PAC1R signaling appear to 
dominate the literature, we have not specifically addressed the possibility of presynaptic 
regulation and thus, it cannot be ruled out.  
 Non-neuronal expression of PACAP receptors, especially on astrocytes, may 
substantially contribute to PACAP-mediated behaviors by significantly impacting 
glutamate neurotransmission. Although PACAP regulation of the astrocytic glial 
glutamate transporters GLT-1 and GLAST could have considerable ramifications on 
synaptic signaling, we have yet to address such actions by PACAP signaling in the 
hypothalamus. However, we have demonstrated augmented astrocytic cystine-glutamate 
exchange by PACAP signaling, with the initial studies conducted in primary cortical 
cultures, while acknowledging the unique cellular physiology compared to hypothalamic 
cells in vivo. Although we did detect significant increases in xCT mRNA in the VMN 
following PACAP injections, inhibition of system xc- activity did not block PACAP-
mediated alterations in feeding behavior. But, without verification of direct action of 
PACAP signaling both in and out of the synapse it is difficult to unequivocally confirm 
the exact mechanism by which PACAP modulates glutamate to alter feeding behavior.  
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Conclusions 
 The impact of PACAP signaling on body weight is complex. Not only do we 
report hypophagia and increased energy expenditure from site-specific hypothalamic 
injections (Resch et al. 2013), recent reports indicate that PACAP-expressing circuits that 
drive hunger  may also exist in the hypothalamus (Krashes et al. 2014). Moreover, 
PACAP's mechanism of action is still unknown. Even though it appears to have a 
stimulatory effect via PAC1R that is dependent upon NMDA receptor signaling, PACAP 
and its receptors have multiple modulatory actions on glutamate signaling in and around 
the synapse that may be critical to their function. Thus, future directions for investigating 
the mechanisms by which PACAP controls hypothalamic function should continue to 
focus on mapping PACAP circuits to and from the hypothalamus, determine which 
subpopulations of neurons express the feeding responsive PAC1 receptor, and confirm 
the specific actions of PACAP signaling on glutamate homeostasis, although the latter 
may prove challenging as differentiating between signals emanating from neurons and 
astrocytes in vivo will necessitate the development of new tools outside of those used 
here. 
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